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Transition metals scaffolds have several advantages over carbon scaffold in the field 
of chemical biology. In particular, the ease of employing combinatorial chemistry and 
multicomponent reaction makes it easy to synthesize metal complex libraries for 
biological activity screening. This, coupled with high-throughput screening, is a 
useful technique in drug discovery but is rarely used in metallo-drug design. We 
report the optimization and validation of a new combinatorial, coordination-directed 
three-component-assembly reaction for the synthesis of a library of 450 Ru(II)-arene 
Schiff-base (RAS) complexes. These RAS complexes were synthesized in a one-pot, 
on-a-plate format using commercially available starting materials under aqueous 
conditions. The library was screened for their anticancer activity and several cytotoxic 
‘hit’ compounds were identified. Through further validation, structural variation, 
structure-activity-relationship and mode-of-action studies, we identified several 
water-soluble and water-stable ‘lead’ compounds that had low micromolar IC50 values 
in a panel of cancer cell lines. They also demonstrated p53-independent activity and 
did not show cross-resistance to cisplatin in cisplatin-resistant cell lineage, suggesting 
a mode-of-action different from cisplatin. 
Multidrug resistance in many cancer types has impeded the success of 
chemotherapy. One particular mechanism of multidrug resistance is the inherent or 
acquired adaptation of the apoptotic pathway that makes cancer cells resistant to 
apoptosis. Since most clinically approved anticancer drugs act by inducing apoptosis, 
finding new drugs that induce alternative forms of programmed cell death becomes an 
attractive strategy to overcome multidrug resistance. In light of this, we further 
investigated the mode-of-action of the ‘lead’ compounds and their ability to induce 
 xiv 
non-apoptotic cell deaths. We identified two structurally-similar compounds, RAS-1H 
and RAS-1T that induced non-apoptotic cell death via pathways distinct for each 
compound. In addition, RAS-1H and RAS-1T were more effective against multidrug-
resistant colorectal cancer cell lines compared to several other clinical drugs, further 
validating the former’s ability to bypass MDR mechanisms. 
We also employed the coordination-directed three-component-assembly 
methodology to design RAS complexes for the inhibition of therapeutic target, 
carbonic anhydrase II. This was met with limited success as addition of the Ru(II)-
arene scaffold did not improve the inhibitory activity of the uncoordinated ligand. 
Employing a similar strategy, we attempted to show that the addition of a Ru(II)-
arene scaffold could confer increased selectivity towards enzymes with multiple 
structurally homologous isozymes. As a proof of concept, we designed RAS 
complexes for the selective inhibition of trypsin or thrombin, two serine proteases 
with high structural homology at the active site. Out of 45 RAS complexes tested, 2 
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Chapter 1  
Introduction 
 
1.1 METAL COMPLEXES IN CHEMICAL BIOLOGY 
Drug development is a multi-million dollar industry. Each year pharmaceutical 
companies spend millions of dollars in the research and development (R&D) of new 
drugs to treat a variety of diseases. However, despite technological advances in recent 
years and the huge spending on R&D, the new drugs released each year by 
pharmaceutical companies remains limited.1 The major focus of pharmaceutical 
companies’ R&D efforts has been on organic drug molecules. Their syntheses, 
structural modifications and efficient screening for biological activity are tedious and 
time-consuming. Moreover, organic molecules built based on a ‘carbon scaffold’ have 
very limited structural diversity. Out of the 24 million organic molecules registered 
under the Chemical Abstract Service (CAS) Registry, half could be classified with 
just 143 scaffolds, a small number compared to the number of molecules being 
classified.2 Also, 5000 compounds in the Comprehensive Medicine Chemistry (CMC) 
database were analyzed for diversity in topological shapes and half of them belonged 
to only 32 shape classification.3 The problem with this limited structure diversity is 








Chemical spaces could be visualized as a three dimensional space and occupying 
these spaces are chemicals with various physical and chemical properties such as 
solubility, hydrophobicity, melting/boiling point, size, geometry, etc. Molecules with 
very similar properties would occupy places close to each other and molecules with 
largely differing properties would occupy places far apart in these chemical spaces. 
To have unexplored ‘biologically relevant chemical space’ would mean that 
molecules with biologically relevant properties that would otherwise occupy these 
spaces have not been discovered. These unexplored ‘spaces’ may contain many 
promising drug candidate as compared to ‘spaces’ that are largely covered by current 
organic scaffolds. Exploring these uncharted ‘spaces’ could help accelerate the drug 
discovery process as new molecules with unique structures and mode-of-actions are 
being discovered. 
One alternative to the traditional organic drug-discovery is a metal-based approach. 
The discovery of the first metallo-drug cisplatin and its subsequent use for cancer 
treatment has shown that metal-containing compounds could, in fact, be used as 
therapeutic agents and this has led to increased research interest in other transition 
metals-containing compounds.9-10 There are several advantages a metal-based 
approach to drug discovery has over the more traditional organic approach. These 
advantages include (i) a greater structural diversity, (ii) tunable properties and (iii) 
ease of combinatorial chemistry and multicomponent reaction. For the purpose of our 
discussion, ‘drugs’ or ‘pharmacophores’ refer to any molecule with biological activity 
that may potentially be used and is being developed for therapeutic purposes. These 









1.1.1 Structural diversity of metal scaffolds 
The limited structural diversity of organic molecules could be explained by the 
intrinsic limitation of carbon atoms as structural scaffolds. Typically, carbon atoms 
are only able to form molecules with linear, trigonal planar or tetrahedral geometry 
(depending on the degree of s and p orbital hybridization). In contrast, transition metal 
scaffolds have larger structural diversity. Due to the availability of partially-filled, 
energetically accessible d orbitals (for d-block metals), they are able to form more 
than 4 bonds, which allows them to adopt many different types of geometries not 
accessible to carbon atoms (Fig 1.1). The same ligand and metal combinations could 
also give rise to different geometric ‘cis/trans’ isomers, depending on the position of 
binding and arrangement of the ligands. This also greatly increases the number of 
possible structural isomers. For instance, an octahedral metal center bonded to 6 
different substituents could have up to 30 different stereoisomers as compared to the 
maximum of 2 that a tetrahedral carbon bonded to 4 different substituents could have. 
This larger structural diversity gives metal scaffolds an advantage over carbon 
scaffold in the design of molecules with unique shape, which makes exploration into 
uncharted ‘biologically-relevant chemical spaces’ possible.  
 








Meggers and his team were one of the first few to exploit this structural diversity of 
transition metal scaffolds. Using a coordination-directed approach, they discovered 
highly selective, organoruthenium protein kinases inhibitors with novel structures.11 
They made structural variations to Staurosporine (a non-selective inhibitor) by adding 
a Ru metal scaffold. Of the many of modified structures studied, a select few were 
found to have higher and more selective inhibitory activity.4, 12 One such example is 
(S)-HB1052 (Fig 1.2), a selective low nanomolar (IC50 = 0.5 nM) inhibitor of Pim-1, 
one of the 518 protein kinases encoded by the human genome.13  
 
Figure 1.2: Selective organoruthenium protein kinases inhibitors with novel 
structures. 
 
In many cases where the ligands are inert to substitution by biomolecules, the metal 
center only acts as a way to organize its ligand into a fixed geometry and does not 
interact directly with the biological target. Hence, the metal center does not have a 








metallo-enzyme inhibitors, where the overall structure of the inhibitor determines its 
binding affinity to the active site. 
1.1.2 Tunable properties of metals 
Metals possess several tunable properties such as redox activity, ligand exchange 
kinetics and Lewis acidity, that could be exploited in the drug design process. The 
ability of metal to adopt different stable oxidation states could give rise to different 
Lewis acidity and “hardness” and hence, affinity towards different types of ligand. 
The oxidation states of the metal could also influence ligand exchange kinetics, 
preferred geometry and overall charge of the molecule. 
This ability to adopt different oxidation states has been exploited in the design of Pt 
anticancer drugs. Pt(II) complexes have a d8 electronic configuration that leads to a 
preference for 4-coordinate square planar geometry. On the other hand, its Pt(IV) 
counterpart has a d6 electronic configuration that prefers to adopt a 6-coordinate 
octahedral structure. In addition, Pt(IV) complexes are also known to be more inert 
towards ligand exchange compared to their Pt(II) counterparts which allows them to 
act as ‘prodrugs’. These Pt(IV) prodrugs are reduced intracellularly to give the active 
Pt(II) pharmacophore. The additional coordination sites of Pt(IV) also allow the 
coordination of ligands with inherent biological activity or target-sites binding 
affinity.14 This predictability in structural preference, ligand exchange kinetics and 









Figure 1.3: Examples of Pt (II) and Pt (IV) anticancer drugs. Cisplatin and 
Oxaliplatin are FDA-approved for treatment of various types of cancer.15 Iproplatin 
went through phase III clinical trials.16 Satrapatin is currently undergoing clinical 
trials.17 
 
1.1.3 Ease of combinatorial chemistry and multicomponent reaction 
The third advantage metal scaffolds have over carbon scaffolds is the ease of 
building libraries of compounds using combinatorial chemistry and multicomponent 
reactions. Organic reactions typically involve harsh conditions such as high 
temperatures or long hours. Even using the combinatorial approach, it could take a 
long time to perform structural variations to prepare a library for screening against 
therapeutic targets. In contrast, coordination of metal centers to their ligands takes 
place under less stringent conditions and ligand exchange reactions typically occur in 
a predictable manner. Most air and water-stable metal complexes could be formed just 
by mixing of the organic ligands and the metal precursor in a suitable solvent at 
mildly elevated or even at room temperature.  Hence, just by mixing and matching of 
different ligands and metal centers, a large compound library could be synthesized for 









Figure 1.4: Structural variations by mixing and matching of ligands with metal 
precursor. 
 
This combinatorial and multicomponent approach is commonly exploited in the 
synthesis of metal complexes for catalysts and materials.18-20 However, there has been 
little reported use of this same approach for the synthesis of metallo-drugs. A recent 
study used such a combinatorial approach combined with high-throughput screening 
(HTS) to discover a highly active and strongly apoptotic Ru complex with relative 
ease and short time frame.21 The author described the use of a simple two-step ligand 
exchange reaction to synthesize over 500 compounds for screening and identification 
of a potential anticancer drug (Fig 1.5a,c). The synthesis and screening were done in a 
high-throughput method using 96-well plates (Fig 1.5b). Following initial screening 
and additional structure-activity relationship (SAR) studies, they were able to identify 
a strongly apoptotic compound, complex 1, which had an LC50 of 1.3 µM against 
HeLa Cells (Fig 1.5d). Its apoptotic properties were further confirmed by other tests, 









Figure 1.5: Discovery of a strongly apoptotic compound using a plate-format 
combinatorial approach. (a) Reaction Scheme. (b) Photo of a plate with a different 
Ru complex in each well. (c) Examples of ligands used. (d) Complex 1. 
 
There have also been a number of reports of one-pot multicomponent reactions for 
the preparation of metal complexes. A series of ferrocenyl and ruthenocenyl 
thioamide derivatives was synthesized using a one-pot three-component reaction.22 
Similarly, a series of alkali metal thioselenophosphinates was prepared using a one-
step four-component reaction.23 In another study, W(VI) halides complexes were 
generated in-situ and screened for potent olefin metathesis catalysts.24 Nevertheless, 
to the best of our knowledge, there have been no reported studies on the use of 
coordination-directed multicomponent reaction for the purpose of drug discovery. 
This remains an area of research with huge potential but is largely unexplored. 
1.1.4 Use of ruthenium in drug-discovery 
Special considerations are needed for the choice of metal in the design of 
biologically active complexes. Not all metals could be used as metal scaffold for drug 
design due to reasons such as acute toxicity, instability or general lack of chemical 








considered for use in coordination-directed drug design. Ru is particularly suitable for 
use in coordination-directed drug design;4 First, Ru has the ability to form 
coordination bonds that are substitutionally inert.25 For instance, octahedral Ru(II) 
complexes adopt a kinetically inert d6 low-spin configuration which is enhanced by 
the presence of strong field ligands. Moreover the use of chelate ligands could be 
employed to give thermodynamic stability to the target complex (chelate 
effect/entropy effect). Hence, with the use of the right ligands, it is possible to tune 
both the kinetic and thermodynamic stability of the target Ru complex, making such 
Ru complexes less susceptible to ligand substitution in biological conditions. Second, 
Ru has relatively low systemic toxicity as compared to other heavy metals. In cancer 
cells, this is particularly due to their rapid growth and increased need of Fe. This 
results in the upregulation of Fe-uptake proteins, Transferrin, and an increased uptake 
of cytotoxic Ru complexes compared to healthy cells, since Ru (which share 
similarities to iron) is uptake via Transferrin as well.26 Lastly, Ru chemistry is well 
understood making it possible to accurately predict the synthetic product during 
synthesis. These factors combined have encouraged much research in Ru-based 
pharmaceuticals.27  
 





























Research into Ru complexes as therapeutic agents have already begun to show 
promising results. Some of the fruits of such research are Ru(III)-containing NAMI-
A, receiving favorable evaluations in clinical trials, and KP1019, showing promising 
results in preclinical studies (Fig 1.6).28-29 It has been proposed that these compounds 
act as ‘prodrugs’ and undergo in vivo reduction to their active Ru(II) species.26  
1.2 RUTHENIUM (II)-ARENE COMPLEXES IN CHEMICAL BIOLOGY 
AND MEDICINAL CHEMISTRY RESEARCH 
One class of Ru(II) complexes, namely Ru(II)-arene complexes, has been of much 
interest to researchers in the field of metallo-drug design, due to their stability, ease of 
synthesis and possible tuning of pharmacologically relevant features such as solubility 
and hydrophobicity. These complexes typically adopt a pseudo-octahedral geometry, 
which resembles the shape of a three-legged piano stool (Fig 1.7). In this section, the 
most recent synthetic strategy and applications of mononuclear Ru(II)-arene 
complexes in chemical biology and medicinal chemistry are discussed, with special 
focus on anticancer therapeutics. Many of these studies have demonstrated their 
therapeutic properties or inhibitory activity towards enzyme targets implicated in 
cancer progression. This makes Ru(II)-arene complexes a promising choice for 










Figure 1.7: General structure of Ru(II)-arene complexes and design considerations.  
1.2.1 Accessing the ruthenium (II)-arene scaffold 
Comprehensive synthetic strategies for many types of Ru(II)-arene complexes have 
been published.30 Hence, we limited our discussion to the synthesis of structures most 
often seen in the field of chemical biology and medicinal chemistry. Biologically 
active Ru(II)-arene complexes are usually accessed via synthetic route involving the 
[(η6-arene)RuCl2]2 precursor (Fig 1.8). This precursor can be synthesized using 
several methods. The first method (a) involves the birch reduction of ethylbenzoate to 
its cyclohexadiene analogue, followed by a simultaneous reduction-oxidation of the 
hydrated RuCl3 and cyclohexadiene to give the dimer [(η6-ethylbenzoate)RuCl2]2.31 
Subsequent arene exchange (b) could be performed with a wide-range of relatively 
electron-rich substituted benzenes to achieve the desired [(η6-arene)RuCl2]2 precursor. 
This is a versatile method as a huge range of substituted benzene is tolerated. 
However, Birch reduction may be technically challenging to perform as it involves 
the use of toxic and corrosive liquid ammonia and highly reactive Na/Li metal. 
Alternatively, commercially available substituted cyclohexadiene could be purchased 








commercially available substituted cyclohexadienes than there are substituted 
benzenes. The last method (e) involves arene exchange of [(η6-cymene)RuCl2]2, 
which  is only feasible for highly substituted benzenes such as hexamethylbenzene or 
triisopropylbenzene and involves stringent reaction conditions.34-35 Nevertheless, it is 
a frequently used method for the synthesis of [(η6- hexamethylbenzene)RuCl2]2  and 
[(η6-1,3,5-triisopropylbenzene)RuCl2]2,  as [(η6-cymene)RuCl2]2 could be easily 
obtained (d) in high yield from cheap and commercially available starting materials. 
After obtaining the desired [(η6-arene)RuCl2]2, the Ru(II)-arene complexes could be 
synthesized by reaction with stoichiometric amount of monodentate or bidentate 
chelating ligands.  








A large number of studies focusing on understanding drug targets and binding 
modes, drug transport and cellular accumulation has led to an increased understanding 
on how the different parts of the Ru(II)-arene complex contribute to its overall 
activity.36-41 The choice of arene, monodentate ligand X and chelating ligand YZ, is a 
means of modulating the overall physical, chemical and pharmacological properties of 
the Ru(II) complexes (Fig 1.7). The facially-bound neutral arene ligand stabilizes the 
+2 oxidation state of the Ru metal center and modulates the hydrophobicity of the 
complexes depending on the degree of alkyl/aryl functionalization. This in-turn 
modulates the cellular accumulation of the complexes. The arene could also be 
functionalized with targeting groups. The degree of π-donation from the arene could 
also influence the lability of the monodentate ligand X. In addition, the identity of X 
has a direct effect on its rate of hydrolysis. This influences the degree of Ru binding 
towards DNA or proteins, which has a direct effect on the cytotoxicity of the 
complex. Chelate ligands YZ are stable to hydrolysis and are often used in the design 
of Ru(II) complexes. When they are employed, they typically have the greatest 
influence on the activity and mode-of-action of the complex and are the main sites of 
interaction with the biological targets. The overall charge of the complexes would 
depend on the choice of neutral or charged ligands X and YZ. This intricate 
understanding of the Ru(II)-arene structure has led to the ability to rationally design 
new and potent drug candidates.  
1.2.2 New drug candidates with novel structures and mode-of-action 
First generation metallo-drugs such as cisplatin and other Pt (II) complexes often 
induce cell death by targeting nuclear DNA, causing DNA damage by forming 
adducts and leading to p53 activation, cell cycle arrest and apoptosis.42 In response to 








increased DNA repair or p53 loss-of-function.43 Therefore, the identification of new 
drug candidates with varied cellular targets and modes of cell killing may be a way to 
circumvent drug resistance. One approach to the identification of new drugs is the 
‘blind approach’. New complexes are synthesized using starting materials without any 
known biological activity and screened for anticancer activity. In particular, many 
Ru(II)-arene complexes with novel structures and mode-of-action have been 
identified by the blind approach and there are ongoing in vitro and in vivo studies to 
elucidate their biological targets and modes of action. Two of the most studied Ru(II)-
arene complexes are RAPTA-C44 discovered by Dyson’s lab and RM17545 discovered 
by Sadler’s lab (Fig 1.9). 
RAPTA-C is part of a family of water soluble and air-stable Ru(II)-arene complexes 
synthesized using an novel mono-dentate 1,3,5-triaz-7-phosphatricyclo-
[3.3.1.1]decane (pta) ligand. The initial batches of RAPTA complexes demonstrated 
low in vitro toxicity unlike cisplatin. Nevertheless, several examples including 
RAPTA-C showed strong in vivo anti-metastatic activity while having a limited effect 
on the primary tumor.46 More recent studies showed that RAPTA-C was also able to 
inhibit the growth of primary tumor.47 It significantly reduced the growth of A2780 
ovarian and LS174 colorectal carcinoma primary tumors in separate xenograph tumor 
models. In both models, the observed anti-angiogenic effects were in agreement with 
previously established anti-angiogenic activity of RAPTA-C.48 
Results from detailed molecular mechanism studies suggested that RAPTA-C is 
multi-targeting and exerts its anticancer activity through a combination of factors. 
RAPTA-C demonstrated pH-dependent DNA damage, selective towards the hypoxic 
environment around cancer cells.49 It was known to inhibit enzyme targets that are 








recent study using ICP-MS and X-ray crystallography demonstrated that RAPTA-C 
bound preferentially to the histone protein and not DNA in a nucleosome core 
particle.51 Thus, the activity of RAPTA-C might arise as a combination of having 
several cellular targets. Further elucidation showed that RAPTA-C induced p53-
dependent G2/M phase cell cycle arrest and apoptosis.52 The high selectivity towards 
rapidly growing cancer, excellent in vivo activity against both primary tumor and 
metastases and its unique mode-of-action makes RAPTA-C a promising drug 
candidate for clinical studies. This has also spurred ongoing research into further 
structural variations of the RAPTA scaffold in the hope of discovering more potent 
and selective anticancer agents.53-58 
 
Figure 1.9: Structure of RAPTA-C and RM175.  
RM175 is another Ru(II)-arene complexes to have undergone detailed in vitro and 
in vivo investigations. RM175 is synthesized using the common chelating 
ethylenediamine ligand. In contrast to RAPTA-C, RM175 demonstrated high in vitro 
toxicity with IC50 in the same order of magnitude as cisplatin.59 SAR studies have 
shown that the rate of hydrolysis of RM175-type complexes has significant 
correlation to their cytotoxicity.60 This suggested that the DNA-binding ability of 
RM175 is crucial to its activity. This was also in agreement with studies showing that 
RM175 has a strong binding preference to DNA (specifically at Guanine residues) but 








same molecular target as cisplatin, it forms distinct type of adduct with DNA which is 
more resistance to DNA repair mechanisms. In addition, RM175 did not show any in 
vitro or in vivo cross-resistance in cisplatin-resistant A2780cisR ovarian carcinoma. 
This indicated a different mechanism of action as compared to cisplatin.59 Further 
molecular mechanism studies showed that RM175 induced p53-dependent cell cycle 
arrest and apoptosis, which were absent in p53-null subtypes.62 RM175 also 
demonstrated excellent in vivo anti-tumor and anti-metastatic activity similar to 
RAPTA-C.59, 63 
The success of RAPTA-C and RM175 has encouraged much research into the use 
of Ru(II)-arene scaffold for anticancer drug design. A wide range of ligand types has 
been used, with preference for N-coordinating ligands (Fig 1.10). These complexes 
were evaluated in vitro and their cross-resistance with cisplatin or oxaliplatin in 
resistant cell lines, p53-dependence and mode-of-action were among some of the 
properties investigated. A small number of the complexes were also evaluated for 
their in vivo activity. 
Ru(II)-arene complexes (1), (2), (3) and (4) were cytotoxic due to their ability to 
target DNA.64-67 (1), synthesized using diketonate and aminophosphine ligands, was 
found to be highly toxic towards pancreatic and breast cancer cell lines and acted by 
inducing apoptosis.64 The hydrolysis of the Ru-phosphine bond was required before 
binding to DNA. Structural variations also showed correlation between its activity 
and the rate of hydrolysis of the Ru-phosphine bond. (2) was isolated in the aquated 
form, since its chloro- analogue was not active due to its slow hydrolysis rate.65 It had 
moderate activity against ovarian cancer but not breast cancer cell line. In addition, it 
was not cross-resistant with cisplatin, having even better activity in cisplatin-resistant 








and intercalation.66 It showed modest activity against breast cancer and ovarian cancer 
cells. Its activity was similar in both wild type and cisplatin-resistant ovarian cancer. 
(4) interacted with DNA mainly by intercalation and its activity was not dependent on 
its rate of aquation.67 It showed modest efficacy in cervical, breast, kidney and 
colorectal cancer cell lines and inhibited cell viability via p53-dependent cell-cycle 
arrest and apoptosis. This was consistent with the downstream effects of DNA 
damage. Other cytotoxic Ru(II)-arene complexes that targeted DNA have also been 
reported.68-71 
 








Other complexes’ activity did not depend on their ability to interact with DNA. 
Both (5) and (6) were unable to interact with DNA and their activity were presumably 
due to interactions with other bio-targets.72-73 (5) had modest activity against 
cisplatin-resistant PC3 prostate cancer.72 It also prevented cell migration in a wound-
healing assay. (6) demonstrated excellent activity in a panel of cell lines, including 
MDA-MD-231 triple-negative breast cancer cells, and induced p53-independent 
apoptosis.73 Moreover, it had excellent in vivo activity against MDA-DM-231 
xenograft tumor. It was also found to selectively accumulate in the tumor and not the 
kidney or liver.   (7) and (8) only bound to DNA after the dissociation of the pyridine 
ligands by photo-activation.74-75	However, the compounds were found to be cytotoxic 
even prior to photo-activation. It was not known if photo-activation further enhanced 
their activity. Nevertheless, their structure serves as a starting point for the design of 
photo-activated Ru(II)-arene anticancer drugs.76-78  
The biological targets of other Ru(II)-arene complexes like (9), (10), (11) and (12) 
remained unelucidated.79-83 Nevertheless, they exhibited potent in vitro activity. The 
mode-of-action of (9) was strongly dependent on its structure.79 All structures were 
active towards a panel of ovarian, lung, breast and colorectal cancer, induced cell 
cycle arrest and apoptosis. However, only the iodido- analogues demonstrated p53-
independent activity and did not show cross-resistance with cisplatin or oxaliplatin; 
the chloro- analogues demonstrated p53-dependent activity and lower potency in 
cisplatin- and oxaliplatin-resistant cell lines. This highlights how small changes to the 
structure could have significant effect on the mode-of-action. (10) induced significant 
DNA damage as seen in the comet assay but its direct interaction with DNA was not 
studied.80 It had anticancer activity that was not cross resistant with cisplatin, induced 








complexes (11) and (12) with perfluoroalkyl-modified ligands also exhibited 
structural-dependent properties. The longer chain (11) required heat activation; it was 
non-toxic at physiological temperature of 37˚C but highly toxic at 42˚C against 
ovarian, breast and lung cancer cell lines.81 In contrast, the shorter chain (12) did not 
show the same discrimination but was toxic at both temperatures. Further studies 
based on the structure of (11) could yield more thermoactive drugs for targeted 
therapy. In later studies, (12) underwent further in vitro and in vivo investigation.82-83	
It was found to be selectively toxic towards A2780 compared to MDA-MD-231. 
Nevertheless, it did prevented MDA-MD-231 cell migration in a wound-healing assay 
and demonstrated greater anti-angiogenetic activity than RAPTA-C. 
Many more cytotoxic Ru(II)-arene complexes have been reported. They have been 
synthesized using a wide range of mono- and bidentate ligands that include, 
bipyridine- and imidazole-based ligands,84-86	 bithiazole,87 Schiff-base,88 maleimide,89 
alkylphenylsulfide or sulfoxides,90-91 mercaptobenzothiazole, β-ketoamine,92-93 and 
other less commonly used ligand types.94-99 
1.2.3 Bio-catalytic drug candidate 
One strategy of targeting cancer cells is by further disrupting the redox balance 
within the cancer cells. In a normal cell, reactive oxygen species (ROS) and reactive 
nitrogen species (RNS) are part of the signaling pathway of cellular processes and 
their levels are tightly modulated by various oxidants and antioxidants.100 In contrast, 
cancer cells are constantly under oxidative stress due to the disruption of this 
regulation.101 This makes cancer cells more susceptible to perturbation caused by 
redox active therapeutic agents, which allows them to be used for selective targeting 
of cancer cells. In this aspect, metal complexes are advantageous over their non-redox 








reactions within the cell should be given special consideration.102-103 Ru(II)-arene 
complexes have been reported to catalyze reactions implicated in cellular redox 
modulation (NAD+ ßà NADH; GSH ßà GS-SG).104 However, a limited number 
of such studies have been able to demonstrate the translation of this catalytic function 
to anticancer activity. Two such reported Ru(II)-arene complexes are (13) and (14) 
(Fig 1.11).105-106  
The cytotoxic complex (13) caused an increase in oxidative stress by catalyzing the 
oxidation and deactivation of antioxidant GSH to GS-SG, which led to the increase in 
cellular ROS.105 The quenching of ROS with N-acetylcysteine (NAC) resulted in an 
increase in cell viability, suggesting that the catalytic ability of (13) was responsible 
for its low micromolar IC50 in A2780 ovarian and A549 lung cancer cells. 
 
Figure 1.11: Examples of biocatalytic anticancer Ru(II)-arene complexes. 
In contrast, (14) induced reductive stress in the presence of a hydride source.106 (14) 








cytotoxicity increased 14-fold in the presence of formate, a hydride source required 
for the reduction of NAD+ to NADH. Indeed, co-treatment of (14) and formate 
induced a corresponding reduction in cellular NAD+ /NADH ratio and enhancement 
in cytotoxicity, in a manner that was strongly dependent on the formate concentration. 
ROS levels also decreased, presumably due to the decrease in oxidant NAD+. In 
addition, (14) did not induce the classical hallmarks of intrinsic apoptosis. This 
suggest a distinct mechanism of action as compared to cisplatin or other Ru(II)-arene 
complexes discussed so far, which may have significant implications in the treatment 
of drug-resistant cancers. 
1.2.4 Conjugation to biologically active or targeting ligands 
Another approach commonly used for the design of Ru(II)-arene anticancer agents 
involves the conjugation of bioactive ligands to the Ru(II)-arene scaffolds. These 
ligands often display antioxidant, anti-inflammatory, antimicrobial, antiviral, 
antifungal or anticancer activity. Some of the commonly used bioactive ligands are, 
curcumin derivatives,107-109 paullones,110-116 flavonoids,117-120 and 
thiosemicarbozones,121-125 though a diverse range have also been reported.126-134 In 
contrast to the ‘blind approach’, the chances of discovering active anticancer 
complexes are much higher with this approach.  
For instance, a class of Ru(II)-arenes complexes based on paullones, potent CDK 
inhibitors, were tested for anticancer activity.110 This class of complexes, including 
(15), demonstrated good in vitro activity and inhibited DNA synthesis. In addition, 
(15) displayed a concentration-dependent dual mode-of-action; it induced G0/G1 
phase cell cycle arrest at low concentration and apoptosis at high concentration. 








flavonoid, 3-hydroxyflavone.117-118 Although the conjugated complexes had similar in 
vitro activity with the unconjugated 3-hydroxyflavones, the former had stronger 
topoisomerase IIα inhibitory activity. More importantly, the conjugation of the Ru(II) 
scaffold greatly increased solubility and provided an additional site of interaction with 
DNA. These improvements make the Ru-conjugated flavonoids advantageous over its 
precursors. In another study, a Ru-conjugated thiosemcarbozone (17) demonstrated 
stronger anticancer activity and displayed a different mode of interaction with DNA 
compared to the unconjugated ligand.121 Larger bioactive ligands have also been used; 
Guanidinoneomycin, an antibiotic with high affinity and selectivity towards RNA, 
was conjugated to the Ru(II)-arene scaffold and tested for anticancer activity.126 The 
conjugated complex (18) was more than 20 times more cytotoxic than the 
unconjugated guanidinoneomycin. However, (18) showed no selectivity towards 
cancer cells, having similar cytotoxicity in breast, prostate cancer cells and primary 
lung fibroblast cells. These examples highlight the possible enhancement or 
modification of activity that could be achieved by conjugating bioactive ligands to a 
Ru(II)-arene scaffold. 
 








1.2.5 Rational Design of Enzyme Inhibitors  
The opposite of the ‘blind approach’ would be to design drugs specifically for 
biological targets implicated in the progression of diseases. Metallo-inhibitors of 
therapeutic enzyme targets would be a small subset of these. The major advantage of 
this targeted approach would be a significant reduction in the physiological side 
effects that comes with non-targeted treatments. In order to achieve this, therapeutic 
enzyme inhibitors need to have both activity and selectivity. As discussed, the 
inherent qualities of transition metal scaffolds make them prime candidate for 
selective inhibitors design. Meggers and his team pioneered this field of transition 
metal enzyme inhibitors.135 He has successfully demonstrated the use of Ru(II) 
scaffold to design highly potent and selective protein kinases inhibitors.13  Since then, 
there have been many attempts to design enzyme inhibitors using transition metal 
scaffolds.135-137 In particular, there have been several examples of Ru(II)-arene 
complexes designed to inhibit specific targets. The design strategies in most cases are 
similar. Typically, organic ligands with known affinity to the target’s active site are 
chosen [affinity motif]. These ligands are then attached to the Ru(II)-arene scaffold 
either via direct coordination or the use of an optional linker [Linker]. In general, 
most have designs that fall into this ‘[Ru(II)-arene]-[Linker]-[affinity motif]’ 
category. Some examples are shown in Fig 1.13.  
A series of Ru(II)-arene complexes were synthesized using 
phenyldifluoromethylphosphonic acid moiety for the selective targeting of protein 
tyrosine phosphatase (PTP)-1B.138 Among them, (19) showed a 10-fold selectivity for 
therapeutic target PTP-1B over its non-therapeutic isozyme TC-PTP. In contrast, the 








suggesting that the observed selectivity was conferred by the Ru(II)-arene scaffold. 
Similarly, (20) selectively inhibited human adenosine receptor 3 (hA3), implicated in 
a variety of disease, but had no inhibitory activity towards its non-therapeutic 
isozymes, hA1, hA2A and hA2b.139 Changing the pta ligand to a chloride increased its 
potency but decreased its selectivity towards hA3, highlighting the effect of structural 
variations on activity and selectivity.  
 
Figure 1.13: Examples of Ru(II)-arene enzyme inhibitors. 
In some cases, the addition of the Ru(II)-arene scaffold did not improve activity or 
selectivity of the [affinity motif]. Ru(II)-arene scaffold was attached to a 
phenylsulfonamide moiety via a linker for the inhibition of human carbonic anhydrase 
(hCA) II.140 The attempt was met with limited success as the uncoordinated [linker]-
[affinity motif] was more active than the coordinated (21). In separate studies, 
ethacrynic acid was conjugated to the Ru(II)-arene scaffold at 2 different positions for 
the inhibition of glutathione-S-transferase (GST) P1-1;141-142 It was directly 
conjugated to the Ru(II)-scaffold in (22) and indirectly via the arene ligand in (23). In 
both cases, only marginal improvement to the activity was observed compared to the 








for (23) compared to the uncoordinated ligand.141 The marginal increase in GST P1-1 
inhibition could have been sufficient to improve its anticancer activity. 
There have also been reports demonstrating successful translation of selective 
inhibition into actual therapeutic application. A Ru(II)-arene β-carboline complex 
(24) was synthesized as a potent inhibitor of cyclin dependent kinase (CDK) 1, which 
was implicated in cell cycle regulation.143 The inhibition of CDK1 triggered both 
growth arrest at the G2/M phase and downregulation of CDK1 and cyclin B1. This 
was translated to a more potent and selective antitumor activity compared to the 
uncoordinated ligand. 
Other Ru(II)-arene complexes have been synthesized as enzyme inhibitors with 
varying levels of success.144-148 
1.3 KEY CHALLENGES AND EXPLOITING ALTERNATIVE MODES OF 
CELL DEATHS TO OVERCOME MULTIDRUG RESISTANCE   
Chemotherapy remains one of the major treatment options for many cancer types. 
Based on the 2011 statistics consolidated by the American Cancer Society, 
chemotherapy was used in a significant proportion of many early stage cancers in the 
USA either as a stand-alone or combination therapy.149 The percentage is even larger 
for the treatment of late stage cancers (stage III and IV); as much as 64% of all colon 
and female breast cancer and 82% of all rectal cancer cases involved some form of 
chemotherapy.149 However, the effectiveness of chemotherapeutic treatments has 
been greatly diminished150 due to the inherent or acquired multidrug resistance 
(MDR) in many cancers such as gastric cancer, the third and fifth leading cause of 








MDR mechanisms may vary between different cell types. One particular MDR 
mechanism in many cancers has been determined to be defective or selective 
adaptation of the apoptotic pathways.155-158 These includes change in expression of 
pro-/anti-apoptotic genes such as BAX, BAK, Bcl-2 and Bcl-xL, inactivation of 
tumour-suppressor p53, and decreased or loss of expression of apoptosis executor 
caspases.159-160 BAX (pro-apoptotic), Bcl-2 and Bcl-xL (anti-apoptotic) are members 
of the Bcl-2 family of proteins that govern the mitochondrial outer membrane 
permeabilization (MOMP) process, a part of the intrinsic apoptotic pathway.161 
Hence, change in expression of these proteins could affect the sensitivity of cells to 
apoptosis-inducing agents. Fibroblasts deficient in BAX and BAK have been shown 
to be resistant to apoptosis,162 and overexpression of Bcl-2 prevents apoptosis induced 
by most clinical drugs.163-164 Similarly, p53 is implicated in the apoptotic pathway and 
is usually activated in response to DNA damage. It is also involved in the regulation 
and activation of target genes such as Bcl-2 and BAX.165 Inactivation or loss of 
expression of p53 have been shown to reduce the sensitivity of cells to apoptotic 
drugs.166-167 Cancer cells with reduced expression of caspases are also known to be 
apoptosis-resistant.168-170 
Given that most clinical anticancer drugs act by inducing apoptosis as the 
primary mode-of-action,171-172 it is not surprising that the success rates of 
chemotherapy have been less than desirable. In light of this, finding drugs that target 
cancer via distinct pathways of non-apoptotic programmed cell death (PCD) is an 
attractive strategy to circumvent the prevalence of MDR. Currently, several 
alternative PCDs that are morphologically different from apoptosis and occur via the 
activation of different cellular pathways have been identified. These alternative (non-








checkpoints resulting in mitotic failure and cell death;173 paraptosis, characterized by 
cytoplasmic vacuolation and mitochondrial swelling, morphological features distinct 
from apoptosis;174 necroptosis, a form of programmed necrosis mediated by 
RIP1/RIP3 kinase complex;175 ferroptosis, an iron-dependent form of programmed 
necrosis;175 and autophagy, cell death via ‘self-digestion’ by autophagosomes,176 
although autophagy could also be employed by the cells as a pro-survival 
mechanism.177 Interesting, these alternative PCDs all lack the induction of caspases, 
which is a distinct hallmark of apoptosis.178 Hence, caspase induction by anticancer 
complexes could be a starting point of investigation for the identification of 
alternative PCD-inducing agents.  
 
Figure 1.14: Types of programmed cell death. 
A handful of metal complexes have displayed the ability to kill cells via alternative  
PCDs. A class of Cu(II) thioxotriazole complexes and a Cu(I) triazole-phosphine 
complex have demonstrated the ability to induce paraptosis in several cancer cell 
lines.179-181 More recently, 2 Re(V)-oxo complexes were reported to induce cell death 








induce autophagic cell death.183-185 To the best of our knowledge, only one other Ru 
compound has been reported to induce alternative PCD.186 Therefore, the discovery of 
Ru(II)-arene complexes that induce alternative mode of PCD would contribute to the 
ongoing fight against MDR. 
1.4 PROJECT FOCUS AND THESIS ORGANISATION 
Transition metal scaffolds are advantageous over carbon scaffold for the design of 
drug candidates that could potentially access the uncharted ‘biologically-relevant 
chemical space’. Moreover, the ease of applying combinatorial chemistry and 
multicomponent reaction to metal complexes makes them suitable for the synthesis of 
complex libraries. This, combined with HTS, could lead to a more efficient method of 
drug discovery. However, there have been limited studies on the application of 
multicomponent reactions and HTS for metallo-drug discovery. This remains a 
promising area of research that should be exploited. 
Most clinical anticancer drugs act by inducing apoptotic cell death. Many of the 
reported metallo-drug candidates, including most of the discussed Ru(II)-arene 
complexes, also induced apoptosis. This presents a problem for the treatment of MDR 
cancers as apoptosis-resistance is one of the mechanisms of MDR. There is a need for 
new drugs that are able to induce alternative PCDs for the treatment of apoptosis-
resistant cancers. 
Thus, the development of a simple and efficient multicomponent synthesis 
methodology that could be easily translated into a suitable format for HTS, could 
result in the quick identification of biologically active Ru(II)-arene complexes with 
unique modes of actions. This could potentially address some of the current gaps in 








With this in mind, the primary focus of the project is to (i) develop a coordination-
directed multicomponent reaction methodology, (ii) show that it could be used for the 
efficient synthesis and screening of a Ru(II)-arene complex library for anticancer 
activity and (3) identify Ru(II) complexes that could induce alternative PCDs via 
novel mode-of-action. The secondary focus is to identify active and selective enzyme 
inhibitors. Enzyme targets were chosen for their therapeutic value. 
The thesis is organized into 2 sections; Section A (Chapter 2 – 5) focuses on the 
process of anticancer drug discovery, and Section B (Chapter 6 – 7) focuses on the 
design and identification of potent and selective enzyme inhibitors. All experiments, 
unless otherwise mentioned, are performed by me. 
In Chapter 2 and 3, we describe the design and optimization of a one-pot three-
component assembly reaction methodology for the synthesis of a library of Ru(II)-
arene Schiff-base complexes. This library was screened in a high-throughput manner 
to identify cytotoxic ‘hit’ compounds. The ‘hit’ compounds were further validated 
and a potent ‘lead’ compound was identified. The work discussed in these chapters is  
published and were reproduced in parts with permission from [Chow, M. J.; Licona, 
C.; Wong, D. Y. Q.; Pastorin, G.; Gaiddon, C.; Ang, W. H.*, Discovery and 
Investigation of Anticancer Ruthenium-arene Schiff-base Complexes via Water-
promoted Combinatorial Three-component Assembly. J. Med. Chem. 2014, 57 (14), 
6043-6059]. Copyright 2014 American Chemical Society. Flow cytometry data 
presented in Chapter 3 were acquired by Wendy Ong, a final year undergraduate 
student; sample preparations and data analysis were done by me. 
In Chapter 4, we describe the structural variation and SAR studies of the cytotoxic 
‘lead’ compounds. Preliminary mode-of-action studies were performed for  selected 








further investigation. ICP-MS data for [Ru] content in cells were acquired by Daniel 
Wong, PhD student; sample preparations and data analysis were done by me. 
In Chapter 5, we present further molecular mechanism investigation for the two 
selected ‘lead’ compounds. We discuss their distinct mode-of-action and their ability 
to induce non-apoptotic, alternative PCDs. The work discussed in this chapter has 
been prepared as a manuscript for submission [Chow, M. J.;  Licona, C.; Pastorin, G.; 
Mellizer, G.; Ang, W. H.*; Gaiddon, C*, Structural tuning of organoruthenium 
compounds allows oxidative switch to control endoplasmic reticulum stress pathways 
and bypass multidrug resistance mechanisms. Proc. Natl. Acad. Sci. U. S. A. 2015, 
Submitted]. 
In Chapter 6 and 7, we discuss the use of the one-pot three-component assembly 
reaction methodology for the design and synthesis of potent inhibitors of carbonic 
anhydrase II, and selective inhibitors of trypsin vs. thrombin. The work described in 
Chapter 7 was performed by final year undergraduate student, Yap Jian Yu, under 
close supervision. 

















Coordination-Directed Three-component Assembly 




































Three-Component-Assembly Reaction for Library 
Synthesis, Screening and Hit Discovery 
 
2.1 INTRODUCTION 
As discussed, transition metal scaffolds could be uniquely suited for the 
development of potential drug candidates. They could readily accommodate higher 
coordination numbers and thus access different molecular geometries not possible 
with a purely organic framework.1 Transition metal complexes are also endowed with 
tunable properties such as variable oxidation states that are stable under room 
conditions and predictable reactivity based on metal-ligand bonding interactions. 
Since the first successful Pt-containing drug cisplatin was discovered and approved by 
Food and Drug Administration (FDA) for the treatment of testicular and ovarian 
cancer in 1978,2 much research has been directed at uncovering new metallo-drugs 
that are more effective than cisplatin.3-4 This research is beginning to bear fruit with 
Ru-containing NAMI-A receiving favorable evaluations in clinical trials and KP1019 
showing promising results in preclinical studies.5-6 One class of Ru compound in 
particular, namely Ru(II)-arene complexes, has been garnering much interest, with a 
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their inhibitory activity towards enzyme targets linked to cancer. A few examples 
include the antimetastatic RAPTA complexes,7 antitumor [(η6-biphenyl)Ru(en)Cl]+ 
(RM175) scaffold,8 as well as organoruthenium-based paullone complexes.9 These 
studies pave the way for the development of Ru-arene complexes as the next 
generation of metal-based anticancer drugs.  
Yet, discovery of new organoruthenium complexes with the necessary prerequisites 
for therapy is a laborious process involving iterative steps of synthesis, 
characterization, functionalization and testing. For example, good aqueous stability 
and solubility are essential to ensure biocompatibility, but these attributes are not 
easily incorporated into the scaffolds. Combinatorial coordination chemistry and 
multicomponent reactions are potential tools that could generate large libraries of 
diverse compounds for drug screening but they have seldom been applied to metallo-
drug discovery.  
To this end, we designed a water-promoted multicomponent reaction for the 
combinatorial assembly of Ru(II)-arene complexes in aqueous solutions. Using 
water/DMSO system to carry out the assembly, the reaction directly “selects” for 
water-stable complexes of moderate solubility. We report the application of this 
coordination-directed three-component-assembly (3CA) reaction methodology to 
prepare a library of water-soluble Ru(II)-arene Schiff-base (RAS) complexes. We 
performed extensive functional group variations and screened the compound library 
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2.2 RESULTS  
2.2.1 Optimization and validation of a novel one-step three-component-assembly 
reaction in aqueous solvents 
Our approach was to design and optimise a one-pot three-component reaction that 
could be used to synthesize a large library of Ru(II)-arene complexes with ease, 
requiring minimal purification prior to characterization and screening. The reaction 
comprises three components, namely a Ru(II)-arene (RA) precursor, a picoline-2-
aldehyde (PA) and an aniline derivative (AD). Imine condensation between the PA 
and AD forms a Schiff-base ligand that is predisposed for metal chelation. Without 
metal chelation, such ligands are typically poorly stable in aqueous environment due 
to hydrolysis of the imine bond. Incorporation of the RA component yields an 
organoruthenium complex that is stabilized by the electrodonating Schiff-base chelate 
(Fig 2.1). Similar Ru(II)-arene Schiff-base complexes have been reported but they 
have yet been prepared in a manner suitable for library synthesis.10  
 
Figure 2.1: Stabilization of imine using a metallo-“pincer”. 
Thus, 3CA reaction comprises RA with at least 2 accessible coordination sites (via 
labile ligands) that could chelate with Schiff-base ligand from condensation between 
PA and AD, both of which are widely available from commerical sources. 




                                                                                                      Chapter 2 
 
36 
combinatorial fashion in a one-pot reaction to give a library of RAS complexes (Fig. 
2.2). Because the components were initially insoluble in water, complete dissolution 
provided indication of a successful assembly. Reactions that yielded insoluble 
products were assumed to have failed or have led to products that were insufficiently 
soluble to warrant futher studies, and eliminated from the initial library. An initial 
library of 48 RAS complexes were synthesized in D2O and directly characterized with 
1H NMR and ESI-MS without prior work-up or purification. Several complexes were 
analyzed by RP-HPLC to approximate the levels of purity achieved.  
 
Figure 2.2: Combinatorial, three-component assembly of RAS complexes. (a) 
general reaction scheme for RAS complexes. (b) the different functional groups on 
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The 1H NMR spectra typically presented resonances corresponding to the expected 
products with minor observable by-products, indicating that RAS complexes were 
formed almost exclusively (Fig. 2.3a; Appendix A). The RAS complexes exhibited 
two characteristic features: namely, the disappearance of the singlet peak 
corresponding to the aldehyde proton at ca. 10 ppm and the appearance of a singlet 
attributable to the imine proton at 8-9 ppm (a downfield shift from ca. 6 ppm for 
uncoordinated imine). In addition, resonances of the η6-arene protons (for RA = 
toluene, cymene and 1,3,5-triisopropylbenzene) were resolved to distinct peaks due to 
desymmetrization of the arene ligand upon complexation of the Schiff-base at the Ru 
centre. ESI-MS typically revealed only one m/z peak corresponding to the molecular 
[M]+ ions with the characteristic Ru isotopic pattern, further confirming the formation 
of RAS complexes in the 3CA reaction (Fig. 2.3c). RP-HPLC analysis of 7 selected 
RAS complexes from the initial library showed purity levels between 70-90% of the 
crude mixture, which is sufficiently pure for drug screening (Appendix A). The main 
cause of the lower purity is the presence of excess reaction components that were 
added inadvertently and aquation products.  
Structural information was obtained via single crystal X-ray diffraction studies of 
WH-318, with PF6- as the counteranion (Fig. 2.4). The complex adopted an expected 
pseudo “piano stool” structure, with the cymene ligand bonded to the Ru atom as the 
“stool top”. The Schiff-base ligand rotated slightly around N2-C7 to give a “twisted” 
conformation, presumably to reduce the steric interaction with the cymene ligand. 









Figure 2.3: Charazterization of a typical RAS complex. (a) 1H NMR spectrum of 
crude reaction mixture in D2O of representative WH-311 (Fig. 3) without any work-
up or purification; (b) molecular structure and calculated molecular weight of WH-
311 cation; (c) parent molecular peak observed in the ESI-MS spectrum 
corresponding to the expected m/z. 
 
 
Figure 2.4: Molecular representation of WH-318. There are four cationic with 
corresponding anionic PF6- in each unit cell. PF6- anion was omitted for clarity. 
 
At this stage of the methodology development, all complexes were prepared and 
characterized in D2O and thus assumed to be sufficiently water-stable for at least 72 h, 
which encompassed the time of experiment from the start of synthesis to the end of 
characterization. Upon optimization, we noted that a solvent mixture comprising 1:1 
v/v DMSO-d6/D2O to be a more suitable solvent system for 3CA for preparation of 
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Table 2.1: Selected X-ray 
crystallographic data for WH-318. 
Complex WH-318 
Formula RuC23H25N3OClPF6 
Formula weight 640.96 
Temperature [K] 100(2)  
Wavelength [Å] 0.71073  
Crystal size [mm3] 0.24 x 0.12 x 0.10  
Crystal system monoclinic 
Space group P21/n 
a [Å] 9.887(2) 
b [Å] 18.473(4)  
c [Å] 14.002(2)  
α [deg] 90 
β [deg] 104.589(3) 
γ [deg] 90 
V [Å3] 2474.8(9)  
Z 4 
Dc [Mg/m3] 1.720  
µ [mm-1] 0.874 
θ range [deg] 1.86 to 27.50 
no. of unique data 17246 
max., min. transmn 0.9177 and 0.8176 
final R indices R1 = 0.0525 
[I>2σ(I)] wR2 = 0.1214 
R indices (all data) R1 = 0.0823 
 wR2 = 0.1308 
  goodness-of-fit on F2 1.050 
peak/hole [e Å-3] 2.822 and -0.880 
aR = Σ||Fo| - |Fc||/Σ|Fo|, wR2 = [Σ[w(Fo2 - 
Fc2)2]/Σ[w(Fo2)2]]1/2. Goodness-of-fit (GOF) = 
[Σ[w(Fo2 - Fc2)2]/(n - p)]1/2, where n is the 
number of data and p is the number of 
parameters refined. 
 
Table 2.2:   Selected bond lengths [Å] 
and angles [°] for WH-318. 
________________________________ 
Ru(1)-N(1)  2.088(4) 
Ru(1)-N(2)  2.101(4) 
Ru(1)-Cl(1)  2.3976(13) 
N(2)-C(6)  1.293(6) 
N(2)-C(7)  1.425(6) 
N(1)-Ru(1)-N(2)  76.98(15) 
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2.2.2 Mechanistic investigations into formation of RAS complexes 
We performed mechanistic investigation of 3CA reaction to understand the factors 
affecting assembly of the target complexes in order to fully exploit its versatility. 
Several experiments were designed to probe the reaction mechanism and to 
understand how RAS complexes were formed. These experiments were performed in 
deuterated solvents to facilitate immediate 1H NMR analysis (Appendix B). From the 
experimental results, the factors affecting the formation of RAS complexes were 
inferred. 
 Precursor RA exists as a dimer in solid state or when dissolved in non-coordinating 
solvents such as toluene or CHCl3. However, in coordinating solvents such as DMSO, 
MeOH or H2O the dimers are cleaved to form reactive [Ru(arene)(solvent)x+1Cl2-x] 
monomers.11 We theorized that 3CA occurred via these reactive intermediates and 
coordinating solvents were necessary to activate RA. Thus, 3CA was carried out in 
non-coordinating solvent CDCl3, as well as coordinating solvent systems, DMSO-d6, 
MeOD-d4, D2O, 1:1 v/v DMSO-d6/D2O. Components that were soluble in each of the 
solvents were chosen so as to eliminate any possible complications arising from 
difference in solubility. As expected, RAS complexes were not formed at all in 
CDCl3. However, the 3CA reaction was also unsuccessful in coordinating solvent 
DMSO-d6 and MeOD-d4, producing many unexpected side-products. The assembly 
was only successful in solvent systems containing D2O. 
The unexpected observation could be explained by the difference in the reactive 
intermediate formed in DMSO and MeOH compared to that in H2O (Fig. 2.5).11 In 
DMSO and MeOH, mono-solvated species [Ru(arene)(X)Cl2] is formed as the only 
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the mono-solvated [Ru(arene)(H2O)Cl2] to form the di-solvated species 
[Ru(arene)(H2O)2Cl]+. The presence of two labile solvent ligands in the di-solvated 
species allowed rapid reaction with the ligand chelate, giving rise to less side-
reactions and leading to the formation of RAS complexes exclusively. The presence 
of water in DMSO/H2O solvent mixture presumably replaced the second chloride to 
yield the reactive intermediate [Ru(arene)(DMSO)(H2O)Cl]+. This hypothesis was 
further validated by performing the 3CA reaction at different pH conditions (Fig. 2.5). 
We hypothesized that at acidic to neutral pH, the di-solvated [Ru(arene)(H2O)2Cl]+ 
would be formed primarily. At basic pH, the kinetically-inert µ-OH bridged dimer 
[Ru2(arene)2(µ-OH)3]+ would form preferentially, which would hinder 3CA.12-13 Thus, 
3CA was carried out at pH 4.5 and pH 10.0 using deuterated reagents in D2O and 
analyzed by both 1H NMR and ESI-MS. Indeed, the results showed that 3CA was 
hindered in basic pH medium. 
 
Figure 2.5: Formation of intermediate species under different conditions. 
Formation of a di-solvated intermediate is required for the 3CA reaction to work. 
 
Next, we attempted to understand why little or no side-products were obtained in 
3CA by studying the reactivity of the individual components after they had been 
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of the components i.e. (a) PA and AD, (b) RA and PA and (c) RA and AD for 24 h,  
then supplemented each of the reaction mixture with the missing component for a 
further 24 h. Like previous experiments, (a), (b) and (c) were done in deuterated 
solvent D2O so that immediate analysis by 1H NMR was possible. For reaction (a), 
the expected imine ligand was observed after 1 h and majority of the starting material 
had been converted to the imine ligand after 24 h. Subsequent addition of RA yielded 
the expected RAS complex. Reaction (b) yielded multiple products after 24 h. Even 
after C was added, there was further reaction that gave a mixture. Reaction (c) gave a 
mixture of starting materials and products after 24 h. However, addition of PA caused 
the reaction mixture to resolve, yielding a clean 1H NMR spectrum with RAS 
complex being the only product. This suggested that RA reacted reversibly with AD 
and subsequent addition of PA would still drive 3CA reaction to completion. Taken 
together, these experiments explained why the 3CA worked despite possibility of 
forming many different side-products. Firstly, RAS complexes are 
thermodynamically the most stable product due to the “chelate effect”. Secondly, 
RAS complex formation is kinetically favored. At r.t., the reaction between 
[Ru(arene)(H2O)2Cl]+ and PA or AD is slower compared to the reaction between 
[Ru(arene)(H2O)2Cl]+ and the imine ligand (PA+AD). Formation of the imine ligand 








Figure 2.6: Sequence of addition and the resulting products. 
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To validate this hypothesis, we compared 3CA using the more basic aliphatic 
amine, 4-aminomethylbenzenesulfonamide, in place of 4-aminobenzamidine as AD 
component. Although they are both primary amines, aniline is poorly basic by virtue 
of the delocalization of the N-atom lone pair into the aromatic ring. We reasoned that 
aniline would not undergo dative bonding with [Ru(arene)(H2O)2Cl]+ and would not 
directly compete with 3CA. Indeed, 1H NMR analysis revealed that, unlike 4-
aminobenzamidine, 4-aminomethylbenzenesulfonamide reacted irreversibily with RA 
and prematurely arrested 3CA (Appendix B). We further tested the functional group 
tolerance using analogues of PA and AD, and found that functional groups that 
competed for direct Ru-binding, such as thiol and imidazoles, also directly interfered 
with 3CA. Nevertheless, a wide variety of functional groups were tolerated (Fig. 2.2).  
2.2.3 Plate format synthesis, screening and anticancer hit discovery 
To demonstrate the versatility of 3CA, we carried out extensive synthesis of RAS 
complexes using the possible combinations shown in Figure 2.2 in a plate-format. A 
total of 450 compounds were prepared and characterized. Synthesis were performed 
on 96-well plates, in a high-throughput manner with 1:1 v/v DMSO/H2O used as the 
solvent system (Fig. 2.8) to maximize the solubility of the products while maintaining 
some degree of water solubility. DMSO stock solutions of all the starting reagents 
were prepared and mixed in a predetermined order in wells containing an equal 
volume of H2O. Each well gave a different RAS complex at 5 mM in 1:1 v/v 
DMSO/H2O by the end of the reaction, and they were analyzed using ESI-MS. 
Successful assembly was indicated by the molecular [M]+ ion as the predominant m/z 
peak. Out of the 450 complexes synthesized, only one was insoluble and eliminated as 









Figure 2.8: Plate format synthesis of RAS complexes. (a) Diagram of how the 
components were arranged on a 96-well plate. (b) Photo of a  96-well plate containing 
a single batch of RAS complexes. Each well contains a different RAS complex. 
 
For the screening of cytotoxicity, A2780 ovarian cancer cells were used because the 
cells are sensitive to cisplatin treatment and could be transplated to in vivo models as 
xenografts. Cytotoxicity of the assembled RAS complexes were tested at a single 
concentration by using the MTT assay.14 The complexes were first diluted on a 
separate 96-well plate with RPMI 1640 medium to give a final concentration of 25 
µM in medium containing 0.5% (v/v) DMSO. 7 more compounds were insoluble 
under this condition and were removed from the screen. The remaining 442 RAS 
complexes were tested against A2780 cells in quintuplicates and the percentage cell 
viability (CV%) after treatment of each drug was then determined (Appendix C). 
Using this mass screening method, we identified 16 hit compounds with CV% below 








Figure 2.9: Structure of the 16 cytotoxic hit compounds. 16 hit compounds has 
been identified via the 3CA reaction and screening. 
 
To determine if there were any correlation between the hydrophobicity and the 
cytotoxicity of the complexes, CV% could be compared with their clogP. Because 
there are currently no available software to calculate the clogP of these 
organometallic complexes, we developed an alternative standard of measurement by 
adding the clogP values of the arene and the chelate ligand. We assumed that 
differences in their hydrophobicities are largely due the different R, R’ and R’’ 
groups, since all 442 complexes are based on the same core structure. The complex (R 
= R’ = R” = H) was assigned an arbitrary hydrophobicity index (HI) of 0 and the 
remaining complexes were assigned HI values relative to this, calculated from the 
clogP of their ligands. Similar to clogP, the more positive the HI, the greater the 
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(Fig. 2.10a). When HI > 3, CV% decreased significantly. The most cytotoxic RAS 
complexes were relatively hydrophobic, having HI between 4 to 6, suggesting that 
cellular uptake might be via passive diffusion.15  
 
Figure 2.10. Analyses of A2780 cell viability data from the 442-compound 
library. (a) Plot of cell viability % (CV%) against Hydrophobicity index (HI). CV% 
decreases significantly after HI = 3, with the most cytotoxic compounds in the range 4 
< HI < 6 (shaded area). (b-c) Plot of CV% against H-bond acceptor and H-bond donor 
respectively. CV% increases as the number of H-bond acceptor or donor on a 
molecule increases, with most cytotoxic compounds having two or less H-bond 
acceptor or donor (shaded area). (d) Plot of CV% against molecular weight. Most 
cytotoxic compounds appear to have MW between 530 to 660 g/mol (shaded area). 
Each black dot represents one RAS complex. Corresponding cell viability data shown 
is the mean of five replicates. 
 
We further analyzed the cell viability data against additional measures of drug-
likeness from the “Lipinski’s rule of five”16 such as hydrogen bond (H-bond) 
acceptors, H-bond donors and molecular weight, to see if there were any additional 
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of H-bond acceptors and donors, with majority of the cytotoxic RAS complexes 
having less than 2 H-bond acceptors or donors. In addition, the most cytotoxic of 
these complexes tend to have molecular weight between 530 to 660 Da. 
2.3 DISCUSSION 
A one-pot combinatorial 3CA reaction was validated and optimized as a 
methodology to prepare 450 RAS complexes in a high-throughput manner. The 
aqueous reaction conditions directly selects for complexes that exhibit water stability 
and solubility. Fast single concentration screening of these complexes against A2780 
cells led to the identification of several ‘drug-like’ cytotoxic hit compounds. We have 
demonstrated the ease of drug-discovery through the 3CA methodology. It would 
have taken significantly longer to synthesize and test these 450 RAS complexes 
through conventional methods. Further structural analysis also revealed factors that 
correspond to cytotoxicity. This gave us significant information on how to design 
anticancer RAS complexes for future studies. Nevertheless, the identified hit 
compounds need to be further validated to rule out any false positives, which are 
common in HTS. 
2.4 EXPERIMENTAL 
2.4.1 Materials  
All experimental procedures were carried out without additional precautions to 
exclude air or moisture unless otherwise specified. All chemicals and solvents were 
used as received. RuCl3.xH2O was purchased from both Precious Metals Online. [(η6-
benzene)RuCl2]2, [(η6-toluene)RuCl2]2, [(η6-cymene)RuCl2]2, [(η6-
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synthesized according to previously reported protocols.11, 17-19 All other chemicals 
used were purchased from Sigma-Aldrich (Singapore). Penicillin-Streptomycin, 
Thiazolyl blue tetrazolium bromide (MTT) were obtained from Sigma Chemical Co 
(St. Louis, MO, USA). 10x PBS buffer pH 7.4 was purchased from Vivantis Inc., CA, 
USA. HycloneTM RPMI 1640, DMEM medium, Fetal bovine serum (FBS) was 
purchased from Thermo Fisher Scientific Inc., Logan, UT, USA. Ultrapure water used 
was purified by a Milli-Q UV purification system (Sartorius Stedim Biotech SA, 
Aubagne Cedex, France). The human ovarian carcinoma cells A2780 were received 
with gratitude from Prof. Paul Dyson (EPFL).  
2.4.2 Instrumentation 
1H NMR spectrums were obtained using either a Bruker AMX 300, Avance 400 or 
AMX 500 spectrometer and the chemical shifts (δ) were reported in parts per million 
with reference to residual solvent peaks. Electrospray-ionization Mass Spectrometry 
(ESI-MS) spectra were obtained using Thermo Finnigan MAT ESI-MS System.  
2.4.3 HPLC analysis of compound purity  
Determination of the purity of a sample batch of 7 RAS complexes, was done using 
analytical HPLC on a Shimadzu Prominence System equipped with a DGU-20A3 
Degasser, two LC-20AD Liquid Chromatography Pump, a SPD-20A UV/Vis 
Detector and a Shim Pack GVP-ODS 2.0 mm 18 column (5 µM, 120Å, 250 mm x 
4.60 mm i.d.) at r.t. at a flow rate of 1.0 mL/min with detection at 254 nm. The 
gradient elution condition were as follows: 10-30% solvent B for first 10 min 
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2.4.4 Solid state structural determination 
X-ray diffraction data were collected by CMMAC, NUS with a Bruker AXS 
SMART APEX diffractometer using Mo Kα radiation at 223(2) K with the SMART 
suite of Programs.20 Data were processed and corrected for Lorentz and polarization 
effects using SAINT software21 and for absorption effects using the SADABS 
software.22 Structural solution and refinement were then carried out using the 
SHELXTL suite of programs.23 The structure was solved by direct methods. Non-
hydrogen atoms were located using difference maps and were given anisotropic 
displacement parameters in the final refinement. All H atoms were put at calculated 
positions using the riding model. 
2.4.5 General procedure for the synthesis of RAS complexes 
8.16 µmol of RA (Ru-arene dimer), 16.3 µmol of PA (picoline-2-aldehyde 
analogues) and 16.3 µmol of AD (anilines derivatives) were added in one portion and 
suspended in 1 ml of D2O in a 2 mL-graduated microtube with vigourous shaking at 
r.t. for 36 h. The sparingly soluble reactants dissolved at the end of the reaction giving 
coloured solutions. This procedure was repeated with different combinations of the 
three components. Not all combinations were attempted and some of the attempted 
combinations gave insoluble suspensions which were excluded from the library. An 
initial library of 48 RAS complexes was synthesized and they were characterized 
immediately by 1H NMR and ESI-MS without any work-up or purification steps. 
Distinctive signals corresponding to the expected product were observed in 1H NMR 
spectrum in addition to a relatively small amount of impurities (1H NMR and ESI-MS 
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2.4.6 Studies on the effects of solvent on 3CA  
3CA was carried out in 5 different solvent systems (1 mL) namely, DMSO-d6, 
MeOD-d4, CDCl3, D2O and 1:1 v/v DMSO-d6/D2O using [(η6-cymene)RuCl2]2 (10 
µmol), picoline-2-aldehyde (20 µmol) and aniline (20 µmol) with vigourous shaking 
at r.t. for 24 h. Reaction mixtures were characterized immediately by 1H NMR 
without any work-up or purification steps (Appendix B). 
2.4.7 Studies on the effects of pH on 3CA  
[(η6-cymene)RuCl2]2 (10 µmol), 2-picolinaldehyde (20 µmol) and aniline (20 µmol) 
of were suspended in either NaOAc/DOAc/D2O (1 mL, pH 4.5) or 
ND4Cl/ND4OD/D2O buffer (1 mL, pH 10.0) with vigourous shaking at r.t. for 24 h. 
The reaction mixture were characterized immediately by 1H NMR and ESI-MS 
without any work-up or purification steps (Appendix B). 
2.4.8 Studies on the effects of sequential reagent addition on 3CA  
3CA was performed sequentially in 2 separate steps using [(η6-cymene)RuCl2]2 (10 
µmol), picoline-2-aldehyde (20 µmol) and 4-aminobenzamidine dihydrochloride (20 
µmol). Briefly, two reagent components were vigorously shaken in D2O (1 mL) at r.t. 
for 24 h, before the third component was added. Reaction mixture was analyzed by 1H 
NMR following 24 h after addition of third reagent component (Appendix B). 
2.4.9 General procedure for the 450-compound library synthesis on-a-plate for 
screening  
Separate stock solutions containing RA (10 mM), PA (40 mM) and AD (40 mM) 
were prepared in DMSO. The reactions were then carried out on a Microlon® 200 96-
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µL) and ddH2O (100 µL) added to each well in one portion, yielding RAS complexes 
(5 mM) in 1:1 v/v DMSO/H2O (200 µL). Wells containing 1:1 v/v DMSO/H2O were 
included as controls for subsequent experiments. The plates were sealed and 
incubated with shaking at r.t. for 48 h. This procedure was repeated until all 
combinations of the three components were achieved. Only one out of the 450 
products was insoluble and was eliminated from later screening. The remaining 449 
products were analysed by ESI-MS. 
2.4.10 Tissue culture 
The human ovarian carcinoma cells A2780 gastric adenocarcinoma cells was 
cultured in RPMI 1640 medium containing 10% fetal bovine serum (complete RPMI) 
and grown at 37 °C in a humidified atmosphere of 95% air and 5% CO2. Experiments 
were performed on cells within 20 passages. 
2.4.11 Inhibition of cell viability assay (Single concentration screen) 
The anti-proliferation activity of the 442 library of RAS complexes on 
exponentially growing cancer cells were screened using a MTT assay modified from 
one described previously.14 A2780 cells were seeded at 8000 cells/100 μL per well in 
Cellstar® 96-well plates (Greiner Bio-One) and incubated for 24 h. PBS buffer (200 
µL) was added to the wells at the perimeter to prevent evaporation of the media from 
the enclosed wells. After that, cancer cells were exposed to the library of RAS 
complexes in a predetermined order, at a single concentration of 25 µM for 6 h. The 
complex solutions used for the exposure were made by serial dilution of the 
synthesized RAS complexes with RPMI 1640 medium, resulting in a final 
concentration of 25 µM with 0.5% (v/v) DMSO. After the 6 h, the drug-containing 
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were incubated for additional 66 h. At 72 h after drug addition, the medium was 
removed and replaced with MTT solution in PBS (100 μL, 0.5 mg/mL) and incubated 
for an additional 4 h at 37 °C, 5% CO2. Subsequently, the medium was aspirated, and 
the purple formazan crystals dissolved in DMSO (100 μL). The absorbance due to the 
dissolved purple formazan was then obtained at 565 nm. A negative control (cancer 
cells not exposed to any RAS complexes) and a positive control (cancer cells exposed 
to cisplatin) were also included in the experiment. The experiments were performed in 
quintuplicate for each RAS complex and control, and the cell viabilities associated 
with each RAS complex were calculated using the measured absorbance value. The 


































In the previous chapter, we optimized the 3CA methodology and identified 16 
‘drug-like’ hit compunds that demonstrate significant cytotoxicity towards A2780 
ovarian cancer in a single-concentration screen. Further validation is required for 
‘true’ cytotoxic hit compounds. Additional studies and characterization are also 
required to probe the mechanism of cytotoxicity and identify lead compounds with 
interesting mode-of-action that is able to overcome mechanisms of drug resistance. 
As a starting point, we chose to investigate p53-dependence of the lead compound 
and its implication in cancer therapy. 
p53 is a key tumor supressor gene often mutated in human cancers and is involved 
in the mediation of cellular DNA repair, apoptosis induction and cell cycle arrest.1 
p53 activation also mediates neurotoxicity of anticancer drugs.2 Chemoresistance of 
some cancer cell lines towards certain anticancer drugs such as oxaliplatin or 
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deficient p53 levels, which are less effective in inducing apoptosis even when 
significant DNA damage has occurred.3-4 Anticancer agents that are p53-independent 
could be promising drug candidates against such drug-resistant cancers. Previous 
reports indicated that several Ru complexes of various structure, such as RAPTA-C, 
RM175 and RDC11, induced p53 and p53 target genes at various degrees.5-7 
Therefore, identifcation of RAS complexes with p53-independent activity could 
contribute to the growing studies of anticancer Ru complexes. To this end, we identify 
the cytotoxic lead compound and investigate if its activity is dependent on p53 
activation. 
3.2 RESULTS  
3.2.1 Synthesis and characterization of hit compounds 
In order to validate the cytotoxic mechanisms of the hit compounds, it was 
necessary to synthesize them on a preparative scale for detailed in vitro evaluation. 
This would also help us eliminate false positives, which are relatively common in 
HTS. We selected 6 out of the 16 hit compounds (Fig 3.1) with low CV%, and re-
synthesized them individually according to Scheme 3.1. These included 2 outliers 
(WH-139 and WH-239) that did not fit into the general cytotoxicity trend. The 
identity and purity of the hit compounds were ascertained by 1H NMR, ESI-MS and 
RP-HPLC or elemental analysis (EA). The 1H NMR spectra of all hit compounds 
except WH-514 were as expected, with the imine singlet peak appearing around 9.0 to 
9.4 ppm and additional splitting of the arene proton peaks. However, 1H NMR 
spectrum of WH-514 showed 2 sets of compounds instead of 1 (Appendix D). This 
was presumably due to the restriction of free rotation of the C-N bond caused by the 




                                                                                                      Chapter 3  
 
57 
which resulted in the formation of pseudo E and Z stereoisomers (Fig 3.2). By 
increasing the temperature of NMR data acquisition to 343 K, the barrier of rotation 
could be overcomed and the peaks merged, giving rise to only 1 set of resonances. 
Similar E/Z isomerism was previously reported for another class of Ru(II)-arene 
Schiff-base complexes.8 The ESI-MS spectra showed the expected molecular ion 
peaks for all 6 compounds. All 6 compounds were shown to be at least 95% pure, 
either by EA or RP-HPLC analysis. 









Figure 3.1: Structure of selected hit compounds to be validated.  
 
Figure 3.2: Complex WH-514 display pseudo “E-Z” isomerism. Steric hindrance 
between bulky isopropyl and naphthalene groups creates a barrier of rotation of the C-
N bond resulting in pseudo-E/Z isomerism.   
 
3.2.2 Determination of aqueous stability, solubility and Log POW  
The aqueous stability, solubility and Log POW are important factors that affect a 
potential drug’s bioavailability and cell permeability.9 They might also give some 
indication about the molecular targets of the drug. The aqueous stability of the hit 
compounds was established by monitoring their UV profile over a period of 24 h at  1 
h intervals. Each compound was first dissolved in DMSO to make a 5 mM stock, 
which was then diluted with water to make a 50 µM aqueous solution with 1% 
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negligible variation to their UV peak profiles after 24 h. Significant change in the UV 
peak profile of WH-535 was observed with two isobestic points at 290 nm and 454 
nm (Appendix E). When the experiment was repeated for WH-535 in the presence of 
0.6% w/v NaCl, no significant change in its UV peak profile was observed. This 
suggests that the chloride ligand of WH-535 was significantly more labile as 
compared to rest of the complexes, and that aquation could be suppressed with the 
addition of chloride ions.  
The thermodynamic solubilities of WH-139, WH-239, WH-514, WH-536 and WH-
433 were determined at saturation in ddH2O for 24 h (Table 3.1). After 24 h, 
undissolved solid was removed by centrifugation and Ru concentration of the 
resulting saturated solutions were determined via ICP-OES. The hit compounds 
showed high solubilities in water (>1mg/ml), with WH-514 having solubility of 131.6 
mg/ml (216 mM), in the same order of lmagnitude as common inorganic salts. 
Solubility of WH-535 in 0.6% w/v NaCl was too low to warrant further analysis.  
The log POW of the RAS complexes was determined using the shake-flask method.10 
WH-139, WH-239, WH-514, WH-536 and WH-433 were partitioned between n-
octanol and ddH2O and the amount of compounds in the aqueous fractions before and 
after the partitioning were measured using UV-vis spectroscopy at their respective 
λmax (Table 3.1). The same was done for WH-535 using 0.6% w/v NaCl instead of 
ddH2O. WH-139, WH-239, WH-514, WH-536 and WH-433 were relatively 
hydrophilic as shown by their negative log POW values. The ionic nature of the 
complexes endowed them with hydrophilic character despite having hydrophobic 
surface groups. In general, all the hit compounds were considered “drug-like” based 
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between the hydrophilicity (log POW) and the aqueous solubility. In fact, the more 
hydrophilic WH-139 and WH-239 were much less soluble compared to hydrophobic 
WH-514 and WH-536. This could be due to the the ability of WH-139 and WH-239 
to lose a H+ ion from the phenol functional group to form an overall charge-neutral 
zwitterion. 
3.2.3 In vitro evaluation of hit compounds against cancer cell lines 
The efficacy of the RAS complexes in the inhibition of cell viability were evaluated 
against a panel of human cancer cell lines (Table 3.1). All experiments were carried 
out in at least triplicates and IC50 was determined from the average of three separate 
experiments. Ru concentrations of stock solutions were also determined using ICP-
OES and the IC50 values were adjusted to the actual concentration. Contrary to what 
was expected, WH-139 and WH-239 did not show significant cytotoxicity for any of 
the cell lines. We conclude that WH-139 and WH-239 were false positives and 
removed them from further testing.  















WH-139 -1.78 ± 0.07 2.69 ± 0.01 > 50 > 50 > 50 N.A. 
WH-239 -1.92 ± 0.24 7.34 ± 0.01 > 50 > 50 > 50 N.A. 
WH-514 -0.81 ± 0.01 131.6 ± 1.6 9.00 ± 0.62 9.88 ± 2.13 9.75 ± 3.47 1.0 
WH-536 -0.79 ± 0.03 35.0 ± 1.6 2.93 ± 0.21 2.76 ± 0.55 3.17 ± 0.29 1.1 
WH-433 -1.03 ± 0.01 2.16 ± 0.03 6.47 ± 0.45 7.58 ± 0.98 9.78 ± 2.14 1.3 
WH-535  0.57 ± 0.07* N. D.  13.13 ± 1.35 11.19 ± 1.41 7.59 ± 1.24 0.7 
Cisplatin -2.03 ± 0.4712 3.37 ± 0.0512 >50 9.54 ± 2.36 34.30± 4.01 3.6 
aLog Pow values determined via the shake-flake method against 1:1 n-octanol:H2O partitioning. *Log 
Pow for WH-535 was determined in 1:1 n-octanol: 0.6% w/v NaCl.  bCompounds were dissolved in 0.5 
mL of water to saturation at 24 h at r.t. and [Ru] was determined using ICP-OES. cIC50 values is the 
concentration of Ru complexes required to inhibit 50% of cell growth with respect to control groups, 
measured by MTT assay after 6 h drug exposure and 66 h of incubation. Data obtained are based on the 
average of at least three independent experiments, and the reported errors are the corresponding 
standard deviations. The IC50 were corrected using actual [Ru] determined using ICP-OES. dBased on 
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RAS complexes WH-514, WH-536, WH-433 and WH-535 showed good killing 
efficacies against the cancer cell lines tested. Against ovarian cancer A2780, the 
complexes exhibited efficacies comparable to or better than cisplatin, with WH-536 
achieving IC50 values 3 times lower than that of cisplatin. In addition, they did not 
exhibit any cross-resistance towards cisplatin-resistant A2780cisR, with WH-535 
achieving a resistance factor as low as 0.7 and WH-536 having IC50 value 10 times 
lower than that of cisplatin. Furthermore, WH-514, WH-536, WH-433 and WH-535 
also demonstrated good toxicity towards breast cancer MCF7 whereas cisplatin 
showed negligible cytotoxicity.  
We further evaluated the hit compounds against colorectal carcinoma cell lines, 
which have been known to be resistant to treatment by cisplatin. This intrinsic 
resistance to cisplatin had previously been linked to overexpression of organic cation 
transporter (OCT) proteins in colorectal carcinoma cells. On the other hand, 
oxaliplatin, by virtue of its hydrophobic R,R-diaminocyclohexane motif (DACH), 
undergoes aquation to yield cationic species which were postulated to be OCT1/2 
substrates.13 As RAS complexes are persistently cationic and contained hydrophobic 
ligands, they could potentially be substrates of OCT1/2 and have good efficacies in 
colorectal carcinoma cell lines. WH-514, WH-536, WH-433 and WH-535 were tested 
against two such cell lines, HCT116 and SW480 and their activity compared against 
oxaliplatin (Fig 3.3). 
With the exception of WH-535, RAS complexes were more cytotoxic towards 
HCT116 than SW480. WH-514 and WH-433 demonstrated modest toxicity towards 
HCT116 but displayed poor IC50 values above 20 µM in SW480. WH-536 displayed 
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in SW480, compared to oxaliplatin which was equally efficacious against both cell 
lines. Nevertheless, WH-536 demonstrated greater efficacies towards HCT116 
compared to oxaliplatin. 
 
Figure 3.3: Toxicity of RAS complexes in colorectal cancer cells. Dose-dependent 
drug efficacy studies for WH-514, WH-536, WH-433, WH-535 and oxaliplatin on 
colon cancer cell lines HCT116 and SW480. Data represents mean ± s.d. of three 
independent experiments. 
 
3.2.4 Reactivity of WH-536 with biomolecules 
We selected complex WH-536 for further characterization as it demonstrated the 
best activity out of the hit compounds. WH-536 also demonstrated suitable solubility 
and resistance to aquation in water. To further rule out aquation and subsequent 
DNA-binding as the activation mechanism, we incubated hit complex WH-536 with 
DNA nucleoside dGMP and biological nucleophile GSH and monitored its UV-Vis 
profile over a 24 h period (Fig 3.4). No change in its UV-Vis profile was observed in 
the presence of either dGMP (2x molar equiv.) or GSH (10 mM). Furthermore, no 
new adducts were observed in ESI-MS, indicating that WH-536 did not interact with 
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nucleophilic substitution. This means that covalent binding to DNA is unlikely to be 
the mode of action of WH-536. 
 
Figure 3.4: Reaction of WH-536 with biomolecules. (a) UV-Vis spectrum of 4 (50 
µM) with 2 equiv. of dGMP over 24 h. (b) UV-Vis spectrum of 4 (50 µM) with GSH 
(10 mM) over 24 h. 
 
3.2.5 Cell cycle analysis and apoptosis assay of WH-536 
The ability of WH-536 to cause cell cycle arrest and apoptosis was investigated. 
HCT116 cells were treated with WH-536 for 24 h at 2.5 µM (IC75) and 10 µM (IC90). 
The cell cycle profiles of treated cells stained with propidium iodide (PI) were 
obtained by flow cytometry analysis and compared with that of an untreated control. 
Significant cell cycle arrest at the G2/M phase was induced by WH-536 only at the 
higher concentration (Fig 3.5a-c). Similarly, flow cytometry analysis using Annexin 
V-EGFP/PI apoptosis detection assay revealed that WH-536 induced apoptosis only 
at the higher concentration (Fig 3.5d-f). The amount of apoptotic cells at 2.5 µM 
(14%) did not correspond to the expected number of cell death at this concentration 
(75% at IC75). The percentage of necrotic cells remain low at either concentrations (< 
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contribute significantly to the activity of WH-536. WH-536 could be killing the cells 
via a different mode of cell death. 
 
Figure 3.5: Cell cycle analysis and Annexin-V Assay. (a-c) Cell Cycle profile of 
HCT116 cells after 24 h exposure to WH-536 at the concentrations stated. Cells were 
stained with propidium iodide prior to analysis by flow cytometry. Percentages of 
cells in the various stages of cell cycle are stated in red. Results were acquired from at 
least 20000 events. (d-f) Dot plots of HCT116 cells treated at the same conditions. 
Viable cells are shown in the lower left quadrant, early apoptotic cells in the lower 
right quadrant, late-stage apoptotic cells are in the upper right quadrant and necrotic 
cells are in the upper left quadrant. Numbers shown indicate the percentage cells in 
each quadrant. Experiments were performed twice independently. 
 
3.2.6 WH-536 exhibit p53-independent cytotoxicity  
As mentioned, anticancer compounds that are p53-independent could potential 
bypass the drug resistance of p53-deficient cancers. To investigate if WH-536 inhibit 
cell viability via a p53-dependant or independent mechanism, we determined the 
time-based expression of p53 in HCT116 cells treated with various concentrations of 
WH-536. Cells treated with oxaliplatin were used as positive control. We also tested 
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human foreskin cells BJwt and the p53-knockdown BJshp53.12 As a control, DOX 
was also tested against both cell lines and the results were compared. 
 
Figure 3.6: p53-dependence of WH-536. (a) Western blot for detection of p53 
expression in HCT116 cells, treated with WH-536 and oxaliplatin for different 
exposure times. Homogeneous protein loading determined with reference to actin. (b-
c) Inhibition of cell viability on BJwt and BJshp53 cells treated with varying 
concentrations of WH-536 and DOX respectively. (d) A comparison of IC50 values of 
WH-536 and DOX in BJwt and BJshp53 cells. Data represents mean ± s.e.m of three 
independent experiments (* p<0.05; two-tailed Student’s t-test). 
 
As expected, time and concentration-dependent upregulation of p53 was observed 
in cells treated with oxaliplatin. In contrast, p53 expression in HCT116 cells treated 
with WH-536 remained at basal level regardless of the duration or concentration of 
exposure (Fig 3.6a). Furthermore, WH-536 demonstrated similar efficacies in both 
BJwt and BJshp53, while DOX was 7 times more cytotoxic against BJwt than p53-
deficient BJshp53 (Fig 3.6b-d). Taken together, these results suggest that WH-536 








The hit compounds were validated by obtaining their IC50 values in several cancer 
cell lines. Among these, WH-139 and WH-239 did not demonstrate any cytotoxicity 
and was shown to be false positives from the screening stage. WH-514, WH-536, 
WH-433 and WH-535 displayed low micromolar IC50 values in the panel of cell lines 
tested. In addtion, they did not show cross-resistance in cisplatin-resistant A2780cisR. 
Other classes of Ru(II)-arene complexes have also demonstrated activity in lineage 
with reduced susceptability to cisplatin or other platinum anticancer drugs.14-15 In 
particular, RM175-type complexes exhibited resistance factors between 0.7 – 1.0 in 
A2780cisR.16 This was in contrast to the cross-resistance exhibited by Pt anticancer 
drugs such as carboplatin or Pt (II)-oxalato complexes,16-17 suggesting that the 
resistance mechanisms induced by Pt anticancer drugs do not impact the biological 
activity of Ru compounds significantly. 
Next we demonstrated that the activity of WH-536 was independent of p53 
activation. Recent studies by Sadler and co-workers on a class of Ru(II)-arene 
complexes bearing similar structural features as WH-536 also demonstrated p53-
independent mechanism of action.18 Intriguingly, they reported that the halide ligand 
affected p53-dependence and that p53-independent activity was only observed in 
iodido- complexes and not in chlorido- analogues. Our preliminary results were 
contrary to this report.  
Complex WH-536 was also found to be active despite its resistance to aquation and 
stablility towards nucleophilic substituition reactions. Some classes of cytotoxic 
Ru(II)-arene complexes that target DNA are activated by aquation in similar fashion 
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binds DNA, forming metal-DNA adducts which directly interfere with cell 
proliferation. An extensive study was carried out on the mechanism of aquation of 
RM175 and related compounds and showed that it was strongly correlated to their 
cytotoxicity; highly cytotoxic compounds undergo aquation while the inactive 
compounds were resistant to aquation. In contrast, RAS complexes did not exhibit a 
similar trend. RAS compounds WH-514, WH-536 and WH-433 displayed good 
cytotoxicity towards the examined panel of cancer cells even though they were 
resistant to aquation. On the other hand, the ability to undergo aquation did not confer 
improved cytotoxic efficacies to WH-535. This, the inability of WH-536 to bind to 
DNA nucleotide dGMP and earlier results indicating that WH-536 operated via a p53-
independent pathway, indicated that DNA may not be a target of RAS complexes.  
Complex WH-536 also did not induce significant cell cycle arrest or apoptosis at 
concentrations that induced significant cell death. Taken together, our results seems to 
suggest that WH-536 induced cell death via mode-of-action different from Pt 
complexes or other classes of Ru complexes. These results hold promise for treatment 
of cancers that are drug-resistant due to their dysfunctional p53 status or enhanced 
DNA repair mechanisms. To further develop and study this class of complexes, we 
chose WH-536 as the lead compound. Using the structure of WH-536 as a starting 
point, we synthesized additional structurally related RAS complexes and conducted 











3.4.1 Materials  
All experimental procedures were carried out without additional precautions to 
exclude air or moisture unless otherwise specified. All chemicals and solvents were 
used as received. RuCl3.xH2O was purchased from both Precious Metals Online. [(η6-
benzene)RuCl2]2, [(η6-toluene)RuCl2]2, [(η6-cymene)RuCl2]2, [(η6-
hexamethylbenzene)RuCl2]2 and [(η6-1,3,5-triisopropylbenzene)RuCl2]2 were 
synthesized according to previously reported protocols.22-25 All other chemicals used 
were purchased from Sigma-Aldrich (Singapore). Streptomycin,  Thiazolyl blue 
tetrazolium bromide (MTT) were obtained from Sigma Chemical Co (St. Louis, MO, 
USA). 10x PBS buffer pH 7.4 was purchased from Vivantis Inc., CA, USA. 
HycloneTM RPMI 1640, DMEM medium, Fetal bovine serum (FBS) and Pierce ECL 
Western Blotting Substrate was purchased from Thermo Fisher Scientific Inc., Logan, 
UT, USA. Annexin V-EGFP apoptosis detection kit (ab14153) was purchased from 
Apcam (Singapore). Calbiochem® Anti-human p53 (pAb421) was purchased from 
Millipore, Molsheim, France and anti-actin was kindly provided by Dr. Aunis 
(Strasbourg, France). Ultrapure water used was purified by a Milli-Q UV purification 
system (Sartorius Stedim Biotech SA, Aubagne Cedex, France). The human ovarian 
carcinoma cells A2780 and A2780cisR were received with gratitude from Prof. Paul 
Dyson (EPFL). The human breast adenocarcinoma cells MCF7, human colorectal 
carcinoma cells HCT116 and human colorectal adenocarcinoma cells were acquired 
from ATCC® (Manassa,VA). The wild type human foreskin fibroblast cells BJwt and 
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Tai Wei (NUS). Final compounds tested for biological activities have been shown to 
be >95% pure either by elemental analysis or HPLC analysis. 
3.4.2 Instrumentation 
1H NMR spectrums were obtained using either a Bruker AMX 300, Avance 400 or 
AMX 500 spectrometer and the chemical shifts (δ) were reported in parts per million 
with reference to residual solvent peaks. Electrospray-ionization Mass Spectrometry 
(ESI-MS) spectra were obtained using Thermo Finnigan MAT ESI-MS System. UV-
vis spectra were obtained using the Shimadzu UV-1800 UV Spectrophotometer with a 
TCC-240A Temperate Controlled Cell Holder. Ru concentrations were determined 
using the Optima ICP-OES (Perkin-Elmer) operated by CMMAC, NUS. Elemental 
analyses of selected Ru complexes were carried out using a Perkin-Elmer PE 2400 
elemental analyzer by CMMAS, NUS. Cells were analyzed using a BD 
LSRFortressaTM cell analyzer. 
3.4.3 HPLC analysis of compound purity  
Determination of the purity of the Ru(II) complexes WH-514, WH-433 and WH-
535, was done using analytical HPLC on a Shimadzu Prominence System equipped 
with a DGU-20A3 Degasser, two LC-20AD Liquid Chromatography Pump, a SPD-
20A UV/Vis Detector and a Shim Pack GVP-ODS 2.0 mm 18 column (5 µM, 120Å, 
250 mm x 4.60 mm i.d.) at r.t. at a flow rate of 1.0 mL/min with detection at both 214 
nm and 254 nm. The gradient elution conditions were as follows: 20-80% solvent B 






                                                                                                      Chapter 3  
 
70 
3.4.4 Synthesis of 2-quinolinylmethylene-4-aminophenol (L1)  
2-Quinolinecarboxaldehyde (157 mg, 1 mmol) and 4-aminophenol (109 mg, 1 
mmol) was added to MeOH (50 mL) and refluxed for 2 h. The reaction mixture was 
reduced to 1/10 of its original volume and cooled in an ice bath. The resulting 
crystalline precipitate formed was separated by suction filtration, washed with cold 
methanol (3 x 10 mL) and dried in vacuo for 1 h. Yield: 136 mg (54%), 1H NMR (400 
MHz, DMSO-d6): δ 9.72 (s, 1H, OH), 8.79 (s, 1H, PhN=CH), 8.46 (d, 3JHH = 9 Hz, 
1H, quinolinyl), 8.27 (d, 3JHH = 9 Hz, 1H, quinolinyl), 8.10 (d, 3JHH = 8 Hz, 1H, 
quinolinyl), 8.05 (d, 3JHH = 8 Hz, 1H, quinolinyl), 7.83 (t, 3JHH = 8 Hz, 1H, 
quinolinyl), 7.67 (t, 3JHH = 7 Hz, 1H, quinolinyl), 7.40 (d, 3JHH = 9 Hz, 2H, CH4OH), 
6.86 (d, 3JHH = 9 Hz, 2H, CH4OH) ppm. ESI-MS (+ve mode): m/z = 249 [M+H]+; (-
ve mode): m/z = 247 [M-H]-. 
3.4.5 Synthesis of N-(2-Pyridylmethylene)-1-naphthylamine (L2)  
2-Picolinaldehyde (95.1 µL, 1 mmol) and 1-naphthylamine (143 mg, 1 mmol) was 
added to dry EtOH (15 mL) and stirred at r.t. over 72 h. The solvent was removed in 
vacuo and dried. The final product was used for the next step without any further 
purification. 1H NMR (400 MHz, CDCl3): δ 8.75 (d, 3JHH = 4 Hz, 1H, py), 8.71 (s, 
1H, PhN=CH), 8.41 (d, 3JHH = 8 Hz, 1H, napthyl), 8.36 (m, 1H, py), 7.88 (m, 1H, py), 
7.87 (d, 3JHH = 7 Hz, 1H, napthyl), 7.77 (t, 3JHH = 8 Hz, 1H, napthyl), 7.53 (m, 2H, 
napthyl), 7.48 (d, 3JHH = 8 Hz, 1H, napthyl), 7.41 (m, 1H, py), 7.15 (d, 3JHH = 7 Hz, 
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3.4.6 Synthesis of 4-methoxy-N-(2-quinolinylmethylene)-aniline (L3)  
2-Quinolinecarboxaldehyde (157 mg, 1 mmol) and p-anisidine (123 mg, 1 mmol) 
was added to minimal amount of dry EtOH (5 mL) and stirred at r.t. for 72 h. The 
solvent was removed in vacuo and dried. The resulting crude yellowish brown solid 
was used for the next step without any further purification. 1H NMR (500 MHz, 
CDCl3): δ 8.82 (s, 1H, PhN=CH), 8.37 (d, 3JHH = 8 Hz, 1H, quinolinyl), 8.24 (d, 3JHH 
= 8 Hz, 1H, quinolinyl), 8.16 (d, 3JHH = 9 Hz, 1H, quinolinyl), 7.87 (d, 3JHH = 8 Hz, 
1H, quinolinyl), 7.76 (t, 3JHH = 7 Hz, 1H, quinolinyl), 7.60 (t, 3JHH = 7 Hz, 1H, 
quinolinyl), 7.41 (d, 3JHH = 9 Hz, 2H, CH4OMe), 6.98 (d, 3JHH = 9 Hz, 2H, CH4OMe), 
3.86 (s, 3H, OCH3) ppm.  
3.4.7 Synthesis of [(η6-benzene)RuCl(L1)]Cl (WH-139)  
[(η6-Benzene)RuCl2]2 (50.4 mg, 0.101 mmol) and L1 (50.0 mg, 0.202 mmol) was 
added to MeOH (25 mL) and stirred at r.t. over 12 h. The solvent was removed in 
vacuo and the resulting solid was washed with ether (3 x 10 ml). The final product 
was dried in vacuo for 1 h to yield a orange solid. Yield: 98.0 mg (98%). Anal. Calcd 
for RuC22H18N2Cl2O (%): C 53.02, H 3.64, N 5.62; Found: C 52.81, H 3.44, N 5.62. 
1H NMR (400 MHz, MeOH): δ 8.91 (s, 1H, PhN=CH), 8.88 (d, 3JHH = 9 Hz, 1H, 
quinolinyl), 8.77 (d, 3JHH = 8 Hz, 1H, quinolinyl), 8.21 (d, 3JHH = 8 Hz, 2H, 
quinolinyl), 8.15 (t, 3JHH = 8 Hz, 1H, quinolinyl), 7.96 (t, 3JHH = 8 Hz, 1H, quinolinyl), 
7.85 (d, 3JHH = 9 Hz, 2H, CH4OH), 7.02 (d, 3JHH = 9 Hz, 2H, CH4OH), 5.94 (s, 6H, 
C6H6) ppm. ESI-MS (+ve mode): m/z = 463 [M]+. Purity of the complex was 
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3.4.8 Synthesis of [(η6-toluene)RuCl(L1)]Cl (WH-239)  
WH-239 was obtained with [(η6-toluene)RuCl2]2 (53.2 mg, 0.101 mmol) and L1 
(50.0 mg, 0.202 mmol) using the same protocol as used for WH-139 as a red solid. 
Yield: 100 mg (97%). Anal. Calcd for RuC23H20N2Cl2O (%): C 53.91, H 3.93, N 5.47; 
Found: C 53.57, H 4.23, N 5.27. 1H NMR (400 MHz, DMSO): δ 10.42 (s, 1H, OH), 
9.11 (s, 1H, PhN=CH), 8.87 (d, 3JHH = 8 Hz, 1H, quinolinyl), 8.75 (d, 3JHH = 9 Hz, 
1H, quinolinyl), 8.29 (t, 3JHH = 8 Hz, 2H, quinolinyl), 8.14 (t, 3JHH = 7 Hz, 1H, 
quinolinyl), 7.98 (t, 3JHH = 8 Hz, 1H, quinolinyl), 7.87 (d, 3JHH = 9 Hz, 2H, CH4OH), 
7.03 (d, 3JHH = 9 Hz, 2H, CH4OH), 6.06 (t, 3JHH = 6 Hz, 1H, C6H5), 5.98 (d, 3JHH = 6 
Hz, 1H, C6H5), 5.81 (t, 3JHH = 6 Hz, 1H, C6H5), 5.72 (t, 3JHH = 6 Hz, 1H, C6H5), 5.39 
(d, 3JHH = 8 Hz, 1H, C6H5), 2.16 (s, 3H, CH3) ppm. ESI-MS (+ve mode): m/z = 477 
[M]+. Purity of the complex was determined to be >95% pure by elemental analysis. 
3.4.9 Synthesis of [(η6-1,3,5-triisopropybenzene)RuCl(L2)]Cl (WH-514)  
[(η6-1,3,5-Triisopropylbenzene)-RuCl2]2 (87.1 mg, 0.108 mmol) and L2 (50.0 mg, 
0.215 mmol) was added to MeOH (15 mL) and stirred at r.t. over 12 h. The solvent 
was removed in vacuo and the resulting solid was washed with ether (3 x 10 ml). The 
final product was dried in vacuo for 1 h to give a yellow solid. Yield: 126 mg (96%). 
1H NMR (500 MHz, CDCl3, 70˚C): δ 9.59 (d, 3JHH = 4 Hz, 1H, py), 9.02 (s, 1H, 
PhN=CH), 8.35 (m, 2H, py), 8.15 (s(broad), 1H, napthyl), 8.12 (d, 3JHH = 8 Hz, 1H, 
napthyl), 7.95 (m, 1H, py), 7.71 (s(broad), 5H, napthyl), 5.85 (s, 3H, C6H3), 2.19 
(sept, 3JHH = 7 Hz, 3H, CHMe2), 1.06 (d, 3JHH = 7 Hz, 9H, C(CH3)2), 0.93 (s(broad), 
9H, C(CH3)2) ppm. ESI-MS (+ve mode): m/z = 573 [M]+. Purity (HPLC): 95.5% at 
214 nm and 92.4% at 254 nm; tr = 25.6 min. Purity of the complex was determined to 
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3.4.10 Synthesis of [(η6-1,3,5-triisopropybenzene)RuCl(L3)]Cl (WH-536)  
[(η6-1,3,5-Triisopropylbenzene) RuCl2]2 (244 mg, 0.324 mmol) and crude L3 (167 
mg, 0.648 mmol) was added to MeOH (40 mL) and stirred at r.t. over 12 h. The 
solvent was removed in vcauo and reconstituted in minimum amount of MeOH (2 
mL). Diethyl ether (40 mL) was than added to precipitate the product. The suspension 
was filtered and the resulting solid washed with ether (3 x 10 mL). The final product 
was then dried in vacuo for 1 h to give a reddish brown solid. Yield: 290 mg (71%). 
Anal. Calcd for RuC32H38N2Cl2O (%): C 60.16, H 6.00, N 4.39. Found: C 60.26, H 
5.61, N 4.45. 1H NMR (400 MHz, DMSO): δ 9.09 (s, 1H, PhN=CH), 8.96 (d, 3JHH = 9 
Hz, 1H, quinolinyl), 8.85 (d, 3JHH = 8 Hz, 1H, quinolinyl), 8.25 (d, 3JHH = 8 Hz, 2H, 
quinolinyl), 8.12 (m, 1H, quinolinyl), 8.11 (d, 3JHH = 9 Hz, 2H, C6H4OMe), 7.97 (t, 
3JHH = 8 Hz, 1H, quinolinyl), 7.19 (d, 3JHH = 9 Hz, 2H, C6H4OMe), 5.54 (s, 3H, C6H3), 
3.90 (s, 3H, OCH3), 2.44 (sept, 3JHH = 7 Hz, 3H, CHMe2), 1.16 (d, 3JHH = 7 Hz, 9H, 
C(CH3)2), 0.85 (d, 3JHH = 7 Hz, 9H, C(CH3)2) ppm. ESI-MS (+ve mode): m/z = 603 
[M]+. Purity of the complex was determined to be >95% pure by elemental analysis. 
3.4.11 Synthesis of [(η6-hexamethylbenzene)RuCl(3-chloro-N-(2-
quinolinylmethylene)aniline)]Cl (WH-433)  
2-Quinolinecarboxaldehyde (78.6 mg, 0.5 mmol) and 3-chloroaniline (52.9 µL, 0.5 
mmol) was added to dry EtOH (8 mL) and and stirred at r.t. over 72 h. The solvent 
was removed in vacuo and dried. Crude 3-chloro-N-(2-quinolinylmethylene)-aniline 
(135 mg) was treated with [(η6-hexamethylbenzene)RuCl2]2 (167 mg, 0.25 mmol) in 
MeOH (20 mL) and stirred at r.t. over 12 h. The solvent was removed in vacuo and 
the resulting solid purified by gradient elution column chromatography (1:4 v/v 




                                                                                                      Chapter 3  
 
74 
dried in vacuo for 1 h to give a red solid. Yield: 182 mg (61%). 1H NMR (400 MHz, 
CDCl3): δ 9.37 (s, 1H, PhN=CH), 8.68 (d, 3J= 8 Hz, 1H, quinolinyl), 8.52 (d, 3JHH = 9 
Hz, 1H, quinolinyl), 8.48 (d, 3JHH = 8 Hz, 1H, quinolinyl), 8.40 (d, 3JHH = 8 Hz, 1H, 
quinolinyl), 8.34 (s, 1H, C6H4), 7.99 (d, 3JHH = 8 Hz, 1H, C6H4), 7.88 (t, 3JHH = 7 Hz, 
1H, quinolinyl), 7.79 (t, 3JHH = 7 Hz, 1H, quinolinyl), 7.54 (t, 3JHH = 8 Hz, 1H, C6H4), 
7.44 (d, 3JHH = 8 Hz, 1H, C6H4), 1.90 (s, 18H, C6(CH3)6) ppm. ESI-MS (+ve mode): 
m/z = 565 [M]+. Purity (HPLC): 97.4% at 214 nm and 95.6% at 254 nm; tr = 20.3 
min. Purity of the complex was determined to be >95% pure by HPLC. 
3.4.12 Synthesis of [(η6-hexamethylbenzene)RuCl(N-(2-quinolinylmethylene)-8-
hydroxy-1-napthalenamine)]Cl (WH-535)  
[(η6-Hexamethylbenzene)RuCl2]2 (66.85 mg, 0.1 mmol), 2-
quinolinecarboxaldehyde (31.4 mg, 0.1 mmol) and 8-hydroxy-1-napthalenamine (31.8 
mg, 0.1 mmol) was added to 1:1 v/v DMSO/H2O (10 mL) and stirred at r.t. over 48 h. 
MeOH was then added to the resulting suspension until a clear dark red solution was 
formed. The solution was left to stir at r.t. for 24 h. The solvent mixture was removed 
in vacuo and the resulting solid purified by gradient elution column chromatography 
(1:4 v/v EtOH/CHCl3, Rf = 0.2; 1:1 v/v EtOH/CHCl3, Rf = 0.6). The final product was 
dried in vacuo for 1 h to give a dark red solid. Yield: 86.0 mg (69%). 1H NMR (300 
MHz, MeOD): δ 9.11 (s, 1H, PhN=CH), 8.75 (d, 3JHH = 8 Hz, 1H), 8.53 (d, 3JHH = 9 
Hz, 1H), 8.48 (d, 3JHH = 8 Hz, 1H), 8.44 (s(broad), 1H), 8.29 (d, 3JHH = 8 Hz, 1H), 
8.25 (d, 3JHH = 8 Hz, 1H), 8.14 (m, 1H), 7.98 (t, 3JHH = 7 Hz, 2H), 7.62 (t, 3JHH = 8 Hz, 
2H), 7.05 (d, 3JHH = 8 Hz, 1H), 1.83 (s, 18H) ppm. ESI-MS (+ve mode): m/z = 565 
[M]+. Purity (HPLC): 96.1% at 214 nm and 95.1% at 254 nm; tr = 19.5 min. Purity of 
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3.4.13 Aqueous stability studies  
Stock solutions of the hit compounds (5 mM) were each diluted with ddH2O to a 
final concentration of 50 µM with 1% DMSO. The UV-Vis peak profile of the sample 
was then monitored for 24 h at 1 h intervals. The temperature was kept constant at 
25˚C throughout and ddH2O with 1% DMSO was used as the blank sample. 
3.4.14 Determination of thermodynamic aqueous solubility 
Approximately 5 mg of WH-139, WH-239, WH-514, WH-536 and WH-433 was 
added separately to minimal amount of ddH2O until a small amount of each 
compound were left in a saturated solution of the respective compounds. The separate 
mixtures were than left to stand with gentle agitation at r.t. for 24 h. The individual 
mixtures were than centrifuged at 10,000 rpm for 2 min and the supernatant liquid 
collected and analyzed by ICP-OES to determine the maximum solubility of each 
compound. The same procedure was repeated for WH-535 but with 0.6% w/v NaCl 
solution instead of ddH2O. 
3.4.15 Determination of Log POW  
Log Pow of the hit compounds were determined using the shake flask method.10 
WH-139, WH-239, WH-514, WH-536 and WH-433  were predissolved in ddH2O that 
was presaturated with n-octanol (for 24 h and left to stand until phase separation 
occurs). The UV-vis spectrum for each samples was obtained and the absorbances at 
the λmax of each compound were determined. Equal volume of n-octanol was added to 
each sample solution and the heterogeneous mixtures shaked for 96 h before 
centrifuging at 7000 rpm for 1 min to achieve phase separation. The final absorbance 
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octanol partition coefficient were calculated. The experiment was repeated for WH-
535 in 0.6% w/v NaCl solution instead of ddH2O. All experiments were done in 
triplicate. 
3.4.16 Tissue culture  
The human ovarian carcinoma cells A2780 and A2780cisR were cultured in RPMI 
1640 medium containing 10% fetal bovine serum (complete RPMI) and grown at 37 
°C in a humidified atmosphere of 95% air and 5% CO2. 1 µM cisplatin was added to 
A2780cisR every 3 passage to maintain its resistance. The human breast carcinoma 
cells MCF7, colon cancer cell lines HCT116 and SW480 were cultured in DMEM 
medium containing 10% fetal bovine serum (complete DMEM) and grown at 37 °C in 
a humidified atmosphere of 95% air and 5% CO2. The medium used for the colon 
cancer cell lines also contained 1% penicillin/streptomycin. Experiments were 
performed on cells within 20 passages. 
3.4.17 Inhibition of cell viability assay  
The anti-proliferation activity of the hit compounds on exponentially growing 
cancer cells were determined using MTT assay as described previously.26 A2780 
cells, A2780cisR and MCF7 were seeded at 8000, 6000 and 4000 cells, respectively, 
per well (100 µL) in Cellstar® 96-well plates (Greiner Bio-One) and incubated for 24 
h. PBS buffer (200 µL) was added to the wells at the perimeter to prevent evaporation 
of the media from the enclosed wells. Thereafter, cancer cells were exposed to drugs 
at different concentration in RPMI medium (A2780/A2780cisR) or DMEM medium 
(MCF7) without FBS or antibiotics and incubated at 37 °C, 5% CO2 for 6 h. The 
compounds were predissolved as DMSO stock solutions and serially diluted with 
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was 1% (v/v) at which cell viability was not significantly inhibited. After the 6 h, the 
drug-containing medium was removed, and new drug-free complete RPMI 
(A2780/A2780cisR) or DMEM (MCF7) was added and the cells were incubated for 
additional 66 h. At 72 h after initial drug addition, the medium was removed and 
replaced with MTT solution (100 μL, 0.5 mg/mL) in PBS and incubated for an 
additional 4 h at 37 °C, 5% CO2. Subsequently, the medium was aspirated, and the 
purple formazan crystals dissolved in DMSO (100 μL). The absorbance due to the 
dissolved purple formazan was then obtained at 565 nm. The experiments were 
performed in 6 replicates for each drug concentration and were carried out at least 
three times independently. Inhibition to cell viability was evaluated with reference to 
the IC50 value, which is defined as the concentration needed for a 50% reduction of 
survival based on the survival curves. IC50 values were calculated from the dose - 
response curves (cell viability vs drug concentration) obtained in repeated 
experiments and adjusted to actual [Ru] administered, which was determined using 
ICP-OES. For HCT116 and SW480 cells, the protocol was applied as before except 
that cells were plated at 20000 cells per well (100 μL) in Cellstar® 96-well plates 
(Greiner Bio-One) for 24 h and exposed to varying concentration of RAS complexes 
continuously for 48 h in DMEM complete medium containing <0.5% v/v DMSO. 
Similarly for BJwt and BJshp53, cells were plated at 2000 cells per well (100 μL) in 
Cellstar® 96-well plates (Greiner Bio-One) for 24 h and then incubated with varying 
concentration of WH-536 and DOX continuously for 48 h in medium containing 
<0.8% v/v DMSO. The experiments were performed in 8 replicates for each drug 
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3.4.18 Annexin V/ propidium iodide assay  
The ability of WH-536 to induce apoptosis in HCT116 cells were investigated via 
Annexin V/Propidium Iodide Assay previously described.27 HCT116 cells were 
seeded at 200 000 cells per well (1 mL) in Cellstar® 12-well plates (Greiner Bio-One) 
and incubated for 24 h. Thereafter, cancer cells were exposed to 2.5 µM and 10 µM of 
WH-536 in complete DMEM medium and incubated at 37 °C, 5% CO2 for 24 h. The 
supernatant solution and cells detached by trypsinization were collected in separate 
vials and centrifuged at 100 rpm for 10 min to pellet the cells. Cells were resuspended 
in 500 µl of binding buffer containing Annexin V-EGFP and propidium iodide and of 
final concentration 1 µg/ml. The fluorescence was immediately analyzed by flow 
cytometry. The resulting dot plots were acquired from 10 000 events and quantified 
by software BD FACSDivaTM. The experiment was performed independently twice. 
3.4.19 Protein extraction and western blot for p53  
HCT116 cells were grown on Cellstar® 6-well plates (Greiner Bio-One) and treated 
with WH-536 at concentrations 1 µM (IC50), 2.5 µM (IC75) and 10 µM and at 2.5 µM 
and 10 µM for control drug oxaliplatin and incubated at 37˚C, 5 % CO2. Different sets 
of cells were treated for different durations of 2 h, 6h, 12 h and 24 h. The cells were 
lysed with lysis buffer [100 µL, 1% NP40, 150 mM NaCl, 50 mM Tris-HCl (pH 8.0), 
protease inhibitor]. The cell lysate were transferred to separate 2 mL tubes and 
sonicated for 10 s. The samples were then centrifuged at 13000 rpm, 4˚C for 15 min. 
The supernatant liquid containing the proteins were collected and total protein content 
of each sample was quantified via Bradford’s assay. 30 µg of proteins from each 
sample were reconstituted in loading buffer [5% DDT, 1x Protein Loading Dye] and 
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gel by electrophoresis and transferred to a nitrocellulose membrane. Equal loading of 
protein was confirmed by comparison with actin. Immunoblotting for p53 was done 
using anti-human p53 antibodies. The proteins bands were visualized via enhanced 

































Structure-Activity Relationship, Cellular Uptake, 
Preliminary Mode-of-Action Studies 
 
4.1 INTRODUCTION 
In the previous chapter, we identified lead compound WH-536 that displayed p53-
independent anticancer activity. In this chapter, we expand the set of compounds 
under investigation to include eight additional RAS complexes that are structurally 
related to WH-536. WH-433 was also included in this set. These compounds were 
further investigated for cytotoxicity in a panel of colorectal and gastric cancer cells. 
Other characteristics such as stability to aquation, cellular uptake and p53-
independence were also investigated for selected compounds out of this set of nine. 
Some preliminary SAR were also deduced based on these characterizations. The lead 











4.2.1 Synthesis and characterization of RAS complexes 
9 RAS Complexes (Fig 4.1) based on the structure of RAS-1T (WH-536 from 
Chapter 3) were synthesized using the general reaction route as shown in Scheme 4.1. 
2-Quinolinecarboxyaldehyde and different aniline derivatives were first reacted in dry 
ethanol to give the bidentate imine ligand with varying degree of purity. Most of the 
imine ligands could not be isolated as pure compounds due to the ease of hydrolysis 
of the imine bonds. Nevertheless, the crude ligand could be used for the synthesis of 
the RAS complexes by addition of stoichiometric amount of the corresponding 
[Ru(arene)Cl2]2 in methanol. The 9 RAS complexes could be further purified and 
isolated via simple flash column chromatography.  
Their 1H NMR spectra showed resonance typical of RAS complexes (Appendix D; 
Chapter 3.2.1). ESI-MS spectra of these compounds also showed the characteristic 
[M]+ molecular ion peaks. The purity of the complexes was confirmed by either EA 
or RP-HPLC. 
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Scheme 4.1: Synthetic Route for RAS Complexes. 
 
4.2.2 Aqueous stability and Log POW of RAS complexes  
As mentioned, aqueous stability and Log POW are important factors that affect a 
potential drug’s bioavailability and cell permeability.1 It also potentially influences 
the molecular target and mode-of-action of the drug. In Chapter 3, we observed that 
most RAS complexes were stable towards aquation. However, there are some 
exceptions to the rules like WH-535 (Fig 3.1; Appendix E). To determined if the 9 
RAS complexes under investigation are stable to aquation, we monitored their UV-
Vis profile in water over time. Any sign of aquation would manifest as a shift in the 
UV-Vis profile, producing isosbestic point(s) in the overlapping spectrums at 
different time points. The investigated RAS complexes are generally stable in water, 
with the exception of RAS-2T, RAS-3T and RAS-4T (Fig 4.2). Slight shifts in the 
spectrums and the formation of several isosbestic points were observed after 24 h in 
water. The minor shift in spectrums suggest that aquation of RAS-2T, RAS-3T and 








Figure 4.2: Stability of 9 RAS complexes. The stability of the 9 RAS complexes 
were determined by monitoring their UV-Vis profile over 24 h. Ligand exchange is 
evident by the formation of Isosbestic points on the UV-Vis spectrums. 
 
The log POW of RAS-1B – RAS-1T and RAS-4H were determined using the shake-
flask method similar to the procedure in Chapter 3.2 The log POW of RAS-2T, RAS-3T 
and RAS-4T could not be determined as their spectrums were significantly shifted 
after the partitioning and phase separation (data not shown). This was not surprising 
as RAS-2T, RAS-3T and RAS-4T already showed signs of aquation in water. The 
presence of a stronger nucleophile (n-octanol) in the system could have caused a more 
significant displacement of the chloride ion, resulting in a more significantly shifted 
spectrums. Any attempt to determined their log POW from their shifted spectrums 
would be inaccurate. 
In general, there were no observable trend between the structure of the investigated 
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be considered to be resistance to aquation (little or no shift in UV-vis spectrums), only 
some could be considered stable towards interfering nucleophiles as seen in the log 
POW studies. The trend in the log POW studies were as expected, where RAS complexes 
with more hydrophobic ligands displayed higher log POW (Table 4.1). 
4.2.3 In vitro activity studies 
To determine the effect of structural variation to cytotoxicity, we obtained the IC50 
values of the nine RAS complexes in colorectal cancer cell lines HCT116 and 
SW480, and gastric cancer cell lines AGS and KATOIII (Table 4.1). In general, the 
more hydrophobic hexamethylbenzene (HMB) and 1,3,5-triisopropylbenzene (TIPB) 
analogs demonstrated the highest toxicity in all cell lines, having IC50 values in the 
low micromolar range. RAS-1T displayed the greatest efficacy in all cell lines with 
IC50 close to 1 µM in HCT116, AGS and KATOIII and 4.07 µM in SW480. RAS-1T 
was also 34 times and 7 times more cytotoxic than cisplatin in AGS and KATOIII 
respectively. For compounds with the anisole functionality (RAS-1B – RAS-1T), 
there is an observable trend in which the IC50 values decreased with the increasing 
hydrophobicity of the arene ligand, from the least hydrophobic ‘benzene’ in RAS-1B 
to the most hydrophobic ‘TIPB’ in RAS-1T (Table 4.1, Fig 4.5a). As shown, 
variation of the arene ligand could be a way to modulate the cytotoxicity of similar 
singly-charged Ru(II)-arene complexes. 
RAS-1H demonstrated biphasic dose-response curve in AGS cells, where the cell 
viability decreased with increasing concentration of RAS-1H to reach a plateau of 
40% between 5 µM and 20 µM before dropping drastically to 0% above 20 µM (Fig 
4.3a). RAS-4H displayed a similar biphasic profile in KATOIII cells (Fig 4.3b). 
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is yet to be determined. In contrast, the TIPB analogs (RAS-1T and RAS-4T) did not 
display such biphasic dose-response profile. This may be an indication of a different 
mode-of-action between the HMB analogues and the TIPB analogues. 
Table 4.1. Log POW and cytotoxicity data for the RAS complexes. 
 
Complex Log Powa  
 
HCT116 




RAS-1B -2.32 ± 0.22 288 ± 44 155 ± 4 300 ± 10 213 ± 24 
RAS-1To -2.01 ± 0.21 175 ± 22 62.1 ± 17.9 117 ± 10 103 ± 21 
RAS-1C -1.58 ± 0.12 25.5 ± 4.0 27.0 ± 12.0 12.4 ± 1.7 14.2 ± 2.5 
RAS-1H -1.40 ± 0.15 5.76 ± 1.22 34.7 ± 19.3 3.04 ± 0.91 13.7 ± 5.0 
RAS-1T -0.85 ± 0.02 1.19 ± 0.12 4.07 ± 1.35 1.01 ± 0.07 1.22 ± 0.24 
RAS-2T n.d. 3.48 ± 0.36 5.32 ± 2.09 1.16 ± 0.28 1.86 ± 0.24 
RAS-3T n.d 6.87 ± 1.11 13.9 ± 5.5 3.07 ± 0.72 3.89 ± 0.15 
RAS-4T n.d 5.76 ± 0.13 11.0 ± 4.7 2.76 ± 0.82 3.28 ± 1.12 
RAS-4H -1.07 ± 0.03 3.05 ± 0.26 16.0 ± 6.1 1.95 ± 0.40 2.22 ± 0.35 
Oxaliplatin n.d. 1.22 ± 0.18 1.08 ± 0.36 n.d. n.d. 
Cisplatin n.d. n.d. n.d. 34.7 ± 0.8 8.64 ± 0.11 
aLog Pow values determined via the shake-flake method against 1:1 n-octanol:H2O partitioning. bIC50 
values is the concentration of Ru complexes required to inhibit 50% of cell growth with respect to 
control groups, measured by MTT assay after 48 h of incubation. Data obtained are based on the 
average of three independent experiments, and the reported errors are the corresponding standard 








Figure 4.3: Cytotoxic profiling. The dose-response curve of 4 RAS complexes in (a) 
AGS and (b) KATOIII cells are compared. Cell viability curves from three 
independent experiments are shown. RAS complexes with HMB ligands (RAS-1H 
and RAS-4H) demonstrate a cell line specific, biphasic toxicity profile.  
 
We further tested the ‘rate of saturation’ of complex RAS-1T and RAS-2T, which is 
the treatment time required for these complexes to reach a maximum cytotoxicity. 
This was done by varying treatment duration in HCT116 cells and allowing the cells 
to recover in drug-free media before IC50 determination at 48 h. RAS-1T reached 
saturation only at 24 h-treatment (Fig 4.4a). Interestingly, RAS-2T demonstrated a 
much faster rate of saturation with the similar toxicity between the 2 h-treatment and 
48 h-treatment (Fig 4.4b). This observed difference in saturation rate could be due to 
many factors such as active species in cell, rate of cellular uptake, efflux and 
molecular target. As mentioned, RAS-2T is prone to aquation and nucleophilic 
substitution reactions. Therefore, RAS-2T could behave as a ‘pro-drug’ and the 
resulting active species could be structurally very different compared to that of the 
more stable RAS-1T. This could have resulted in very different mode of cellular 
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saturation. Nevertheless, more studies are required to ascertain the mode-of-action of 
these complexes. 
 
Figure 4.4: RAS-1T and RAS-2T demonstrated different rate of saturation. 
Dose-response curve of HCT116 cells treated with various concentrations of (a) RAS-
1T and (b) RAS-2T for the indicated amount of time, before the drugs were removed 
and the cell allowed to recover in drug-free media for the remaining time.  
 
4.2.4 Drug uptake studies in HCT116 
One possibility for the observed higher cytotoxicity of compounds with more 
hydrophobic arene ligands is better cellular uptake via passive diffusion.3 More 
efficient cellular accumulation of the RAS compounds may result in a higher efficacy. 
We investigate (i) if varying the hydrophobicity of the arene ligands affected cellular 
uptake and (ii) if efficiency of drug uptake is the only factor determining the 
cytotoxicity of the RAS complexes. This was done by treating HCT116 cells with 
RAS complexes of varying arene ligands (RAS-1B – RAS-1T) at two different 
conditions for 24 h; one set of cells were treated at a single concentration (1.5 µM) 
and another set at equipotent IC50 concentration of the respective complexes. RAS-2T 
and oxaliplatin were also tested at the same conditions for comparison purposes. The 
samples were then washed, collected and digested separately in concentrated HNO3 
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Table 4.2: Log POW and drug uptake in HCT116 cells. 
 
Complex Log Powa  
Drug Uptake ng of Ru/ 106 cells 
      at 1.5 µM b                   at [IC50] c 
[IC50] in 
HCT116 / µM 
RAS-1B -2.32 ± 0.22 0.38 ± 0.05 12.9 ± 6.2 288 ± 44 
RAS-1To -2.01 ± 0.21 0.48 ± 0.05 17.1 ± 7.1 175 ± 22 
RAS-1C -1.58 ± 0.12 0.80 ± 0.14 13.6 ± 7.0 25.5 ± 4.0 
RAS-1H -1.40 ± 0.15 1.97 ± 0.54 6.09 ± 1.79 5.76 ± 1.22 
RAS-1T -0.85 ± 0.02 2.85 ± 0.85 2.48 ± 1.04 1.19 ± 0.12 
RAS-2T n.d. 0.64 ± 0.10 1.63 ± 0.69 3.48 ± 0.36 
Oxaliplatin n.d. 0.28 ± 0.26 0.29 ± 0.34 1.22 ± 0.18 
aLog Pow values determined via the shake-flake method against 1:1 n-octanol:H2O partitioning. bAfter 
treatment of HCT116 cells at a fixed concentration of 1.5 µM and cat equipotent [IC50] concentration 
for 24 hours, cells are collected, counted and digested in 70% HNO3 and then diluted to 2% for 
determination of [Ru] via ICP-MS. Drug uptake is expressed as ng of Ru per 106 of cells. Data shown 
is the mean ± s.d. of three independent experiments. 
 
As expected, there is a positive correlation between hydrophobicity, cellular 
accumulation and cytotoxicity for RAS-1B – RAS-1T (Fig 4.5a-b). When treated at 
the same concentration (1.5 µM), the most hydrophobic RAS-1T had 7.5 times higher 
uptake than the least hydrophobic RAS-1B. Higher uptake also corresponded with 
lower observed IC50 values, showing that efficiency of uptake is at least partially 
responsible for the cytotoxicity of the RAS complexes.  
However, uptake efficiency was not the only factor affecting the activity of the RAS 
complexes. The cellular accumulation of RAS-1B – RAS-1T varied significantly 
when treated at equipotent concentrations (Fig 4.5c). Accumulation of RAS-1T (2.48 
ng/106 cells) was 5 times less than for RAS-1B (12.9 ng/106 cells). This indicates that 
5 times less RAS-1T is required in the cell to reach similar toxicity as RAS-1B. Taken 
together, this shows that the arene ligands play a larger role than just modulating 
hydrophobicity of the RAS complexes; the molecular target or mode-of-action may be 








Figure 4.5: Drug uptake studies in HCT116 cells. (a) A plot of IC50 of RAS-1B – 
RAS-1T in 4 different cell lines against their respective Log POW. (b) A plot of 
cellular [Ru] accumulation of each complex against their respective Log POW when 
treated at a fixed concentration of 1.5 µM. (c) A plot of cellular [Ru] accumulation of 
each complex against their respective Log POW when treated at a equipotent IC50 
concentration of the respective complexes. (b-c) Ru amount determined by digesting 
known number of treated cells with concentrated HNO3 followed by measurement 
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Next, we investigated if organic cation transporters (OCT) could be responsible for 
the activity of RAS complexes in colorectal cancer in a similar fashion to oxaliplatin. 
Oxaliplatin is more effective in the treatment of colorectal cancer compared to 
cisplatin. This was attributed to the fact that oxaliplatin is a substrate of OCT 1/2 and 
had a more efficient cellular accumulation in colorectal cancer cells.4 HCT116 cells 
were treated with RAS-1T and RAS-2T for 7 h in the presence and absence of OCT 2 
inhibitor cimetidine. The complexes were then removed and replaced with drug-free 
media. Oxaliplatin was used as a positive control. Cimetidine did not have any effect 
on the viability of cells treated with RAS-1T and RAS-2T suggesting that both are not 
substrates of OCT 2 (Fig 4.6a-b). In contrast, viability of cells treated with oxaliplatin 
increased in the presence of cimetidine (Fig 4.6c). 
In general, our data seem to suggest that RAS complexes accumulated in the cell 
mainly via passive diffusion. Increasing hydrophobicity resulted in increased cellular 
uptake, which was characteristic of compounds that accumulate in the cell by passive 
diffusion. In addition, OCT transporters that are responsible for oxaliplatin’s cellular 
accumulation were not involved in the uptake of RAS complexes. Nevertheless, more 
studies are require to determine if other forms of energy-dependent uptake 








Figure 4.6: OCT 2 is not involved in the cellular uptake of RAS-1T or RAS-2T. 
Cell viability of colorectal cancer HCT116 after treatment with different 
concentrations of (a) RAS-1T, (b) RAS-2T and (c) oxaliplatin were determined, in 
the presence or absence of OCT 2 inhibitor cimetidine (1.5 mM). Cells were treated 
for 7 h before the drug solution was removed and replaced with drug-free media. Data 
represent Data represents mean ± sem of four replicates. Experiments were done 
independently for three times. 
 
4.2.5 Mode-of-action studies 
Previous findings in Chapter 3 showed that RAS-1T induced cell death in HCT116 
cells without the induction of p53. This suggested that RAS-1T was killing the cancer 
cells via a p53-independent pathway. To verify the p53-independence of the RAS 
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that has been treated with a subset of the RAS complexes. Treatments were carried 
out for 2 h, 6 h and 24 h at IC50 and IC75 of RAS-1H, RAS-1T, RAS-4T and RAS-4H.  
Western blot analysis was done for the expression of p53 and its targets, cell cycle-
regulating genes p21 and Cyclin D1 (Fig 4.7a).5-7 There was a lack of induction of 
these proteins by RAS-1H, RAS-1T and RAS-4H. RAS-4T demonstrated some 
induction of p53. However, it did not show any significant induction of p21 or Cyclin 
D1. In contrast, oxaliplatin exhibited a concentration and time-dependent upregulation 
of p53 and target gene p21. RT-qPCR analysis was done for the expression of p53-
regulated, anti-apoptotic gene Bcl-2, pro-apoptotic genes NOXA and BAX in cells 
treated with the RAS complexes (Fig 4.7b).8-10 RAS-1H, RAS-1T and RAS-4H 
induced a slight increased in expression of NOXA, particularly at the later time points 
(6 h and 24 h) while RAS-4T did not cause significant change in NOXA expression. 
All complexes induced negligible change in expression of BAX and Bcl-2. This was 
in contrast to the 3-fold induction of NOXA, 5.5-fold increase of BAX and a 
significant reduction in Bcl-2, after 24 h treatment with oxaliplatin at IC75 
concentration. 
The lack of significant induction of p53 and target genes, cyclin D1, p21, NOXA 
and BAX seems to suggest that all four complexes exerted it antiproliferation effect 
via a p53-independent pathway.  Even though RAS-4T induced some p53 
upregulation, it did not significantly change the expression of p21, NOXA, BAX or 
Bcl-2. This means that the antiproliferation effect of RAS-4T was not due to p53-
mediated cell cycle arrest or p53-mediated apoptosis. On the other hand, oxaliplatin 
significantly increased the expression of p21, NOXA and BAX. This was in 
agreement with previous studies, which showed that oxaliplatin induces p53-mediated 








Figure 4.7: Expression profile of p53 and its targets in HCT116 cells treated with 
RAS-1H, RAS-1T, RAS-4T and RAS-4H. (a) Western blot analysis of p53, cyclin 
D1 and p21, (b) expression levels of p53-target, pro-apoptotic and anti-apoptotic gene 
in HCT116 cells after treatment with RAS-1H, RAS-1T and oxaliplatin at IC50 and 
IC75 for 2h, 6h and 24h. Data represent mean ± s.d. of duplicates. Homogenenous 
protein loading determined with reference to actin and gene expression normalized 
against TBP levels. 
 
4.3 DISCUSSION 
Nine RAS complexes including lead compound RAS-1T was investigated and SAR 
studies on these complexes were done. In general, the more hydrophobic complexes 
displayed higher cellular accumulation and cytotoxicity across a panel of cancer cell 
lines. However, it was determined that more efficient uptake was not the only factor 
influencing cytotoxicity and that variation of the arene ligand appeared to also alter 
the mode-of-action. This was further confirmed by the biphasic cytotoxicity curve 
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anticancer compounds that exhibit similar biphasic dose-response. One such 
compound is Doxetaxal, which induced mitotic catastrophe at lower doses and p53-
independent apoptosis at higher doses in prostate cancer (PC3, DU145) and breast 
cancer cell lines (MCF7, MDA-MB-231).13-16 RAS-1H and RAS-4H could possibly 
possess similar concentration-dependent dual mode-of-action. 
The RAS complexes studied also seem to exert its anticancer activity via p53-
independent mode-of-action. In contrast with oxaliplatin, RAS-1H, RAS-1T, RAS-4T 
and RAS-4H did not upregulate expression of p53 or its target genes. As mentioned, 
this has important implications in treatment of drug-resistant cancers. The unique 
p53-independence, arene ligand-dependent, biphasic cytotoxicity profile of RAS 
complexes warrants further investigation. Therefore, we studied in detail RAS-1H and 
RAS-1T in the next chapter, in order to gain more insight into their molecular mode-
of-action. We also investigate their ability to bypass drug-resistance mechanisms. 
4.4 EXPERIMENTAL 
4.4.1 Materials 
All experimental procedures were carried out without additional precautions to 
exclude air or moisture unless otherwise specified. All chemicals and solvents were 
used as received. RuCl3.xH2O was purchased from both Precious Metals Online. [(η6-
benzene)RuCl2]2, [(η6-toluene)RuCl2]2, [(η6-cymene)RuCl2]2, [(η6-
hexamethylbenzene)RuCl2]2 and [(η6-1,3,5-triisopropylbenzene)RuCl2]2 were 
synthesized according to previously reported protocols.3, 17-19 Thiazolyl blue 
tetrazolium bromide (MTT), Trizma® Base BioUltra, Nonidet P-40, DL-
Dithiothreitol, Non-fat Dried Milk Bovine, TWEEN® 20, Ponceau S and Cimetidine, 
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Sigma-Aldrich (Singapore). Ultrapure water used was purified by a Milli-Q UV 
purification system (Sartorius Stedim Biotech SA). Gibco® Versene solution, 
Gibco® Trypsin/EDTA solution, 10% SDS solution, Penicillin-Streptomycin (10 000 
U/mL), Dulbecco's Phosphate-Buffered Saline (10x), TRIzol® Reagent and Applied 
Biosystem® High Capacity cDNA Reverse Transcription Kit were purchased from 
Life Technologies. HycloneTM RPMI 1640, DMEM medium and Fetal bovine serum 
(FBS) was purchased from Thermo Fisher Scientific Inc. Bio-rad Protein Assay Dye 
Reagent Concentrate, 40% Acrylamide/Bis solution, 10x Tris/glycine buffer, 
TEMED, 4x Laemmli Sample Buffer, Nitrocellulose Membrane, 0.2 µm and 0.45 µm 
were purchased from Bio-rad Laboratories. cOmplete, mini Protease Inhibitor 
Cocktail Tablets, RNase A, FastStart Universal Probe Master (Rox) were purchased 
from Roche Diagnostics.  LuminataTM Classico Crescendo Western HRP Substrate 
were purchased from Merck Millipore Corporation.  
4.4.2 Instrumentation 
1H NMR spectrums were obtained using either a Bruker AMX 300, Avance 400 or 
AMX 500 spectrometer and the chemical shifts (δ) were reported in parts per million 
with reference to residual solvent peaks. Electrospray-ionization Mass Spectrometry 
(ESI-MS) spectra were obtained using Thermo Finnigan MAT ESI-MS System. UV-
vis spectra were obtained using the Shimadzu UV-1800 UV Spectrophotometer with a 
TCC-240A Temperate Controlled Cell Holder. Ru concentrations were determined 
using the Optima ICP-OES (Perkin-Elmer) operated by CMMAC, NUS. Elemental 
analyses of selected Ru complexes were carried out using a Perkin-Elmer PE 2400 
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4.4.3 HPLC analysis of compound purity 
Determination of the purity of the RAS Complexes were done using analytical 
HPLC on a Shimadzu Prominence System equipped with a DGU-20A3 Degasser, two 
LC-20AD Liquid Chromatography Pump, a SPD-20A UV/Vis Detector and a Shim 
Pack GVP-ODS 2.0 mm 18 column (5 µM, 120Å, 250 mm x 4.60 mm i.d.) at r.t. at a 
flow rate of 1.0 mL/min with detection at both 214 nm and 254 nm. The gradient 
elution conditions were as follows: 20-80% solvent B over 30 min, where solvent A is 
10 mM NH4OAC pH 7.0 and solvent B is CH3CN. 
4.4.4 Synthesis of [(η6-benzene)RuCl(4-methoxy-N-(2-quinolinylmethylene)-
aniline)]Cl (RAS-1B) 
2-Quinolinecarboxaldehyde (78.6 mg, 0.5 mmol) and p-anisidine (61.5mg, 0.5 
mmol) was added to dry EtOH (10 mL) and and stirred at r.t. over 24 h. The solvent 
was removed in vacuo and dried. The resultant crude 4-methoxy-N-{2-
quinolinylmethylene}-aniline (94 mg, approx. 0.358 mmol) was treated with [(η6-
hexamethylbenzene)RuCl2]2 (89.6 mg, 0.179 mmol) in MeOH (20 mL) and stirred at 
r.t. over 12 h. The solvent was removed in vacuo and the resulting solid purified by 
gradient elution column chromatography (1:1 v/v EtOH/CHCl3, Rf = 0.2; EtOH, Rf = 
0.5). The purified product was redissolved in CHCl3 and filtered through a syringe 
colomn to remove trace amount of dissolved silica, before the solvent was removed in 
vacuo. The final product was then dried in vacuo for 1 h to give a dark red solid. 
Yield: 40 mg (22%). 1H NMR (400 MHz, D2O): δ 8.68 (d, 3J= 9 Hz, 1H, quinolinyl), 
8.57 (s, 1H, PhN=CH), 8.35 (d, 3JHH = 8 Hz, 1H, quinolinyl), 8.07 (t, 3JHH = 8 Hz, 1H, 
quinolinyl), 8.01 (d, 3JHH = 8 Hz, 1H, quinolinyl), 7.87 (t, 3JHH = 8 Hz, 1H, 
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C6H4OMe), 7.05 (d, 3JHH = 9 Hz, 2H, C6H4OMe), 5.83 (s, 6H, C6H6), 3.88 (s, 3H, 
OCH3) ppm. ESI-MS (+ve mode): m/z = 477 [M]+.  
4.4.5 Synthesis of [(η6-toluene)RuCl(4-methoxy-N-(2-quinolinylmethylene)-
aniline)]Cl (RAS-1To) 
RAS-1To was obtained with [(η6-toluene)RuCl2]2 (94.6 mg, 0.179 mmol) and crude 
4-methoxy-N-{2-quinolinylmethylene}-aniline (94 mg, approx. 0.358 mmol)  using 
the same protocol as used for RAS-1B (Gradient elution: 1:4 v/v EtOH/CHCl3, Rf = 
0.2; EtOH, Rf = 0.7). The final product was then dried in vacuo for 1 h to give a dark 
red solid. Yield: 65 mg (35%). 1H NMR (400 MHz, DMSO-d6): δ 9.16 (s, 1H, 
PhN=CH), 8.89 (d, 3JHH = 8 Hz, 1H, quinolinyl), 8.76 (d, 3JHH = 9 Hz, 1H, 
quinolinyl), 8.31 (t, 3JHH = 8 Hz, 2H, quinolinyl), 8.15 (t, 3JHH = 7 Hz, 1H, quinolinyl), 
7.99 (m, 3H, quinolinyl /C6H4OMe), 7.22 (d, 3JHH = 9 Hz, 2H, C6H4OMe), 6.07 (t, 
3JHH = 6 Hz, 1H, C6H5), 6.01 (d, 3JHH = 6 Hz, 1H, C6H5), 5.81 (t, 3JHH = 6 Hz, 1H, 
C6H5), 5.71 (t, 3JHH = 6 Hz, 1H, C6H5), 5.37 (d, 3JHH = 6 Hz, 1H, C6H5), 3.90 (s, 3H, 
ArOCH3), 2.17 (s, 3H, CH3) ppm. ESI-MS (+ve mode): m/z = 491 [M]+.  
4.4.6 Synthesis of [(η6-cymene)RuCl(4-methoxy-N-(2-quinolinylmethylene)-
aniline)]Cl (RAS-1C) 
RAS-1C was obtained with [(η6-cymene)RuCl2]2 (109.72 mg, 0.179 mmol) and 
crude 4-methoxy-N-{2-quinolinylmethylene}-aniline (94 mg, approx. 0.358 mmol) 
using the same protocol as used for RAS-1B (Gradient elution: 1:4 v/v EtOH/CHCl3, 
Rf = 0.3; 1:1 v/v EtOH/CHCl3, Rf = 0.5). The final product was then dried in vacuo 
for 1 h to give a dark orange solid. Yield: 125 mg (61%). 1H NMR (400 MHz, 
DMSO-d6): δ 9.15 (s, 1H, PhN=CH), 8.91 (d, 3JHH = 8 Hz, 1H, quinolinyl), 8.73 (d, 
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Hz, 1H, quinolinyl), 8.01 (t, 3JHH = 7 Hz, 1H, quinolinyl), 7.96 (d, 3JHH = 9 Hz, 2H, 
C6H4OMe), 7.23 (d, 3JHH = 9 Hz, 2H, C6H4OMe), 6.11 (d, 3JHH = 6 Hz, 1H, i-
PrC6H4Me), 5.89 (d, 3JHH = 6 Hz, 1H, i-PrC6H4Me), 5.75 (d, 3JHH = 6 Hz, 1H, C6H4), 
5.39 (d, 3JHH = 6 Hz, 1H, C6H4), 3.91 (s, 3H, ArOCH3), 2.32 (sept, 1H, 3JHH = 7 Hz, 
CH(Me)2), 2.24 (s, 3H, i-PrArCH3), 0.90 (d, 3JHH = 7 Hz, 3H, CH(CH3)2), 0.74 (d, 
3JHH = 7 Hz, 3H, CH(CH3)2) ppm. ESI-MS (+ve mode): m/z = 533 [M]+.  
4.4.7 Synthesis of [(η6-hexamethylbenzene)RuCl(4-methoxy-N-(2-
quinolinylmethylene)-aniline)]Cl (RAS-1H)  
RAS-1H was obtained with [(η6-hexamethylbenzene)RuCl2]2 (167. mg, 0.25 mmol) 
and crude 4-methoxy-N-{2-quinolinylmethylene}-aniline (131 mg, approx. 0.50 
mmol)  using the same protocol as used for RAS-1B (Gradient elution: 1:4 v/v 
EtOH/CHCl3, Rf = 0.4; 1:1 v/v EtOH/CHCl3, Rf = 0.7). The final product was then 
dried in vacuo for 1 h to give a deep red solid. Yield: 110 mg (37%). 1H NMR (400 
MHz, DMSO-d6): δ 8.99 (s, 1H, PhN=CH), 8.83 (d, 3JHH = 8 Hz, 1H, quinolinyl), 
8.37 (d, 3JHH = 9 Hz, 1H, quinolinyl), 8.28 (t, 3JHH = 8 Hz, 2H, quinolinyl), 8.15 (t, 
3JHH = 9 Hz, 1H, quinolinyl), 7.96 (m, 3H, quinolinyl/C6H4OMe), 7.22 (d, 3JHH = 9 
Hz, 2H, C6H4OMe), 3.88 (s, 3H, ArOCH3), 1.75 (s, 18H, C6(CH3)6) ppm. ESI-MS 
(+ve mode): m/z = 561 [M]+. Purity of the complex was determined to be >98% pure 
by elemental analysis and RP-HPLC. Analysis (Calcd., found for 
C29H32N2Cl2ORu.0.5H2O): C (57.52, 57.55), H (5.49, 5.23) N (4.63, 4.58). RP-HPLC 
(% Purity): 98.1% at 214 nm and 98.6% at 254 nm; tr = 19.8 min. 
4.4.8 Synthesis of [(η6-1,3,5-triisopropybenzene)RuCl(4-methoxy-N-(2-
quinolinylmethylene)-aniline)]Cl (RAS-1T/WH-536) 
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4.4.9 Synthesis of [(η6-1,3,5-triisopropybenzene)RuCl(N-(2-quinolinylmethylene)-
1-naphthylamine)]Cl.H2O (RAS-2T) 
2-Quinolinecarboxaldehyde (78.6 mg, 0.5 mmol) and 1-napthylamine (53.2 mg, 0.5 
mmol) was added to dry EtOH (10 mL) and and stirred at r.t. over 24 h. The solvent 
was removed in vacuo and dried. The resultant crude N-(2-quinolinylmethylene)-1-
naphthylamine (141 mg, approx. 0.5 mmol) was treated with [(η6-1,3,5-
triisopropylbenzene)RuCl2]2 (188 mg, 0.25 mmol) in MeOH (20 mL) and stirred at 
r.t. over 12 h. The solvent was removed in vacuo and the resulting solid purified by 
column chromatography (1:4 v/v EtOH/CHCl3, Rf = 0.6). The purified product was 
redissolved in CHCl3 and filtered through a syringe colomn to remove trace amount 
of dissolved silica, before the solvent was removed in vacuo. The final product was 
then dried in vacuo for 1 h to give a dark red solid. Yield: 198 mg (62%). 1H NMR 
(400 MHz, MeOD-d4): δ 9.12 (s, 1H, PhN=CH), 8.91 (d, 3JHH = 12 Hz, 1H, 
quinolinyl), 8.86 (d, 3JHH = 11 Hz, 1H, quinolinyl), 8.18 (m, 8H, quinolinyl/napthyl), 
7.72 (m, 3H, quinolinyl/napthyl), 5.86 (s, 3H, C6H3), 2.18 (sept, 3JHH = 9 Hz, 3H, 
CHMe2), 1.07 (d, 3JHH = 9 Hz, 9H, CH(CH3)2), 0.98 (d, 3JHH = 9 Hz, 9H, CH(CH3)2) 
ppm. ESI-MS (+ve mode): m/z = 623 [M]+. Purity of the complex was determined to 
be >95% pure by elemental analysis. Anal. Calcd for C35H38Cl2N2Ru.H2O (%): C 
62.12, H 5.96, N 4.14; Found: C 62.29, H 5.59, N 4.18. 
4.4.10 Synthesis of [(η6-1,3,5-triisopropybenzene)RuCl(3-trifluoromethyl-N-(2-
quinolinylmethylene)aniline)]Cl.3H2O (RAS-3T) 
2-Quinolinecarboxaldehyde (78.6 mg, 0.5 mmol) and 3-(trifluoromethyl)aniline 
(62.5 µl, 0.5 mmol) was added to dry EtOH (10 mL) and and stirred at r.t. over 24 h. 
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N-(2-quinolinylmethylene)aniline (150 mg, approx. 0.5 mmol) was treated with [(η6-
1,3,5-triisopropylbenzene)RuCl2]2 (188 mg, 0.25 mmol) in MeOH (20 mL) and 
stirred at r.t. over 12 h. The solvent was removed in vacuo and the resulting solid 
purified by gradient elution column chromatography (1:4 v/v EtOH/CHCl3, Rf = 0.4; 
1:1 v/v EtOH/CHCl3, Rf = 0.7). The purified product was redissolved in CHCl3 and 
filtered through a syringe colomn to remove trace amount of dissolved silica, before 
the solvent was removed in vacuo. The final product was then dried in vacuo for 1 h 
to give a light brown solid. Yield: 156 mg (46%). 1H NMR (400 MHz, DMSO-d6): δ 
9.23 (s, 1H, PhN=CH), 8.96 (d, 3JHH = 9 Hz, 1H, quinolinyl), 8.91 (d, 3JHH = 8 Hz, 
1H, quinolinyl), 8.53 (s(broad), 1H, C6H4), 8.43 (d, 3JHH = 8 Hz, 1H, C6H4), 8.31 (t, 
3JHH = 8 Hz, 2H, quinolinyl), 8.16 (t, 3JHH = 9 Hz, 1H, quinolinyl/C6H4), 8.01 (t, 3JHH 
= 8 Hz, 2H, quinolinyl/C6H4), 7.91 (t, 3JHH = 8 Hz, 1H, quinolinyl/C6H4), 5.60 (s, 3H, 
C6H3), 2.37 (sept, 3JHH = 7 Hz, 3H, CHMe2), 1.16 (d, 3JHH = 7 Hz, 9H, CH(CH3)2), 
0.84 (d, 3JHH = 7 Hz, 9H, CH(CH3)2) ppm. ESI-MS (+ve mode): m/z = 641 [M]+. 
Purity of the complex was determined to be >95% pure by elemental analysis. Anal. 
Calcd for C32H35Cl2F3N2Ru · 3H2O (%): C 52.60, H 5.66, N 3.83; Found: C 52.43, H 
5.46, N 3.84. 
4.4.11 Synthesis of [(η6-1,3,5-triisopropybenzene)RuCl(3-chloro-N-(2-
quinolinylmethylene)aniline)]Cl.3H2O (RAS-4T) 
2-Quinolinecarboxaldehyde (78.6 mg, 0.5 mmol) and 3-chloroaniline (52.9 mg, 0.5 
mmol) was added to dry EtOH (10 mL) and and stirred at r.t. over 24 h. The solvent 
was removed in vacuo and dried. The resultant crude 3-chloro-N-(2-
quinolinylmethylene)aniline (133 mg, approx. 0.5 mmol) was treated with [(η6-1,3,5-
triisopropylbenzene)RuCl2]2 (188 mg, 0.25 mmol) in MeOH (20 mL) and stirred at 
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column chromatography (1:4 v/v EtOH/CHCl3, Rf = 0.6). The purified product was 
redissolved in CHCl3 and filtered through a syringe colomn to remove trace amount 
of dissolved silica, before the solvent was removed in vacuo. The final product was 
then dried in vacuo for 1 h to give a dark red solid. Yield: 89 mg (28%). 1H NMR 
(400 MHz, MeOD-d4): δ 9.02 (d, 3JHH = 9 Hz, 1H, quinolinyl), 9.00 (s, 1H, 
PhN=CH), 8.79 (d, 3JHH = 8 Hz, 1H, quinolinyl), 8.25 (m, 3H, quinolinyl/C6H4), 8.15 
(t, 3JHH = 8 Hz, 1H, quinolinyl/C6H4), 8.06 (dt, 3JHH = 5 Hz, 1H, quinolinyl/C6H4), 
7.99 (t, 3JHH = 8 Hz, 1H, quinolinyl/C6H4), 7.65 (d, 3JHH = 5 Hz, 2H, quinolinyl/C6H4), 
5.60 (s, 3H, C6H3), 2.49 (sept, 3JHH = 7 Hz, 3H, CHMe2), 1.23 (d, 3JHH = 7 Hz, 9H, 
CH(CH3)2), 0.97 (d, 3JHH = 7 Hz, 9H, CH(CH3)2) ppm. ESI-MS (+ve mode): m/z = 
607 [M]+. Purity of the complex was determined to be >95% pure by elemental 
analysis. Anal. Calcd for C31H35Cl3N2Ru · 3H2O (%): C 53.41, H 5.93, N 4.02; 
Found: C 53.02, H 5.66, N 3.87. 
4.4.12 Synthesis of [(η6-hexamethylbenzene)RuCl(3-chloro-N-(2-
quinolinylmethylene)aniline)]Cl (RAS-4H/WH-433) 
RAS-4H was synthesized according to the procedure in Chapter 3. 
4.4.13 Tissue culture 
The human colorectal carcinoma cells HCT116, human colorectal adenocarcinoma 
cells SW480, human gastric adenocarcinoma AGS, human gastric carcinoma 
KATOIII were acquired from ATCC® (Manassa,VA). HCT116 and SW480 were 
cultured in DMEM medium containing 10% FBS and 1% Penicillin/Steptomycin 
(complete DMEM). AGS was cultured in RPMI 1640 medium containing 10% FBS 
and 1% Penicillin/Steptomycin. KATOIII was cultured in RPMI 1640 medium 
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°C in a humidified atmosphere of 95% air and 5% CO2. Experiments were performed 
on cells within 20 passages. 
4.4.14 Determination of Log Pow 
Log Pow of the RAS complexes were determined using the shake flask method.2 The 
RAS complex were predissolved in ddH2O that was presaturated with n-octanol (for 
24 h and left to stand until phase separation occurs). The UV-vis spectrum for each 
samples was obtained and the absorbances at the λmax of each compound were 
determined. Equal volume of n-octanol was added to each sample solution and the 
heterogeneous mixtures shaked for 2 h before centrifuging at 4000 rpm for 1 min to 
achieve phase separation. The final absorbance of the aqueous phase at the λmax of 
each compound were determined and their water-octanol partition coefficient were 
calculated. All experiments were done in triplicate. 
4.4.15 Inhibition of cell viability assay 
The anti-proliferation activity the RAS Complexes on exponentially growing cancer 
cells were determined using MTT assay as described previously.20 HCT116, SW480, 
AGS and KATOIII were seeded at 10 000 cells per well (100 µL) in Cellstar® 96-
well plates (Greiner Bio-One) and incubated for 24 h. Thereafter, cancer cells were 
exposed to drugs at different concentration in media for 48 h. The final concentration 
of DMSO in medium was < 1% (v/v) at which cell viability was not significantly 
inhibited. The medium was removed and replaced with MTT solution (100 µL, 0.5 
mg/mL) in media and incubated for an additional 45 min. Subsequently, the medium 
was aspirated, and the purple formazan crystals dissolved in DMSO (100 µL). The 
absorbance due to the dissolved purple formazan was then obtained at 565 nm. 
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defined as the concentration needed for a 50% reduction of survival based on the 
survival curves. IC50 values were calculated from the dose - response curves (cell 
viability vs drug concentration) obtained in repeated experiments and adjusted to 
actual [Ru] administered, which was determined using ICP-OES. The experiments 
were performed in 4 replicates for each drug concentration and were carried out at 
least three times independently. 
For cell viability assays involving inhibitors, Cimetidine (1.5 mM) were added 
together with test compounds and incubated for 7h. Thereafter, the drugs were 
removed and replace with fresh media for the remainder of the 48 h. Cell viability in 
the absence and presence of inhibitor was normalized against untreated control. 
Experiments were performed in 4 replicates and carried out at least three times 
independently.  
4.4.16 Drug uptake studies 
HCT116 cells were grown on Cellstar® 6-well plates (Greiner Bio-One) at a density 
of 500 000 cells/well for 24 h before being treated with RAS-1B – RAS-1T, RAS-2T 
and oxaliplatin at either at 1.5 µM or [IC50] for 24h. Thereafter, the drug-containing 
media was removed and washed once with EDTA/PBS followed by trypsinization. 
The cells were collected, counted and digested separately with 69% nitric acid. The 
samples were diluted to a final concentration of 2% nitric acid and the Ru or Pt 
content quantified via ICP-MS. 
4.4.17 Antibodies and western blot protocol 
HCT116 cells were grown on Cellstar® 6-well plates (Greiner Bio-One) at a 
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RAS-4T and RAS-4H at IC50 and IC75 for 2h, 6h and 24h. Oxaliplatin treatment at 
IC50 and IC75 was used as a positive control for several experiments. The cells were 
lysed with lysis buffer [100 µL, 1% NP40, 150 mM NaCl, 50 mM Tris-HCl (pH 8.0), 
protease inhibitor]. The cell lysate were transferred to separate 2 mL tubes and 
sonicated for 10 s. The samples were then centrifuged at 13000 rpm, 4˚C for 15 min. 
The supernatant liquid containing the proteins were collected and total protein content 
of each sample was quantified via Bradford’s assay. 50 µg of proteins from each 
sample were reconstituted in loading buffer [5% DDT, 1x Protein Loading Dye] and 
heated at 95˚C for 5 min. The protein mixtures were resolved on a 10% SDS-PAGE 
gel by electrophoresis and transferred to a nitrocellulose membrane. The proteins 
bands were visualized via enhanced chemiluminescence imaging (PXi, Syngene) after 
treatment with the primary antibodies and the appropriate secondary antibodies. Equal 
loading of protein was confirmed by comparison with actin. The following antibodies 
were used: p53 (FL-393), p21 (F-5) and Cyclin D1 (H-295) from Santa Cruz 
Biotechnologies. β-Actin (ab75186)  from Abcam. ECL Anti-rabbit IgG (NA934V) 
and ECL Anti-mouse IgG (NA931) from GE Healthcare Life Sciences. All antibodies 
were used at 1:1000 dilutions except for actin (1:10000), anti-mouse and anti-rabbit 
(1:5000). 
4.4.18 Primers and qPCR protocol 
Treatment conditions for HCT116 cells were similar to the protocol in western blot. 
RNA was extracted using TRIzol® Reagent and reverse transcription was performed 
with 2 µg of the extracted RNA using Applied Biosystem® High Capacity cDNA 
Reverse Transcription Kit with an Applied Biosystem® 2720 Thermal Cycler. 
Quantitative PCR was done on the resulting cDNA using FastStart Universal Probe 
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starting quantities of genes of interest were normalized against the housekeeping 
genes TBP and samples were done in duplicates. The specificity of the amplification 
was controlled by a melting curve. The gene and Assay ID of TaqMan probes are as 
follows: NOXA (Hs00560402_m1), BAX (Hs00180269_m1), Bcl-2 














RAS complexes Bypass Multidrug-Resistance 




The effectiveness of chemotherapeutic treatments could be greatly diminished1 due 
to the inherent or acquired MDR in many cancers such as gastric cancer, the third and 
fifth leading cause of cancer mortality in men and women respectively worldwide.2-5 
One particular MDR mechanism in these cancers has been determined to be defective 
or selective adaptation of apoptotic pathways.6-9 These includes the inactivation of 
p53, change in expression of pro-/anti-apoptotic genes such as BAX, Bcl-2 and Bcl-
xL, and decreased or loss of expression of apoptosis executors caspases.10-11 In 
addition, the overexpression of membrane-bound ‘efflux’ transporter P-gp, one of the 
main causes of MDR, is also known to inhibit apoptosis by preventing caspase 
activation.12-15  Given that most clinically used drugs act by inducing apoptosis as the 
primary mode-of-action,16-17 finding drugs that act via distinct pathways to induce 
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MDR. As mentioned, most metallo-drugs, including Ru(II)-arene complexes induce 
apoptotic cell death. There is still a need for new metallo-drugs that are able to bypass 
this MDR mechanism and induce alternative PCDs. 
In the previous chapter, RAS-1H and RAS-1T demonstrated low micromolar IC50 
values in several cancer cell lines. The lack of hydrolysis, interaction with nucleotide 
dGMP or induction of p53 also suggested that RAS-1T acted via a mode-of-action 
different from cisplatin and many other reported anticancer Ru(II) complexes.  Using 
gastric cancer as a model in this chapter, we show that both RAS-1H and RAS-1T are 
able exert its anticancer activity by bypassing a specific mechanism of MDR to 
induce non-apoptotic PCD. In addition, we demonstrate that varying the facially-
bound arene ligands could have drastic effect on the compounds’ mode-of-action. 
Further comparison of the efficacy of RAS-1H and RAS-1T to other clinical drugs 
such as doxorubicin, etoposide and 5-fluorouracil in drug-sensitive and drug-resistant 
colorectal cancer cell line further validated the ability of RAS-1H and RAS-1T to 
circumvent drug-resistance mechanisms. 
5.2 RESULTS  
5.2.1 Cytotoxic profiling of anticancer RAS-1H and RAS-1T 
Earlier, we reported the synthesis and screening of 450 RAS complexes for 
anticancer activity in Chapter 2. We observed that the complexes with hydrophobic 
ligands elicit a stronger cytotoxic effect in Chapter 4 and identified RAS-1H and 
RAS-1T (Fig 5.1a) as having excellent anticancer activity in a panel of gastric and 
colorectal cancer cell lines (Table 5.1). The IC50 of RAS-1T were also 34 times and 7 
times lower than that of cisplatin in gastric cancer cell lines AGS and KATOIII 
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values 11 times lower than cisplatin in AGS and 1.5 times higher in KATOIII. A 
closer scrutiny of the cytotoxicity curve of RAS-1H in AGS revealed a bi-phasic 
profile that is different from that of RAS-1T (Fig 5.1b). This suggest a different 
mode-of-action between RAS-1H and RAS-1T that is yet to be determined. Hence, 
we determined two equipotent concentrations at low dose (LD) and high dose (HD) 
of each complex for cell treatments and all other mode-of-action studies. 
 
 
Figure 5.1: The RAS complexes studied and their cytotoxicity in AGS gastric 
adenocarcinoma. (a) The structure of complexes RAS-1H and RAS-1T. (b) Cell 
viability curve of Compound RAS-1H and RAS-1T. Overlapping curves of three 
independent experiments are shown. RAS-1H displayed a biphasic cytotoxicity curve 
unlike RAS-1T, hinting at a differing mode-of-action.  Two equipotent concentrations 
at low-dose (LD) and high-dose (HD) were chosen for cell treatment in proteins and 
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Table 5.1. Log POW and cytotoxicity data taken from Table 4.1. 
 
Complex 
Log Powa   
HCT116 






RAS-1H -1.40 ± 0.15 5.76 ± 1.22 34.7 ± 19.3 3.04 ± 0.91 13.7 ± 5.0 
RAS-1T -0.85 ± 0.02 1.19 ± 0.12 4.07 ± 1.35 1.01 ± 0.07 1.22 ± 0.24 
Oxaliplatin n.d. 1.22 ± 0.18 1.08 ± 0.36 n.d. n.d. 
Cisplatin n.d. n.d. n.d. 34.7 ± 0.8 8.64 ± 0.11 
aLog Pow values determined via the shake-flake method against 1:1 n-octanol:H2O partitioning. 
bIC50 
values is the concentration of Ru complexes required to inhibit 50% of cell growth with respect to 
control groups, measured by MTT assay after 48 h of incubation. Data obtained are based on the 
average of three independent experiments, and the reported errors are the corresponding standard 
deviations. The IC50 were corrected using actual [Ru] determined using ICP-OES. 
 
5.2.2 RAS-1H and RAS-1T induce non-apoptotic programmed cell death 
To investigate if RAS-1H and RAS-1T induced apoptotic form of PCD, we first 
investigate apoptosis biomarkers commonly induced by cisplatin treatment. Cisplatin 
induces cell death by activating the intrinsic apoptosis pathway, resulting in the 
induction of p53, upregulation of pro-apoptotic BAX and down-regulation of anti-
apoptotic Bcl-2.18 The subsequent release of cytochrome C from the mitochondrial 
signals a cascade of events such as caspase 3 and PARP-1 cleavage, which eventually 
lead to apoptosis.19-20 Indeed, western blot analysis of AGS cells showed that there 
was significant upregulation of p53 and cleavage of caspase 3 and PARP-1 in cells 
treated with cisplatin for 24h (Fig 5.2a). Concurrent increase of BAX and decrease of 
Bcl-2 gene expression were also observed at 24h (Fig 5.2b). In contrast, cells treated 
with RAS-1H and RAS-1T did not demonstrate these hallmarks of apoptosis 
regardless of the concentration or duration of treatment (Fig 5.2a-b). This suggests 
that RAS-1H and RAS-1T did not induce cell death via the intrinsic apoptosis 








Figure 5.2: Complexes RAS-1H and RAS-1T do not induce intrinsic apoptosis 
biomarkers. (a) Western blot analysis of proteins related to the apoptosis pathway 
and (b) expression levels of pro-apoptotic and anti-apoptotic genes in AGS cells after 
treatment with RAS-1H, RAS-1T and cisplatin at LD and HD for 6h and 24h. Data 
represent mean ± s.d. of duplicates (* p<0.05, *** p<0.001; two-tailed Student’s t-
test). Homogenenous protein loading determined with reference to actin and gene 
expression normalized against TBP levels.  
 
One of the distinct hallmarks of apoptosis is the activation of apoptosis executor 
caspases.21 To validate that RAS-1H and RAS-1T induced non-apoptotic PCD, we 
studied their activity in the absence and presence of a broad-spectrum caspase-
inhibitor, Z-VAD-FMK. Co-treatment of cells with Z-VAD-FMK did not reduce the 
efficacy of RAS-1H or RAS-1T, as seen in their unchanged IC50 values (Fig 5.3). To 
rule out the possibility of randomized necrotic cell death, we also tested the activity of 
RAS-1H and RAS-1T in the absence and presence of IM-54, an inhibitor of necrosis. 
Cell viability of cell treated with various concentration of RAS-1H and RAS-1T did 
not change significantly in the presence of IM-54, ruling out necrosis as the form of 
cell death (Appendix G). Taken together, RAS-1H and RAS-1T appear to induce a 









Figure 5.3: Complexes RAS-1H and RAS-1T induces caspase-independent cell 
death. IC50 values of RAS-1H, RAS-1T and cisplatin after 48h treatment in AGS 
cells, in the absence and presence of apoptosis inhibitor Z-VAD-FMK (5 µM). Data 
represent mean ± s.e.m. of two independent experiments (* p < 0.05; two-tailed 
Student’s t-test). 
 
5.2.3 RAS-1H and RAS-1T induces early ROS and activate cellular antioxidant 
defense 
Many Ru(II) complexes have been reported to induce cellular ROS.22-23 We 
investigate cellular ROS generation in AGS gastric cancer cells using a cell-
permeable ROS probe, carboxy-H2DCFDA. Indeed, we observed that ROS was 
induced in cells treated with both RAS-1H and RAS-T in a concentration-dependent 
manner. ROS was also induced at an early time point of 3 h and decreased with time 
(Fig 5.4a). In addition, the fluorescence images of cells treated with RAS-1H and 
RAS-1T for 6 h showed significantly more fluorescence cells as compared to 








Figure 5.4: Complexes RAS-1H and RAS-1T induces early time point ROS. (a) 
Detection of ROS in AGS cells with carboxy-H2DCFDA (20 µM) after treatment with 
RAS-1H and RAS-1T for 3 h, 6 h and 9 h using microplate assay. Data represent 
mean ± s.e.m. of eight replicates (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 
0.0001; two-tailed Student’s t-test). Experiment was performed twice independently. 
(b) Detection of ROS after treatment for 6 h with fluorescence microscope. Image 
was taken at 112x magnification (scale bar = 100 µm). Comparison with visible-light 
image of cells is shown in (Appendix H).  
 
ROS production is usually followed by the activation of cellular antioxidant 
defense. Central to the antioxidant defense is the transcription factor Nrf-2.24-25 Nrf-2 
is responsible for the regulation of several downstream targets that mediate oxidative 
stress. These include gclc, encoding a protein involved in the synthesis of 
detoxification molecule GSH and GST;26 mrp2, encoding a membrane-bound protein 
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sequestering ROS.28 When ROS levels are elevated, Nrf-2 is activated and it increases 
the expression of its target genes (Fig 5.5a). We measured the expression levels of 
Nrf-2 and its target genes to investigate if cellular antioxidant defense was activated. 
As expected, Nrf-2 upregulation was observed after 6 h treatment at HD for both 
RAS-1H and RAS-1T (Fig 5.5b). Similarly, mRNA levels for three Nrf-2 target 
genes, mrp2, gclc and nqo1, were induced by both compounds at 6 h treatment at HD 
(Fig 5.5c).  This was consistent with the induction of ROS observed at early time 
points. However, there were differences in the Nrf-2 expression and activity pattern 
for both compounds. First, the protein levels for Nrf-2 were higher after RAS-1H 
treatment compared to RAS-1T.  In addition, Nrf-2 returned to basal levels at 24 h for 
RAS-1T while Nrf-2 induction remained elevated at 24 h for both concentration of 
RAS-1H treatment. Finally, the RNA level of gclc were more significantly induced by 
RAS-1H than RAS-1T. Since ROS induction was similar for both compounds, there 
could be additional factors regulating Nrf-2 in RAS-1H treated cells. To note, 
upregulation of mrp2 mRNA was more modest and only detected at 6 h HD treatment 
(Fig 5.5c). Taken together, these suggest that RAS-1H and RAS-1T induce early time 








Figure 5.5: Complexes RAS-1H and RAS-1T activate cellular antioxidant 
defense mechanism. (a) A simplified diagram of the genes involved in the cellular 
antioxidant defense mechanism. (b) Western blot analysis of Nrf-2, a central protein 
in cellular antioxidant defense and (c) expression levels of Nrf-2 target gene in AGS 
cells after treatment with RAS-1H, RAS-1T and cisplatin at LD and HD for 6 h and 
24 h. Data represent mean ± s.d. of duplicates. Homogenenous protein loading 
determined with reference to actin and gene expression normalized against TBP 
levels. 
 
5.2.4 Endoplasmic reticulum stress, unfolded protein response and autophagy 
pathway 
The relationship between ROS and endoplasmic reticulum (ER) stress has been well 
established.29-30 ROS is intricately linked to ER stress both directly and indirectly and 
could occur upstream or downstream of ER stress as ‘Cause’ or ‘Consequence’. ER 
stress is characterized by the unfolded protein response (UPR), which could lead to 
recovery, cellular dysfunction or cell death.31 Three distinct UPR signaling pathways 
have been identified, namely the PERK/eif2α, IRE1α/XPB-1s or ATF6 pathway (Fig 
5.6a).32 Within each pathway, various biomarkers could be used to detect ER stress. 
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RAS-1H and RAS-1T induce ER stress biomarkers and if ER stress-induction was 
critical to the activity of these compounds.  
 
Figure 5.6: Complexes RAS-1H and RAS-1T induce ER stress via the 
IRE1α/XPB-1s pathway. (a) A simplified diagram summarizing the three pathway 
of UPR and the key proteins involved. (b) Western blot analysis of several 
biomarkers of UPR in AGS cells after treatment with RAS-1H, RAS-1T and cisplatin 
at LD and HD for 6 h and 24 h. Homogenenous protein loading determined with 
reference to actin. 
 
Indeed, preliminary investigation showed that both RAS-1H and RAS-1T induced 
ER stress via the IRE1α/XPB-1s pathway as seen by the increased accumulation of 
XBP-1s after 6 h treatment at HD (Fig 5.6b). Induction of downstream target CHOP 
at both 6 h and 24 h HD treatments also confirmed the induction of ER stress.33 
Interestingly, the RAS-1H was more potent to induce CHOP, while RAS-1T favored 
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compounds might trigger different signaling pathways. It is also worth noting that 
CHOP has a pro-apoptotic function and is usually involved in a signaling cascade 
leading to the activation of caspases and apoptosis. Since RAS-1H and RAS-1T did 
not induce apoptosis, CHOP could possibly have a separate function. Alternatively, 
there could be other factors suppressing CHOP-induced apoptosis. 
 
Figure 5.7: Complex RAS-1H induces autophagy inhibition. (a) A simplified 
diagram summarizing the biomarkers involved in the autophagy pathway. (b) Western 
blot analysis of several biomarkers of autophagy in AGS cells after treatment with 
RAS-1H, RAS-1T and cisplatin at LD and HD for 6 h and 24 h. Homogenenous 
protein loading determined with reference to actin. 
 
To further understand the molecular mechanisms linking RAS-1H and RAS-1T to 
cell death, we investigated their involvement in the autophagy pathway, as autophagy 
is closely linked to ER stress and some cross talk exist between the two pathways.34 
Moreover, autophagy is also connection to Nrf-2 regulation.35 During autophagy, p62 
(SQSTM1) undergoes degradation and LC3-I is converted to LC3-II.35-36 Conversely, 
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and LC3-II (Fig 5.7a).37 Interestingly, treatment with RAS-1H caused a substantial 
accumulation of p62 and LC3 as observed during autophagy inhibition (Fig 5.7b). In 
contrast, RAS-1T has almost no effect on p62 and LC3 protein levels, highlighting 
again the strong differences existing between RAS-1T and the novel compound RAS-
1H. 
5.2.5 RAS-1H and RAS-1T induce cell death via distinct pathways 
The question remained as to whether the induction of ROS and ER stress was 
critical to the activity of RAS-1H and RAS-1T. To ascertain the role that ROS and ER 
stress played in signaling PCD in RAS-1H and RAS-1T treated cells, we measured 
the cell viability at various treatment concentrations of both compounds in the 
absence or presence of ROS quencher, N-acetylcysteine (NAC). We also measured 
protein expression of Nrf-2, XBP-1s and CHOP in treated cells with and without 
NAC. Cell death induced by treatments up to 2.5 µM (HD) of RAS-1T was 
completely suppressed by co-treatment with NAC. 50% of cells at 10 µM of RAS-1T 
treatment were rescued by co-treatment with NAC (Fig 5.8a). In addition, the 
induction of Nrf-2 by RAS-1T was suppressed in cells co-treated with NAC (Fig 
5.8b). This showed that ROS induction was an important factor contributing to the 
anticancer activity of RAS-1T and that quenching ROS would impede the activity of 
RAS-1T and ‘turn off’ antioxidant defense. Likewise, ER stress markers XBP-1s and 
CHOP were also mostly suppressed in cell co-treated with NAC. Taken together, this 
shows that ROS were important for the activity of RAS-1T and that it induced cell 
death via ROS-mediated ER stress. 
In contrast, RAS-1H seemed to have a different mode-of-action compared to RAS-
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less than 30 µM (HD) (Fig 5.9a). Surprisingly, NAC treatment did not block RAS-
1H-induced Nrf-2 protein levels at 6 h treatment and had only a partial effect at the 24 
h time point (Fig 5.9b). Moreover, quenching of ROS also did not suppress XBP-1s 
or CHOP induction. In fact, co-treatment of RAS-1H with NAC increased ER stress 
as indicated by the marked increase in XBP-1s and CHOP accumulation. This 
suggested that the cell death induced by RAS-1H was not directly dependent on the 
elevated ROS level and that the ER stress was not a consequence of this elevated ROS 
level. It also indicated that the induction of CHOP and XBP-1s by RAS-1H was not 
sufficient to induce cell death.  
ROS accumulation also seems to be linked to the autophagy inhibition by RAS-1H. 
Importantly, the accumulation of p62 and LC3 caused by RAS-1H was suppressed in 
the presence of NAC (Fig. 5.9c). This same treatment partly increased cell viability 
(Fig. 5.9a). These observations suggest that the production of ROS caused the 
inhibition of autophagy, and that when the autophagy process was restored by the 
treatment with NAC, cells were partly protected from death.  The inverse correlation 
between p62/LC3 accumulation and CHOP/XBP-1s protein levels suggested a strong 
interplay between the ER stress and the autophagy pathway in the impact of RAS-1H 
on cell death. Nevertheless, further studies are required to confirm if autophagy 














Figure 5.8: RAS-1T induces cell death via ROS-mediated ER stress. (a) Cell 
viability (%) of AGS cells treated with RAS-1T for 48 h in the presence and absence 
of NAC (2 mM). Data represent mean ± s.e.m. of three independent experiment. (** p 
< 0.01, *** p < 0.001, **** p < 0.0001; two-tailed Student’s t-test). (b) Western blot 
analysis of key protein markers of ER stress markers and (c) western blot analysis of 
key protein markers of autophagy in AGS cells after treatment with RAS-1T at HD in 
the absence and presence of NAC (2 mM). Homogenenous protein loading 















Figure 5.9: Quenching of ROS did not mitigate the cytotoxic effect of RAS-1H. 
(a) Cell viability (%) of AGS cells treated with RAS-1H for 48 h in the presence and 
absence of NAC (2 mM). Data represent mean ± s.e.m. of three independent 
experiment. (** p < 0.01, *** p < 0.001, **** p < 0.0001; two-tailed Student’s t-test). 
(b) Western blot analysis of key protein markers of ER stress markers and (c) western 
blot analysis of key protein markers of autophagy in AGS cells after treatment with 
RAS-1H at HD in the absence and presence of NAC (2 mM). Homogenenous protein 
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5.2.6 Cytotoxic profile of RAS-1H and RAS-1T in sensitive and drug-resistant 
colorectal cancer 
TC7 is a cell line cloned from parental colorectal adenocarcinoma Caco-2 by the 
limited dilution technique.38 It is less sensitive to drug treatment compared to other 
cell lines of the same type. It also has a p53-null status and a higher basal expression 
of anti-apoptotic Bcl-2 and Bcl-xL, as well as a lower expression of pro-apoptotic 
BAX. A study done on the activity of 5-fluorouracil in a panel of colorectal cancer 
cell lines, including TC7, showed a positive correlation between their resistance to 5-
fluorouracil treatment, and their basal (Bcl-2 + Bcl-xL) / BAX expression ratio.39 This 
suggests that the drug resistance observed in TC7 is in part due to apoptosis-
resistance. In principle, compounds that induced alternative PCD should have a better 
activity in TC7 compared to apoptosis-inducing drugs. 
In order to validate the ability of RAS-1H and RAS-1T to overcome drug resistance 
associated with altered apoptosis pathway, we tested these compounds in drug-
resistant colorectal cancer TC7 and its drug-sensitive counterparts HT-29 and 
HCT116. We compared their activity to known clinical drugs doxorubicin, 5-
fluorouracil, etoposide and oxaliplatin. The resistance factor (RF) was calculated 
based on the quotient of the IC50 of TC7 and the IC50 of either HT-29 or HCT116. 
This was used as a measure of the susceptibility of the compounds to the resistance 
mechanism of TC7 with a higher value indicating a greater susceptibility. 
Indeed, both RAS-1H and RAS-1T were less affected by the resistance mechanism 
of TC7 compared most tested clinical drugs (Fig 5.10 and Fig 5.11; Table 5.2). In 
particular, RAS-1T had the lowest RF amongst all the tested compounds, obtaining a 
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and 60.0 (HCT116) observed for doxorubicin, and RF of > 111 (HT-29) and >123 
(HCT116) observed for 5-fluorouracil. RAS-1H also obtained low RF values of 13.9 
(HT-29) and 13.6 (HCT116), which were better than most of the tested clinical drug 
except for oxaliplatin with an RF of 7.6 (HCT116). In addition, RAS-1T also had the 
lowest IC50 value amongst the tested drug against TC7. Again, this highlights the 
ability of RAS-1T to circumvent apoptosis resistance. 
Our results seem to suggest that the drug resistance of TC7 did not impact the 
efficacy of RAS-1H or RAS-1T to a great extent, unlike what was observed in the 
tested clinical drugs. This was in agreement with our hypothesis that RAS-1H and 
RAS-1T were able to bypass the apoptosis resistance of TC7. 











RAS-1H 99.6 ± 18.1 7.15 ± 0.66 7.33 ± 0.78 13.9 13.6 
RAS-1T 14.7 ± 3.6 1.93 ± 0.56 3.08 ± 1.04 7.6 4.8 
Oxaliplatin 17.4 ± 0.6 0.87 ± 0.25 2.29 ± 0.7 20.0 7.6 
Etoposide 468 ± 0 17.5 ± 5.5 16.6 ± 0.8 26.7 28.2 
5-Fluorouracil > 1000 8.99 ± 3.62 8.16 ± 1.97 >111 >123 
Doxorubicin 25.8 ± 2.51 0.36 ± 0.04 0.43 ± 0.17 71.7 60.0 
aIC50 values is the concentration of Ru complexes required to inhibit 50% of cell growth with respect to 
control groups, measured by MTT assay after 48 h of incubation. Data obtained are based on the 
average of three independent trials, and the reported errors are the corresponding standard deviations. 
The IC50 were corrected using actual [Ru] determined using ICP-OES. Resistance Factor (RF) is 
















Figure 5.10: Cytotoxicity data for drug-resistant and drug-sensitive cell lines (1). 
Efficacy of RAS-1H and RAS-1T in drug-resistant TC7 and drug-sensitive HT-29 are 













Figure 5.11: Cytotoxicity data for drug-resistant and drug-sensitive cell lines (2). 
Efficacy of RAS-1H and RAS-1T in drug-resistant TC7 and drug-sensitive HCT116 
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5.3 DISCUSSION  
One of the hallmarks of cancer cells is their inherent ability to evade cell death.40 To 
complicated matters, some cancer types have adapted apoptosis pathway that confer 
them further resistance to drug-induced apoptosis. One strategy to overcome this 
mechanism of MDR is to restore the expression or function of the lost pro-apoptotic 
gene in cancer cell through chemical or genetic means.41-43 A more attractive strategy 
would be to bypass this mechanism of MDR entirely to induce cancer cell death via a 
non-apoptotic PCD. Since most clinical drugs act by inducing apoptosis, there is need 
for more anticancer drug candidates that are able to induce alternative forms of PCDs. 
RAS-1H and RAS-1T displayed good activity in a panel of colorectal and gastric 
cancer cell lines. They are able to exert their activity via non-apoptotic PCD. This was 
apparent by the lack of involvement of caspases in signaling cell death. We further 
validated the ability of RAS-1H and RAS-1T to bypass the ‘apoptosis-resistance’ 
mechanism of MDR by demonstrating that ‘apoptosis-resistant’ TC7 cells was more 
sensitive to RAS-1H and RAS-T compared to several other apoptosis-inducing drugs.  
Although RAS-1H and RAS-1T are structurally similar and both induced non-
apoptotic PCD, the cell death pathway implicated is different for each compound. We 
conclusively showed that RAS-1T induced cell death via ROS-mediated ER stress 
and that quenching of ROS with NAC has a cyto-protective effect and reduced ER 
stress. In contrast, the cell death induced by RAS-1H was not directly dependent on 
the elevated ROS level. The same is true for RAS-1H-induced ER stress. Preliminary 
investigation seems to suggest that autophagy inhibition may at least be partly 
responsible for the activity of RAS-1H. Autophagy is a pro-survival mechanism under 
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autophagy increased the sensitivity of cancer cells to drug treatment.23, 37, 46 In 
scenarios where autophagy act as a pro-survival mechanism, inhibition of autophagy 
could complement alternative PCD to overcome MDR.47  
Variation of the arene ligand in half-sandwich Ru complexes is commonly used as a 
means to modulate physical properties such as hydrophobicity and solubility. Limited 
studies have been done on how arene ligands could influence the cellular mode-of-
action. In the current studies, we demonstrated that a subtle change in the arene ligand 
could have a drastic effect on its mode-of-action. This should to be taken into 
consideration when designing such compounds as anticancer agents. 
 
Figure 5.12: Proposed mode-of-actions of compound RAS-1H and RAS-1T. 
RAS-1H causes alternative PCD via autophagy dysfunction while RAS-1T does so 










5.4.1 Materials  
All experimental procedures were carried out without additional precautions to 
exclude air or moisture unless otherwise specified. All chemicals and solvents were 
used as received. RuCl3.xH2O was purchased from both Precious Metals Online. [(η6-
hexamethylbenzene)RuCl2]2 and [(η6-1,3,5-triisopropylbenzene)RuCl2]2 were 
synthesized according to previously reported protocols.48-49 Thiazolyl blue tetrazolium 
bromide (MTT), Trizma® Base BioUltra, Nonidet P-40, DL-Dithiothreitol, Non-fat 
Dried Milk Bovine, TWEEN® 20, Ponceau S, N-acetylcysteine, IM-54, Necrostatin-
1, Ferrostatin-1, were purchased from Sigma-Aldrich. All other chemicals used were 
purchased from Sigma-Aldrich (Singapore). Ultrapure water used was purified by a 
Milli-Q UV purification system (Sartorius Stedim Biotech SA). Molecular Probes® 
5-(and-6)-carboxy-2’,7’-dichloro-dihydrofluorescein diacetate mixed isomer, Gibco® 
Versene solution, Gibco® Trypsin/EDTA solution, Gibco® MEM Non-essential 
Amino Acids solution (NEAA), 10% SDS solution, Penicillin-Streptomycin (10 000 
U/mL), Dulbecco's Phosphate-Buffered Saline (10x), TRIzol® Reagent and Applied 
Biosystem® High Capacity cDNA Reverse Transcription Kit were purchased from 
Life Technologies. HycloneTM RPMI 1640, DMEM medium and Fetal bovine serum 
(FBS) was purchased from Thermo Fisher Scientific Inc. Bio-rad Protein Assay Dye 
Reagent Concentrate, 40% Acrylamide/Bis solution, 10x Tris/glycine buffer, 
TEMED, 4x Laemmli Sample Buffer, Nitrocellulose Membrane, 0.2 µm and 0.45 µm 
were purchased from Bio-rad Laboratories. cOmplete, mini Protease Inhibitor 
Cocktail Tablets, RNase A, FastStart Universal Probe Master (Rox) and FastStart 
Universal SYBR Green Master (Rox) were purchased from Roche Diagnostics.  
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purchased from Merck Millipore Corporation. Pan Caspase Inhibitor Z-VAD-FMK 
was purchased from R&D SystemsTM. 
5.4.2 Instrumentation 
1H NMR spectrums were obtained using either a Bruker AMX 300, Avance 400 or 
AMX 500 spectrometer and the chemical shifts (δ) were reported in parts per million 
with reference to residual solvent peaks. Electrospray-ionization Mass Spectrometry 
(ESI-MS) spectra were obtained using Thermo Finnigan MAT ESI-MS System. UV-
vis spectra were obtained using the Shimadzu UV-1800 UV Spectrophotometer. Ru 
concentrations were determined using the Optima ICP-OES (Perkin-Elmer) operated 
by CMMAC, NUS. Elemental analyses of selected Ru complexes were carried out 
using a Perkin-Elmer PE 2400 elemental analyzer by CMMAS, NUS. Absorbance 
and fluorescence on 96-well plates were measured using TriStar2 Multimode Reader 
LB942 from Berthold Technologies. mRNA was quantified using Thermo Scientific 
Nanodrop 1000 Spectrophotometer. Reverse Transcriptase-PCR was done using 
Applied Biosystems® 2720 Thermal cycler. qPCR was done using Applied 
Biosystems® 7500 Real Time PCR System. Fluorescence microscope images was 
taken with a AxiomZoom.V16. 
5.4.3 Synthesis of RAS-1H, [(η6-hexamethylbenzene)RuCl(4-methoxy-N-(2-
quinolinylmethylene)-aniline)]Cl 
Complex RAS-1H was synthesized according to methods described in Chapter 4.  
5.4.4 Synthesis of RAS-1T, [(η6-1,3,5-triisopropybenzene)RuCl(4-methoxy-N-(2-
quinolinylmethylene)-aniline)]Cl  
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5.4.5 Cell lines and tissue culture 
The human colorectal carcinoma cells HCT116, human colorectal adenocarcinoma 
cells SW480 and HT-29, human gastric adenocarcinoma AGS, human gastric 
carcinoma KATOIII were acquired from ATCC® (Manassa,VA). TC7 cells were 
cloned from parental colorectal adenocarcinoma Caco-2 by the limited dilution 
technique.38 HCT116, HT-29 and SW480 were cultured in DMEM medium 
containing 10% FBS and 1% Penicillin/Steptomycin (complete DMEM). TC7 was 
cultured in DMEM medium containing 20% FBS, 1% Penicillin/Steptomycin and 1% 
NEAA. AGS was cultured in RPMI 1640 medium containing 10% FBS and 1% 
Penicillin/Steptomycin. KATOII was cultured in RPMI 1640 medium containing 20% 
FBS and 1% Penicillin/Steptomycin. All cell lines were grown at 37 °C in a 
humidified atmosphere of 95% air and 5% CO2. Experiments were performed on cells 
within 20 passages. 
5.4.6 Inhibition of cell viability assay 
The anti-proliferation activity of RAS-1H and RAS-1T on exponentially growing 
cancer cells were determined using MTT assay as described previously.50 HCT116, 
HT-29, SW480, AGS, KATOIII and TC7 cells were seeded at 10 000 cells per well 
(100 µL) in Cellstar® 96-well plates (Greiner Bio-One) and incubated for 24 h. 
Thereafter, cancer cells were exposed to drugs at different concentration in media for 
48 h. The final concentration of DMSO in medium was < 1% (v/v) at which cell 
viability was not significantly inhibited. The medium was removed and replaced with 
MTT solution (100 µL, 0.5 mg/mL) in media and incubated for an additional 45 min. 
Subsequently, the medium was aspirated, and the purple formazan crystals dissolved 




                                                                                                      Chapter 5  
 
131 
obtained at 565 nm. Inhibition to cell viability was evaluated with reference to the 
IC50 value, which is defined as the concentration needed for a 50% reduction of 
survival based on the survival curves. IC50 values were calculated from the dose - 
response curves (cell viability vs drug concentration) obtained in repeated 
experiments and adjusted to actual [Ru] administered, which was determined using 
ICP-OES. The experiments were performed in 4 replicates for each drug 
concentration and were carried out at least three times independently. 
For cell viability assays involving inhibitors, N-acetylcysteine (2 mM), IM-54 (10 
µM), Necrostatin-1 (60 µM), Ferrostatin-1 (10 µM) were added together with test 
compounds and incubated for 48 h. Z-VAD-FMK (5 µM) was added 1 h prior to the 
addition of the test compounds. Cell viability in the absence and presence of inhibitor 
was normalized against untreated control. Experiments were performed in 4 replicates 
and carried out at least two times independently.  
5.4.7 Antibodies and western blot protocol 
AGS cells were grown on Cellstar® 6-well plates (Greiner Bio-One) at a density of 
500 000 cells/well for 24 h before being treated with RAS-1H and RAS-1T at LD and 
HD for 6h and 24h. Cisplatin treatment at 40 µM (IC75) was used as a positive control 
for several experiments. The cells were lysed with lysis buffer [100 µL, 1% NP40, 
150 mM NaCl, 50 mM Tris-HCl (pH 8.0), protease inhibitor]. The cell lysate were 
transferred to separate 2 mL tubes and sonicated for 10 s. The samples were then 
centrifuged at 13000 rpm, 4˚C for 15 min. The supernatant liquid containing the 
proteins were collected and total protein content of each sample was quantified via 
Bradford’s assay. 50 µg of proteins from each sample were reconstituted in loading 
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mixtures were resolved on a 10% SDS-PAGE gel by electrophoresis and transferred 
to a nitrocellulose membrane. The proteins bands were visualized via enhanced 
chemiluminescence imaging (PXi, Syngene) after treatment with the primary 
antibodies and the appropriate secondary antibodies. Equal loading of protein was 
confirmed by comparison with actin and GADPH. The following antibodies were 
used: p53 (FL-393), SQSTM1/p62 (D-3), GADD153 (F-168), Nrf-2 (sc13032) from 
Santa Cruz Biotechnologies. Cleaved caspase-3 (Asp175) from Cell Signaling 
Technology. PARP-1 (ab137653), β-Actin (ab75186) and GAPDH (ab9483) from 
Abcam. LC3 (NB100-2220) from Novus Biologicals. XBP-1s (Clone: 143F) from 
BioLegend. ECL Anti-rabbit IgG (NA934V) and ECL Anti-mouse IgG (NA931) from 
GE Healthcare Life Sciences. All antibodies were used at 1:500 dilutions except for 
actin (1:10000), GADPH, anti-mouse and anti-rabbit (1:5000). 
5.4.8 Primers and qPCR protocol 
Treatment conditions for AGS were similar to the protocol in western blot. RNA 
was extracted using TRIzol® Reagent and reverse transcription was performed with 2 
µg of the extracted RNA using Applied Biosystem® High Capacity cDNA Reverse 
Transcription Kit with an Applied Biosystem® 2720 Thermal Cycler. Quantitative 
PCR was done on the resulting cDNA using FastStart Universal Probe Master (Rox) 
or FastStart Universal SYBR Green Master (Rox) with Applied Biosystem® 7500 
Real Time PCR System. The relative starting quantities of genes of interest were 
normalized against the housekeeping genes TBP and samples were done in duplicates. 
The specificity of the amplification was controlled by a melting curve. The gene and 
Assay ID of TaqMan probes are as follows: BAX (Hs00180269_m1), Bcl-2 
(Hs00608023_m1) and TBP (Hs00427620_m1). Primer sequence for SYBR Green 
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5’-AGAAGACAGTCAGGTTCCCAAC-3’ (reverse). gclc, 5’-
ATGCCATGGGATTTGGAAT-3’ (forward) and 5’-
GATCATAAAGGTATCTGGCCTCA-3’(reverse). nqo1, 5’-
GCCCAGATATTGTGGCTGA-3’ (forward) and 5’-ACCACTGCAGGGGGAACT-
3’ (reverse). TBP, 5’-CGCTGGAACTCGTCTCACTA-3’ (forward) and 5’-
GCCCATAGTGATCTTTGCAGT-3’ (reverse). 
5.4.9 ROS detection 
AGS cells was seeded at 20,000 cells per well (100 µL) in Cellstar® 96-well plates 
(Greiner Bio-One) and incubated for 24 h. Thereafter, the cells were exposed to RAS-
1H and RAS-1T at LD and HD. H2O2 (100 µM) was used as a positive control. 
Separate plates were used for each time point of 3 h, 6 h and 9 h. Cells were washed 
once with HBSS and incubated with ROS probe, carboxy-H2DCFDA (20 µM) in 
HBSS for 45 mins. The probe solution was then removed and replaced with 50 µL of 
HBSS. The fluorescence was measured using a microplate reader (excitation 485 
nm/emission 535 nm). For fluorescence images, cells were seeded in Cellstar® 6-well 
plates (Greiner Bio-One) at 200,000 cells per well. Treatment conditions were similar 
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Design and Synthesis of Carbonic Anhydrase II 




Carbonic Anhydrase (CA) is a class of ubiquitous metalloenzymes found in both 
prokaryotes and eukaryotes. They are encoded by four evolutionarily unrelated gene 
families to give 4 classes; α-, β-, γ- and δ, of which, 16 α-CAs Isozymes are found in 
mammals.  Their primary function is to catalyze the formation of bicarbonate ions 
from carbon dioxide. This reaction is involved in many pathological and 
physiological processes such as respiratory transport of CO2 and bicarbonate ions, 
CO2 and pH regulation, and other biosynthesis reactions.  Playing such a pivotal role 
in the body, its not surprising that problems could arise when their production and 
catalytic activity becomes unregulated. Several of the CAs are significant therapeutic 
targets for a variety of diseases such as epilepsy, glaucoma, oedema, obesity and 
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Inhibitors (CAIs) to treat such disorders. An extensive review on this has been done 
by Supuran.1 
CAIs work mainly by targeting the active site of CAs. Of the 16 α-CAs Isozymes 
found in mammals, many contain a zinc metal ion at the tip of the active site that has 
a high affinity to sulfonamides, sulfamate and sulfamide functional groups. Also, the 
region around the active site is shaped like a cone. These properties have been 
exploited in the design of the CAIs and many, if not all, CAIs contain such functional 
groups. One general design template for CAIs was developed first by Supuran and co-
workers and used later by Poulsen and co-worker in the design of organometallic 
CAIs. In this approach, a CAI consisted of a zinc-binding group, an aromatic moiety 
that could interact with amino acid residues in the active site pocket and a “tail” 
moiety that could interact with the mouth of the active site ([tail]-[aromatic]-[ZBG]).2-
4 Using this approach, Supuran synthesized 25 potential CAIs, many of which 
inhibited human CA (hCA) II with single-digit nanomolar Ki values.2 
In a recent paper, a number of rhenium arylsulfonamides have been synthesized and 
tested against 12 α-CAs Isozymes found in mammals. Out of the few tested, one 
complex showed strong activity and selectivity towards hCA II, IX, XII and XIV.5 In 
a separate research, 20 metallocene-based CAIs were synthesized and evaluated and 
several of them were found to display selectivity towards cancer associated hCA IX 
and XII compared to other hCAs.4 In both cases, the organometallic CAIs 
demonstrated a higher selectivity than their organic counterparts. It is noteworthy that 
in both cases, the [tail]-[aromatic]-[ZBG] approach was followed closely. 
Despite the potential in the use of organometallic scaffold in CAIs design and 
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of scaffolds and structures that could be tested and evaluate for CA inhibitions. In 
view of this, an attempt was made to synthesize new CAIs using the 3CA 
methodology. The 3CA methodology used also incorporated the [tail]-[aromatic]-
[ZBG] approach (Fig 6.1). As a prove of concept, we tested these inhibitors against 
bovine CA (bCA) II and compared if the incorporation of a Ru(II)-arene scaffold 
could improve the inhibitory activity of these complexes as compared to their 
corresponding ligand. 
  
Figure 6.1: General structure of sulfonamide-containing RAS complexes that are 
potential CAIs. These complexes are to be synthesized using the 3CA methodology. 
The R and R” group could be varied. 
 
6.2 RESULTS 
6.2.1 Design and testing of the CAII inhibitors (1st generation) 
Several RAS complexes were synthesized using the 3CA methodology and 
screened against bCA II for inhibitory activity, in hope of finding a metallo-inhibitor 
that is more active than their organic counterparts. These complexes contain a 
sulfonamide moiety for binding to the zinc metal ion at the active site. Also, the shape 
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site pocket. A steady state kinetic assay was used to determined the inhibitory ability 
of these RAS complexes.6 
In the CA steady state kinetic assay, the rate of enzyme catalysis is monitor by the 
change in absorbance when p-nitrophenyl acetate (PNPA) is hydrolyzed to give a 
chromophore, p-nitrophenol (PNP). The change in absorbance over time could be 
measured at 348 nm. When an inhibitor is introduced, the rate of hydrolysis is 
reduced causing the rate of change in absorbance to decrease. In order to screen the 
sulfonamide-containing RAS complexes for inhibitory activity in a short time, the 
intial rate of hydrolysis in the presence of a fixed concentration of these complexes 
were measured and compared with that of the negative control (no inhibitors) and the 
blank sample (no enzyme). 
To ascertain that bCA II active site indeed has the ability to discriminate between 
different types of functional group and selectively bind to sulfonamide groups, 15 
RAS complexes that contain 3 types of functional groups (amide, amidine and 
sulfonamide; Fig 6.2a) were screened at a fixed concentration of 100 µM and the 
initial rates of hydrolysis in the presence of each of these complexes were compared. 
As expect, only the sulfonamide-containing RAS complexes showed inhibition of the 
enzyme (Fig 6.2b). 
Having established the selectivity of bCA II active sites towards sulfonamide 
containing RAS complexes, 15 sulfonamide-containing RAS complexes were 
synthesized using the 3CA methodology with different aryl-aldehydes (Fig 6.3a) and 
their identity confirmed by 1H NMR and ESI-MS. Thereafter, they were screened 
together with the precursor ADa (positive control) at a single concentration of 10 µM 
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inhibitory activity i.e. lower initial rate of hydrolysis than the precursor ADa. Of the 
15 complexes that were tested, only 3c demonstrated such activity (Fig 6.3b). This 
complex was tested at a range of concentrations and the initial rate at each 
concentration was plotted against the concentration of 3c and the Ki(bCA II) of 3c 
was obtained using an equation previously derived by Srivastava (Fig 6.4a).6 The Ki 
of 3c was calculated to be 712.6 nM which is 6 times lower than that of precursor 
ADa (Fig 6.4c). This results suggest that the addition of the Ru(II)-arene scaffold 
could increase inhibitory activity, making 3CA a quick method for synthesis, 
screening and identification of potent enzyme inhibitors. 
 
Figure 6.2: Functional group screening for bCA II inhibition activity. (a) 
Structure of RAS complexes screened. (b) Initial rate of hydrolysis in the presence of 








Figure 6.3: Screening sulfonamide-containing RAS complexes for bCA II 
inhibition activity. (a) Structure of RAS complexes screened. (b) Initial rate of 
hydrolysis in the presence of RAS complexes (10 µM). 
 
 
Figure 6.4: Inhibitory activity of complex 3c. (a) A plot of initial rate Vi against 
concentration of 3c and AD10. (b) Structure of 3c and AD10. (c) Ki of both 
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6.2.2 Design and testing of the CAII inhibitors (2nd generation) 
Although 3c demonstrated better inhibitory activity compared to ADa, it still had a 
much higher Ki than most organic CAIs. The less-than-ideal inhibition could be due 
to a poor fit to the enzyme’s cone-shaped active site. The 15 compounds tested has a 
more globular shape rather than a cone shape. In view of this, an attempt was made to 
synthesize more cone-shaped RAS complexes using another sulfonamide-containing 
component, 4'-amino[1,1'-biphenyl]-4-sulfonamide (ADf). ADf differed from ADa by 
the additional phenyl group, extending the distance between the Ru(II)-arene scaffold 
and the binding sulfonamide moiety. An additional 15 sulfonamide containing RAS 
complexes were synthesized, screened (Fig 6.5) and the Ki of the hit structure 5d was 
obtained (Fig 6.6). The Ki of ADf and a commercially available CAI drug, 
acetazolamide were also obtained for comparison. As seen from their respective Ki, 
the addition of a organometallic scaffold to ADf via the 3CA did not improve the 








Figure 6.5: Screening of sulfonamide-containing RAS complexes (2nd generation) 
for bCA II inhibition activity. (a) Structure of RAS complexes screened. (b) Initial 
rate of hydrolysis in the presence of RAS complexes (10 µM). 
 
 
Figure 6.6: Inhibitory activity of complex 5d. (a) A plot of initial rate Vi against 
concentration of 5d, ADf and acetazolamide. (b) Structure of 5d, ADf and 








We have applied the 3CA methodology to the synthesis, screening and 
identification of bCA II inhibitors with limited success. Screening of 15 sulfonamide-
containing RAS complexes revealed hit compound 3c, which had 6 times higher 
inhibitory activity compared to its precursor ADa. Although a modest improvement, 
the Ki of 3c was still much higher then most commercially available CAIs. In an 
attempt to improve on this, we synthesized and screened another 15 sulfonamide-
containing RAS complexes and identified hit compound 5d. However, further 
evaluation showed that incorporation of an organometallic scaffold did not 
significantly improve the Ki value of RAS complex 5d as compared to its organic 
precursor ADf. Taken together, our results seems to suggest that the length of the 
aromatic group in the [tail]-[aromatic]-[ZBG] approach (Fig 6.1) significantly 
influence the activity of the CAIs. Presumably, the ‘[aromatic]’ portion would 
influence greatly the position of the Ru(II)-arene ‘[tail]’ fragment with respect to the 
active site pocket and thus its ability to interact with the active site. In addition, the 
different type of functional group in the ‘[aromatic]’ portion would provide different 
interaction with the active sites. Further structural variation could be performed to 
optimize and study the length and functional group dependence of the ‘[aromatic]’ 
portion in order to identify more potent organoruthenium CAIs. 
At this stage, we have studied the effect of the addition of a Ru(II)-arene scaffold on 
inhibitory ‘activity’. We have yet to study its effect on ‘selectivity’. In order to 
identify selective inhibitors of specific hCAs, the same screening method employed 
here could be used on several types of hCAs and the inhibitory activity of the 
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hCA. The Ideal selective CAI would show inhibitory activity in one type of hCA but 
not the others. 
6.4 Experimental 
6.4.1 Materials and instrumentations 
All experimental procedures were carried out without additional precautions to 
exclude air or moisture unless otherwise specified. All chemicals and solvents were 
used as received. RuCl3.xH2O was purchased from both Precious Metals Online. [(η6-
benzene)RuCl2]2, [(η6-toluene)RuCl2]2, [(η6-cymene)RuCl2]2, [(η6-
hexamethylbenzene)RuCl2]2 and [(η6-1,3,5-triisopropylbenzene)RuCl2]2 were 
synthesized according to previously reported protocols.7-10 All other chemicals used 
were purchased from Sigma-Aldrich (Singapore). Bovine carbonic anhydrase II 
(C2522) was purchased from Sigma-Aldrich (Singapore). 1H NMR spectrums were 
obtained using either a Bruker AMX 300, Avance 400 or AMX 500 spectrometer and 
the chemical shifts (δ) were reported in parts per million with reference to residual 
solvent peaks. Electrospray-ionization Mass Spectrometry (ESI-MS) spectra were 
obtained using Thermo Finnigan MAT ESI-MS System. UV−vis absorbance for the 
steady state kinetic assay was measured using either a Tecan M200 or F200 
microplate reader. 
6.4.2 General procedure for the synthesis of sulfonamide-containing RAS 
complexes (1st generation) 
RA precursors (10.0 µmol), PA (0.020 mmol) and ADa (0.02 mmol) was 
suspended in D2O (1 ml) with vigourous shaking for 36 hrs to give a final product 
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the reaction giving solutions with colour ranging from yellow to red to dark brown. 
Solution may be characterized immediately by 1H NMR and ESI-MS without any 
work-up or purification steps. Quantitative yield were typically obtained as observed 
in 1H NMR spectrum  
6.4.3 Synthesis of N4-(Imidazol-2-ylidene)sulfanilamide (PA8ADa)  
Sulfanilamide, ADa (172.2 mg, 1.0 mmol), was added to boiling methanol (20 ml) 
with stirring.  2-imidazolecarboxaldehyde, PA8 (96.09 mg, 1.0 mmol), was then 
added to the solution. The reaction mixture was heated till refluxed for 24 hours. The 
reaction mixture was allowed to cool slightly before reducing its volume to  
approximately 2 ml via the rotary evaporator. The product was recrystallized from 
96% ethanol, filtered and dried to give an off white solid. Yield: 83.1 mg (33%). 1H 
NMR (300 MHz, DMSO-d6): δ (ppm) = 7.23 (s, 1H, -HC=CH-), 7.36 (s, 1H, -
HC=CH-), 7.37 (s(broad), 2H, SO2NH2), 7.42 (d, 3J= 14 Hz, 2H, C6H4), 7.85 (d, 3J= 
14 Hz, 2H, C6H4), 8.42 (s, 1H, PhN=CH), 13.21 (s(broad), 1H, -NH-). MS (ESI): m/z 
(%) = 274 (78) [M]+ / 249 (100) [M-H]-, 499 (92) [2M-H]-, 748 (85) [3M-H]-. Purity 
(HPLC): 87.1% at 254 nm, tr =4.1 min. 
6.4.4 Synthesis of [(Cymene)(N4-(Imidazol-2-ylidene)sulfanilamide)RuCl]+Cl-, 3c 
RA3 (20.0 mg, 0.0326 mmol) and PA8ADa (16.4 mg, 0.0653 mmol) was added to 
methanol (5 ml) and stirred at room temperature for 24 hrs. The reaction mixture, 
with brown residue suspended on an orange solution, was filtered and the filtrate 
collected. The methanol was removed by vacuum to give a light brown solid. Yield: 
30.3 mg (89%) 1H NMR (300 MHz, D2O): δ (ppm) = 0.94 (d, 3J= 7 Hz, 6H, 
(CH3)2CH), 2.09 (s, 3H, Ar-CH3), 2.41 (sept, 3J= 7 Hz, 1H, CH3CHCH3), 5.45 (d, 3J= 
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MeC6H4iPr), 5.95 (d, 3J= 6 Hz, 1H, MeC6H4iPr), 7.63 (s, 1H, -HC=CH-), 7.82 (d, 3J= 
9 Hz, 2H, C6H4), 7.96 (s, 1H, -HC=CH-), 8.05 (d, 3J= 9 Hz, 2H, C6H4), 8.46 (s, 1H, 
PhN=CH). MS (ESI): m/z (%) = 485 (60) [M-HCl]+, 521 (100) [M]+.Purity (HPLC): 
93.3% at 254 nm, tr = 15.7 min 
6.4.5 Determination of percentage purity of 3c by HPLC 
Determination of the purity of 3c was done using analytical HPLC on a Shimadzu 
Prominence System equipped with a DGU-20A3 Degasser, two LC-20AD Liquid 
Chromatography Pump, a SPD-20A UV/Vis Detector and a Shim Pack GVP-ODS 2.0 
mm 18 column (5 µM, 120Å, 250 mm x 4.60 mm i.d.) at r.t. at a flow rate of 1.0 
mL/min with detection at 254 nm. The gradient elution conditions were as follows: 
10-95% solvent B over 40 min, where solvent A is 10 mM NH4OAC pH 4.5 and 
solvent B is CH3CN. 
6.4.6 General procedure for the synthesis of 2nd batch of sulfonamide-containing 
RAS complexes 
Stock solutions of RA precursors (200 mM) and ADf (200 mM) in DMSO-d6 were 
prepared. aryl-aldehydes (0.020 mmol) was suspended in D2O (800 µl) and 100 µl of 
the stock solution of Ru-arene precursors and ADf were added to the suspension with 
vigourous shaking for 36 hrs to give a final product concentration of 20 mM. Any 
undissolved reactant were dissolved at the end of the reaction giving solutions with 
colour ranging from yellow to red to dark brown. Solution were characterized 
immediately by 1H NMR and ESI-MS without any work-up or purification steps. 
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6.4.7 Screening of RAS complexes at a single inhibitor concentration 
The following stock solution were prepared for the enzyme assay: bCA II (10 µM) 
in 50 mM HEPES pH7.4 buffer, inhibitors (1 mM or 100 µM) in 50 mM HEPES 
pH7.4 buffer, inhibitors (100 µM or 1 mM) in 50 mM HEPES pH7.4 buffer, p-
nitrophenylacetate (PNPA, 20 mM) in DMSO. The 1 mM or 100 µM inhibitor stock 
were used depending on the final concentration of inhibitors required. The reagent 
were mixed according to accordingly to give a final concentration of 1 µM of bCA II, 
1 µM, 10 µM or 100 µM of inhibitor, 0.5 mM of PNPA and 5% (v/v) DMSO. The 
reaction mixture was incubated at room temperature for 10 mins before PNPA was 
added. Once added, absorbance measurement was started immediately and monitored 
over 10 mins at 1 min intervals, with shaking in between measurements. The rate of 
change of absorbance was used as a measure of the rate of reaction and the rate was 
calculated using the software Prism Graphpad 5. 
6.4.8 Determination of Ki  
The following stock solution were prepared for the enzyme assay: bCA II (10 µM) 
in 50 mM HEPES pH7.4 buffer, inhibitors (100 nM, 1µM, 10 µM, 100 µM) in 50 
mM HEPES pH7.4 buffer, p-nitrophenylacetate (PNPA, 20 mM) in DMSO. The 
reagent were mixed according to accordingly to give a final concentration of 1 µM of 
bCA II, 0.5 mM of PNPA and 5% (v/v) DMSO. The final inhibitor concentration 
varied from 0 to 10 µM. The reaction mixture was incubated at room temperature for 
10 mins before PNPA was added. Once added, absorbance measurement was started 
immediately and monitored over 10 mins at a 1 min interval, with shaking in between 
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concentration and the data further analysed using an equation previously derived by 



















Discovery and Investigation of Selective Inhibitor of 




The overexpression or change in function of certain enzymes has been linked to 
diseases ranging from Alzheimer’s disease to cancer and/or drug resistance in their 
treatment.1-3 Inhibition of these overexpressed enzymes could be an effective strategy 
for the disease treatment making this an attractive therapeutic target.3-8 However, the 
design of an inhibitor selective to such enzyme could be a challenging task. Enzymes 
often have multiple isoforms with highly conserved active sites; only 1 or 2 of these 
isoforms might be involved in a specific disease. Hence targeting these specific 
isoforms would require access to well-defined structures and scaffolds that could 
discriminate between the small differences in their highly conserved active sites. 
Transition metal scaffolds are advantageous compared to their organic counterpart in 
this aspect. They could readily accommodate higher coordination numbers and thus 
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We postulated that the 3CA methodology could be a quick strategy to synthesize, 
screen and identify selective inhibitors that are able to discriminate between enzymes 
that share similar structural homology at the active site. As a proof-of-concept, we 
applied the 3CA methodology to RAS complexes with the goal of differentiating 
between Trypsin and Thrombin, 2 of the serine proteases with active sites that share 
high structural homology.10 We performed extensive functional groups variation and 
screened 45 RAS complexes for selective inhibitors towards either thrombin or 
trypsin. 
7.2 RESULTS 
7.2.1 Design concept, synthesis and  characterization of inhibitors 
Thrombin and trypsin are serine proteases that share extensive structural homology, 
containing similar amino acid sequences within their primary structures.10 They both 
contain a cone-shaped ‘S1-pocket’ within the active site. Inside the S1-pocket, the 
residues Asp189 and Gly219 are capable of forming strong ionic interactions and 
hydrogen bonds with basic groups such as alkylamine, amidine, benzamidine or 4-
aminopyridine groups.11 Structural differences between both enzymes could be found 
in the peripheral space outside of the S1-pocket. Hence, a selective inhibitor should 
contain a basic functional group able to bind to the S1-pocket and have structural 
features that is able differentiate between the peripheral spaces of trypsin and 
thrombin. This was taken into consideration in the design of our RAS complexes (Fig 
7.1). We prepared a series of 45 RAS complexes, including 30 new complexes, using 
the one-pot 3CA methodology (Fig 7.2). Benzamidine or sulfoguanidine motif were 
chosen to target the S1-pocket; arene capping ligands were varied as a means to fine-
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included to probe the effect of hydrophobic or hydrogen-bonding interaction with the 
enzyme surface. These compounds were sufficiently soluble to be synthesized directly 
in D2O to a final concentration of 20 mM. Immediate characterization with 1H NMR 
and ESI-MS was done without any work-up or purification. The purity of several 




Figure 7.1: Design of organoruthenium inhibitors. The basic moiety (red) should 
bind to amino acid residue Asp189 and Gly219, inhibiting the enzymes. The 
component in the peripheral structural space should confer selectivity to the inhibitor 








Figure 7.2: Combinatorial, three-component assembly of RAS complexes with basic 
functional groups. 
 
The 1H NMR spectra of the 45 RAS complexes showed the expected resonance 
with very little by-products (Fig 7.3a). A characteristic disappearance of the singlet 
peak corresponding to the starting aldehyde proton at ca. 10 ppm, as well as the 
appearance of a new singlet  of  the imine proton at 8-9 ppm is indicative of the 
successful synthesis of the RAS complexes. (Uncoordinated ligand typically have 
imine protons at a more upfield position at 6.5 ppm in D2O). ESI-MS of the RAS 
complexes typically showed a base peak consistent with the molecular [M]+ ions with 
the distinctive Ru isotopic pattern, further verifying the formation of the RAS 
complexes (Fig 7.3c). RP-HPLC analysis demonstrated excellent purity of between 
87-99% the batch of 6 RAS complexes analyzed (Fig 7.4). This was assumed to be 








Figure 7.3: Characterization of potential inhibitor (a) 1H NMR spectrum of crude 
reaction mixture in D2O of 1b without any work-up or purification; (b) molecular 
structure and calculated molecular weight of 1b cation; (c) parent molecular peak 
observed in the ESI-MS spectrum corresponding to the expected m/z. 
 
Figure 7.4: RP-HPLC spectrum of 1d. Sample purity is approximately 99% pure. 
7.2.2 Screening of Inhibition 
In order to identify selective inhibitors towards either thrombin or trypsin, we 
performed steady state kinetic assay (similar to Chapter 6) in the presence and 
absence of the synthesized RAS complexes 1a – 9e. Chromozym TH was used as a 
substrate of both thrombin and trypsin in this assay. It releases the chromophore, 4-
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reaction could be quantified by measuring the release of 4-nitroaniline over time at 
405 nm. Thus, the initial rate of the enzymatic reactions was obtained in the presence 
of a single concentration of 1a – 9e (100 µM) and compared to the initial rate in the 
absence of inhibitors. The initial rates obtain in thrombin catalyzed reactions were 
then compared to that of trypsin and the selective inhibitors identified. 
 
Figure 7.5. Relative activity of enzymes incubated with 1a – 9e. RAS complex 1b 
and 1e demonstrate selectivity towards inhibition of trypsin. 
 
Out of the 45 complexes screened, 1b and 1e were identified to be selective 
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reduced the initial rate by more than half. Both complexes did not manage to inhibit 
thrombin significantly. Analogues with more substituted arene rings (1a, 1c and 1d) 
did not seem to have any inhibitory effect, possibly due to the inability of the bulkier 
groups to fit into the active site of the enzymes. In fact, with the exception of 1b and 
1e, none of the other complexes demonstrated any significant inhibitory activity 
towards either thrombin or trypsin. This was presumably due to unfavorable structural 
features towards active site binding. For example, methyl- and hydroxyl-substitution 
on the pyridine ring (4 – 9) could increase steric bulk, meta-substituted amidines (2, 5 
and 8) could be significantly deviated from the ideal ‘cone-shape’ and the 
sulfoguanidine moiety (3, 6 and 9) could have low affinity to the active site. All of 
these features could have prevented most of the RAS complexes from having 
inhibitory activity. 
7.2.3 Preliminary docking studies 
Preliminary docking studies with the active site of trypsin and thrombin were done 
with 1b and the bulkier analogues 1c using Molsoft ICM-Pro software. The molecular 
structures of 1b and 1c were optimized using Gaussian 9.0. For both compounds, the 
most stable binding conformation at the active site was calculated. A slight distortion 
to the arene ligands were observed that were not representative of their actual 
molecular structure. Nevertheless, we used these structures for preliminary analysis. 
For 1b, the most stable conformation was the binding of the amidine functional group 
to amino acid residue Gly219 and Asp189 in the S1 pocket of the active site (Fig 
7.6a-b). This was in agreement to the expected binding of basic groups to the enzyme 
active site. In contrast, the most stable conformation of 1c was the H-bonding of the 
amidine group to amino acid residue outside of the active site pocket (Fig 7.6c-d). 
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between the amidine group and the amino acid residues in the S1 pocket. The docking 
results further explained the lack of inhibitory activity seen in RAS complexes with 
bulky steric groups. 
 
Figure 7.6: Docking results using Molsoft ICMpro showing the most stable 
conformation of compounds at the active site. (a) RAS complex 1b binding to the 
active site; (b) H-bonding between the basic amidine group of 1b and the amino acid 
residue G219 and D189 of the active site; (c) RAS complex 1c remaining outside the 
active site; (d) H-bonding between the amidine group of 1c and amino acid residue 
F41 outside the active site. 
 
7.3 DISCUSSION 
We have successfully applied the 3CA methodology to the synthesis, screening and 
identification selective inhibitors of trypsin. 2 out of the 45 RAS complexes, namely 
1b and 1e demonstrated selective inhibition of trypsin and not thrombin. The 
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trypsin or thrombin, presumably due to the unfavorable structural features that 
prevented the amidine group from interacting with the amino acid residue in the 
active sites. To further validate the selectivity of 1b and 1e, their Ki should be 
obtained by repeating the steady state kinetic assay at varying inhibitor and enzymes 
concentrations. 
Using this study as a proof-of-concept, we have demonstrated the potential of the 
3CA methodology as an efficient way to synthesize and screen RAS complexes for 
selective enzyme inhibitors. By expanding the library of the complexes through plate-
format synthesize (Chapter 2) and by applying similar inhibitor design strategies 
(Chapter 6 & 7), we could potentially identify selective inhibitors of other 
therapeutically relevant enzymes. 
7.4 EXPERIMENTAL 
7.4.1 Materials 
All experimental procedures were carried out without additional precautions to 
exclude air or moisture unless otherwise specified. All chemicals and solvents were 
used as received. RuCl3.xH2O was purchased from both Precious Metals Online. [(η6-
benzene)RuCl2]2, [(η6-toluene)RuCl2]2, [(η6-cymene)RuCl2]2, [(η6-
hexamethylbenzene)RuCl2]2 and [(η6-1,3,5-triisopropylbenzene)RuCl2]2 were 
synthesized according to previously reported protocols.12-15 Chromozym TH was 
purchased from Roche Diagnostic (Basel, Switzerland). Other reagents were of 
analytical grade and purchased from Sigma Aldrich (St Louis, USA), Alfa Aesar 
(Ward Hill, Massachusetts) or TCI Chemical Co (Chuo-ku, Tokyo). Ultrapure water 
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Aubagne Cedex, France). Lyophilized Porcine Trypsin and Bovine Thrombin were 
purchased from Merck (Darmstadt, Germany).  
7.4.2 Instrumentation 
1H NMR spectrums were obtained using either a Bruker AMX 300, Avance 400 or 
AMX 500 spectrometer and the chemical shifts (δ) were reported in parts per million 
with reference to residual solvent peaks. Electrospray-ionization Mass Spectrometry 
(ESI-MS) spectra were obtained using Thermo Finnigan MAT ESI-MS System. UV-
Vis spectra were obtained using the Shimadzu UV-1800 UV Spectrophotometer with 
a TCC-240A Temperate Controlled Cell Holder. Enzyme kinetic assays were done 
using a Biotek Synergy H1 microplate reader. 
7.4.3 HPLC analysis of compound purity 
Determination of the purity of a sample batch of 6 RAS complexes, was done using 
analytical HPLC on a Shimadzu Prominence System equipped with a DGU-20A3 
Degasser, two LC-20AD Liquid Chromatography Pump, a SPD-20A UV/Vis 
Detector and a Shim Pack GVP-ODS 2.0 mm 18 column (5 µM, 120Å, 250 mm x 
4.60 mm i.d.) at r.t. at a flow rate of 1.0 mL/min with detection at 254 nm. The 
gradient elution condition were as follows: 10-90% solvent B for first 25 min 
followed by 90% for another 5 min, where solvent A is 10mM NH4OAc at pH 5.5 and 
solvent B is ACN. 
7.4.4 General procedure for the synthesis of RAS complexes  
10 µmol of RA dimer, 20 µmol  PA analogues and 20 µmol of 4-
aminobenzamidine or sulfaguanidine were suspended in 1 ml of D2O in a 2 mL-
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of 20 mM. The sparingly soluble reactants dissolved at the end of the reaction giving 
coloured solutions. This procedure was repeated with different combinations of the 
three components. A series of 45 RAS complexes was synthesized and they were 
characterized immediately by 1H NMR and ESI-MS without any work-up or 
purification steps. Distinctive signals corresponding to the expected product were 
observed in 1H NMR spectrum in addition to a relatively small amount of impurities. 
7.4.5 Screening for selective inhibition by stable state kinetic assay 
Inhibition assays were conducted in 10 mM Tris buffer at pH 8.0 of 0.1%BSA and 
0.10M NaCl on a Greiner 96-well round bottom plate. 1U of Trypsin was incubated at 
37°C with 100µM of each of the 45 RAS complex in separate well. Chromozym TH 
was added quickly using a multichannel pipette into every well to make a final 
concentration of 400µM and a total volume of 200 µL. The product of the enzymatic 
reaction, 4-nitroaniline was quantified over time at 405 nm. In all experiments, plates 
were agitated briefly before 20 measurements were taken over 10 minutes. The data 
points in the linear region were fitted by linear regression [using graphpad prism 5] to 
obtain activity of enzyme for each compound. The experiment was done in triplicate 
for all 45 RAS complexes and repeated using Thrombin. 
7.4.6 Optimization of molecular structure and protein docking 
Optimization of the molecular structure of 1b and 1c was done according to a 
reported protocol.16 Briefly,  both complexes were optimized using Gaussian 9.0 with 
density functional theory (DFT) with B3LYP and the Hartree-Fock (HF) level.17 The 
6-31 G* basis set was used for carbon, nitrogen and oxygen atoms while the 
LanL2DZ was used for the Ru atom.18 The geometry was optimized to the minimum-
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The protein conformation of Thrombin and Trypsin are constructed based on the 
crystallographic structures from Protein Data Bank (PDB). The structures selected for 
Thrombin (PDB ID: 1PPC) and Trypsin (PDB ID:1ETR) were originally obtained 
from protein co-crystallized with benzamidine and arginine ligands, which were 
similar functional groups to that of 1b and 1c. These complex structures were used in 
the docking simulation by removing ligands and adding hydrogen atoms using 
CHARMM biomolecular simulation package.19 
AMBER simulation was performed with each of the enzymes crystal structure as 
the starting conformation. The enzymes were solvated and ions (Na+ and Cl-) 
removed. The docking of 1b and 1c with each enzyme was done with Molsoft ICM-


















Conclusion and Future Works 
 
In this current work, we demonstrated the application of a multicomponent reaction 
methodology to the process of anticancer drug discovery. An on-a-plate, one-pot 3CA 
methodology for the synthesis of a library of 450 RAS complexes was successfully 
optimized. This library was screened in a high-throughput manner for anticancer 
activity and several cytotoxic ‘hits’ were discovered. Through further structural 
variations, SAR and detailed mode-of-action studies, we identified RAS complexes 
RAS-1T and RAS-1H as anticancer drug candidate with novel mode-of-actions. Both 
complexes induced non-apoptotic PCD, as seen in the lack of p53, caspase 3 or 
PARP-1 activation. In addition, co-treatment with a broad spectrum caspase inhibitor, 
Z-VAD-FMK, had no impact on the activity of both complexes. This further proves 
that the induction of apoptosis did not contribute to their activity. This ability to 
induce an alternative form of PCD has promising application to the treatment of MDR 
cancers, which was validated by the efficacy of RAS-1H and RAS-1T in MDR 
colorectal cancer lineage. Interesting, both compounds induced non-apoptotic PCD 
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leading to cell death.  In contrast, RAS-1H induced ROS-independent ER stress and 
ROS-mediated autophagy inhibition.  
Several questions remained unanswered and required further investigation. First, it 
is not yet clear if the observed ROS-independent ER stress contributed the 
cytotoxicity of RAS-1H. Second, the exact type of PCD induced by RAS-1H and 
RAS-1T has yet to be elucidated. It could be that both compounds induced different 
forms of PCD. Next, although we have demonstrated the in vitro potency of these 
complexes, their in vivo efficacy has yet to be established. This would be the logical 
‘next step’ to bring these compounds closer to the clinical trial stages. 
We also applied the 3CA methodology to the synthesis of CAII inhibitors, though 
our efforts were met with limited success. The addition of the Ru(II)-arene scaffold 
did improve the inhibitory activity of the uncoordinated ligand. However, the 
inhibitory activity of the ‘lead’ inhibitor was still much less potent than most 
commercially available CAII inhibitor. Further structural variation to the ‘lead’ 
inhibitor failed to demonstrate any improvement of inhibitory activity by the Ru(II)-
arene scaffold. The same strategy was applied to the synthesis of selective trypsin 
inhibitors and we identified 2 selective inhibitors out of the 45 RAS complexes 
screened. However, their selectivity needs to be further validated. 
For the design of potent and selective enzyme inhibition, we have yet to employ the 
same high-throughput synthesis and screening strategy that has been used for the 
anticancer drug discovery; limited number of RAS complexes have been screened for 
inhibitory activity. By expanding the library to include more structural variation, we 
could potentially discover more potent and selective inhibitors. In addition, this same 
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So far, we have only applied the 3CA methodology to the discovery of biologically 
active compounds. The same library of compounds synthesized using 3CA could also 
be screened for catalytic activity, especially since Ru(II)-arene complexes have been 
known to catalyze many types of organic reactions. Moreover, we have only explored 
one type of structure, using conjugated Schiff-base ligands and Ru(II)-arene scaffold. 
Potentially, we could expand the work to include the use of other ligand types and 
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Appendix A – Characterization Data for 3CA 
1. 1H NMR Data for 63 RAS complexes from initial library 
 
General procedure for the synthesis of RAS complexes: RAx (8.16 µmol), PAy 
(0.0163 mmol) and ADz (0.0163 mmol) was either suspended in D2O (1 ml) or 
dissolved in 1:1 v/v DMSO-d6/D2O (1 ml) with vigourous shaking for 36 hrs. The 
sparingly soluble reactants were dissolved at the end of the reaction giving solutions 
with colour ranging from yellow to red to dark brown. Solution may be characterized 
immediately by 1H NMR and ESI-MS without any work-up or purification steps. 
Quantitative yield were typically obtained as observed in 1H NMR spectrum 
(relatively small amt of impurities observed in 1H NMR spectrum. 
WH-111: 1H NMR (500 MHz, D2O): δ (ppm) = 5.85 (s, 6H, C6H6), 7.55 (m, 3H, 
C6H5), 7.67 (m, 2H, C6H5), 7.75 (m, 1H, py), 8.11 (m, 1H, py), 8.16 (m, 1H, py), 8.61 
(s, 1H, PhN=CH), 9.44 (d, 3J= 6 Hz, 1H, py). MS (ESI): m/z (%) = 319 (12) [M-
C6H6]+, 397 (100) [M]+. 
WH-112: 1H NMR (500 MHz, D2O): δ (ppm) = 5.87 (s, 6H, C6H6), 7.74 (t, 3J= 8 Hz, 
1H, C6H4), 7.79 (m, 1H, py), 7.86 (d, 3J= 8 Hz, 1H, C6H4), 7.94 (d, 3J= 8 Hz, 1H, 
C6H4), 7.97 (s, 1H, C6H4), 8.17 (m, 2H, py), 8.69 (s, 1H, PhN=CH), 9.47 (d, 3J= 5 Hz, 




































Aniline Derivative Ru-Arene Schiff-base 
Complex (WH-xyz) 
(RAXPAYADZ)
RA1 RA2 RA3 RA4 RA5 
PA1 PA2 PA3 
AD1 AD2 AD3 AD4 AD5 AD6 AD7 








WH-113: 1H NMR (500 MHz, D2O): δ (ppm) = 5.87 (s, 6H, C6H6), 7.53 (m, 2H, 
C6H4), 7.60 (dt, 3J= 7 Hz, 1H, C6H4), 7.69 (m, 1H, C6H4), 7.77 (m, 1H, py), 8.15 (m, 
2H, py), 8.62 (s, 1H, PhN=CH), 9.45 (d, 3J= 6 Hz, 1H, py). MS (ESI): m/z (%) = 355 
(6) [M- C6H6]+, 431 (100) [M]+. 
WH-114: 1H NMR (500 MHz, 70˚C, D2O): δ (ppm) = 6.35 (s, 6H, C6H6), 8.32 (m, 
4H, napthyl), 8.48 (m, 1H, py), 8.54 (m, 1H, napthyl), 8.72 (m, 2H, napthyl), 8.84 (m, 
2H, py), 9.33 (s, 1H, PhN=CH), 10.10 (s (broad), 1H, py). MS (ESI): m/z (%) = 447 
(100) [M]+. 
WH-116: 1H NMR (500 MHz, D2O): δ (ppm) = 3.85 (s, 3H, OMe), 5.84 (s, 6H, 
C6H6), 7.08 (m, 2H, C6H4), 7.65 (m, 2H, C6H4), 7.72 (m, 1H, py), 8.05 (d (broad), 3J= 
8 Hz, 1H, py), 8.13 (dt, 3J= 8 Hz, 1H, py), 8.51 (s, 1H, PhN=CH), 9.41 (d, 3J= 5 Hz, 
1H, py). MS (ESI): m/z (%) = 349 (11) [M- C6H6]+, 427 (100) [M]+. 
WH-117: 1H NMR (500 MHz, D2O): δ (ppm) = 5.84 (s, 6H, C6H6), 7.73 (m, 2H, 
C6H4), 7.76 (m, 1H, py), 7.75 (m, 1H, py), 8.11 (m, 2H, C6H4), 8.12 (m, 1H, py), 8.16 
(m, 1H, py), 8.63 (s, 1H, PhN=CH), 9.45 (d, 3J= 5 Hz, 1H, py). MS (ESI): m/z (%) = 
363 (4) [M- C6H6]+, 441 (100) [M]+. 
WH-118: 1H NMR (500 MHz, D2O): δ (ppm) = 5.89 (s, 6H, C6H6), 7.79 (m, 2H, 
C6H4), 7.80 (m, 1H, py), 7.97 (m, 2H, C6H4), 8.19 (m, 2H, py), 8.68 (s, 1H, 
PhN=CH), 9.48 (d, 3J= 6 Hz, 1H, py). MS (ESI): m/z (%) = 362 (5) [M- C6H6]+, 440 
(100) [M]+. 
WH-119: 1H NMR (500 MHz, D2O): δ (ppm) = 5.87 (s, 6H, C6H6), 7.01 (m, 2H, 
C6H4), 7.62 (m, 2H, C6H4), 7.75 (t (broad), 3J= 6 Hz,  1H, py), 8.07 (d (broad), 3J= 8 
Hz, 1H, py), 8.16 (t, 3J= 8 Hz, 1H, py), 8.53 (s, 1H, PhN=CH), 9.43 (d, 3J= 6 Hz, 1H, 
py). MS (ESI): m/z (%) = 335 (11) [M- C6H6]+, 413 (100) [M]+. 
WH-11a: 1H NMR (500 MHz, D2O): δ (ppm) = 5.91 (s, 6H, C6H6), 7.83 (m, 1H, py), 
7.90 (m, 2H, C6H4), 8.10 (m, 2H, C6H4), 8.21 (m, 2H, py), 8.75 (s, 1H, PhN=CH), 
9.50 (d, 3J= 6 Hz, 1H, py). MS (ESI): m/z (%) = 440 (4) [M- C6H6]+, 476 (100) [M]+. 
WH-11d: 1H NMR (500 MHz, D2O): δ (ppm) = 5.90 (s, 6H, C6H6), 7.82 (m, 1H, py), 
7.90 (m, 2H, C6H4), 7.98 (m, 2H, C6H4), 8.21 (m, 2H, py), 8.75 (s, 1H, PhN=CH), 
9.50 (d, 3J= 6 Hz, 1H, py). MS (ESI): m/z (%) = 439 (100) [M]+. 
WH-211: 1H NMR (500 MHz, D2O): δ (ppm) = 2.11 (s, 3H, PhCH3), 5.57 (d, 3J= 6 
Hz, 1H, C6H5Me), 5.72 (t, 3J= 6 Hz, 2H, C6H5Me), 5.78 (t, 3J= 6 Hz, 1H, C6H5Me), 
5.99 (t, 3J= 6 Hz, 1H, C6H5Me), 7.61 (m, 3H, C6H5), 7.73 (m, 2H, C6H5), 7.82 (m, 1H, 
py), 8.20 (m, 2H, py), 8.61 (s, 1H, PhN=CH), 9.45 (d, 3J= 5 Hz, 1H, py). MS (ESI): 
m/z (%) = 411 (100) [M]+. 
WH-212: 1H NMR (500 MHz, D2O): δ (ppm) = 2.12 (s, 3H, PhCH3), 5.53 (d, 3J= 6 
Hz, 1H, C6H5Me), 5.74 (m, 3H, C6H5Me), 6.01 (t, 3J= 6 Hz, 1H, C6H5Me), 7.79 (t, 3J= 
8 Hz, 3H, C6H4), 7.82 (t, 3J= 7 Hz, 1H, py), 7.91 (d, 3J= 8 Hz, 1H, C6H4), 7.97 (d, 3J= 
8 Hz, 1H, C6H4), 7.91 (s (broad), 1H, C6H4), 8.21 (m, 2H, py), 8.74 (s, 1H, PhN=CH), 
9.46 (d, 3J= 5 Hz, 1H, py). MS (ESI): m/z (%) = 479 (100) [M]+. 
WH-213: 1H NMR (500 MHz, D2O): δ (ppm) = 2.11 (s, 3H, PhCH3), 5.57 (d, 3J= 6 
Hz, 1H, C6H5Me), 5.75 (m, 3H, C6H5Me), 6.00 (t, 3J= 6 Hz, 1H, C6H5Me), 7.58 (m, 
2H, C6H4), 7.63 (m, 1H, py), 7.74 (s (broad), 1H, C6H4), 7.82  (t, 3J= 7 Hz, 1H, C6H4), 




8.20 (m, 2H, py), 8.66 (s, 1H, PhN=CH), 9.44 (d, 3J= 6 Hz, 1H, py). MS (ESI): m/z 
(%) = 445 (100) [M]+, 672 (15). 
WH-214: 1H NMR (500 MHz, 70˚C, D2O): δ (ppm) = 2.60 (s, 3H, PhCH3), 5.90 (d, 
3J= 6 Hz, 1H, C6H5Me), 6.08 (t, 3J= 6 Hz, 2H, C6H5Me), 6.34 (t, 3J= 6 Hz, 1H, 
C6H5Me), 6.45 (t, 3J= 6 Hz, 1H, C6H5Me), 8.37 (m, 3H, napthyl), 8.51 (m, 1H, py), 
8.53 (m, 2H, napthyl), 8.78 (m, 2H, napthyl), 8.92 (m, 2H, py), 9.35 (s, 1H, 
PhN=CH), 10.08 (d, 3J= 6 Hz, 1H, py). MS (ESI): m/z (%) = 425 (31) [M-HCl]+, 461 
(100) [M]+. 
WH-216: 1H NMR (500 MHz, D2O): δ (ppm) = 2.09 (s, 3H, PhCH3), 5.56 (d, 3J= 6 
Hz, 1H, C6H5Me), 5.72 (t, 3J= 6 Hz, 2H, C6H5Me), 5.78 (t, 3J= 6 Hz, 1H, C6H5Me), 
5.98 (t, 3J= 6 Hz, 1H, C6H5Me), 7.14 (d, 3J= 9 Hz, 2H, C6H4), 7.70 (d, 3J= 9 Hz, 2H, 
C6H4), 7.78 (t, 3J= 7 Hz, 1H, py), 8.11 (d, 3J= 8 Hz, 1H, py), 8.18 (t, 3J= 8 Hz, 1H, 
py), 8.58 (s, 1H, PhN=CH), 9.40 (d, 3J= 6 Hz, 1H, py). MS (ESI): m/z (%) = 441 
(100) [M]+. 
WH-217: 1H NMR (500 MHz, D2O): δ (ppm) = 2.10 (s, 3H, PhCH3), 5.54 (d, 3J= 6 
Hz, 1H, C6H5Me), 5.74 (m, 3H, C6H5Me), 5.99 (t, 3J= 6 Hz, 1H, C6H5Me), 7.78 (d, 
3J= 9 Hz, 2H, C6H4), 7.82 (m, 1H, py), 8.17 (d, 3J= 9 Hz, 2H, C6H4), 8.19 (m, 2H, py), 
8.60 (s, 1H, PhN=CH), 9.45 (d, 3J= 6 Hz, 1H, py). MS (ESI): m/z (%) = 455 (100) 
[M]+. 
WH-218: 1H NMR (500 MHz, D2O): δ (ppm) = 2.10 (s, 3H, PhCH3), 5.55 (d, 3J= 6 
Hz, 1H, C6H5Me), 5.74 (m, 3H, C6H5Me), 5.98 (t, 3J= 6 Hz, 1H, C6H5Me), 7.79 (d, 
3J= 8 Hz, 2H, C6H4), 7.82 (m, 1H, py), 7.98 (d, 3J= 8 Hz, 2H, C6H4), 8.19 (m, 2H, py), 
8.68 (s, 1H, PhN=CH), 9.44 (d, 3J= 6 Hz, 1H, py). MS (ESI): m/z (%) = 454 (100) 
[M]+. 
WH-219: 1H NMR (500 MHz, D2O): δ (ppm) = 2.08 (s, 3H, PhCH3), 5.55 (d, 3J= 6 
Hz, 1H, C6H5Me), 5.67 (t, 3J= 6 Hz, 2H, C6H5Me), 5.77 (t, 3J= 6 Hz, 1H, C6H5Me), 
5.96 (t, 3J= 6 Hz, 1H, C6H5Me), 7.01 (d, 3J= 9 Hz, 2H, C6H4), 7.61 (d, 3J= 9 Hz, 2H, 
C6H4), 7.76 (t, 3J= 7 Hz, 1H, py), 8.07 (d, 3J= 8 Hz, 1H, py),  8.16 (d, 3J= 8 Hz, 1H, 
py), 8.54 (s, 1H, PhN=CH), 9.38 (d, 3J= 5 Hz, 1H, py). MS (ESI): m/z (%) = 427 
(100) [M]+. 
WH-21a: 1H NMR (500 MHz, D2O): δ (ppm) = 2.11 (s, 3H, PhCH3), 5.57 (d, 3J= 6 
Hz, 1H, C6H5Me), 5.75 (m, 3H, C6H5Me), 6.00 (t, 3J= 6 Hz, 1H, C6H5Me), 7.84 (t, 3J= 
6 Hz, 1H, py), 7.91 (d, 3J= 9 Hz, 2H, C6H4), 8.11 (d, 3J= 8 Hz, 2H, C6H4), 8.22 (m, 
2H, py), 8.76 (s, 1H, PhN=CH), 9.44 (d, 3J= 6 Hz, 1H, py). MS (ESI): m/z (%) = 490 
(100) [M]+. 
WH-21b: 1H NMR (500 MHz, D2O): δ (ppm) = 2.11 (s, 3H, PhCH3), 5.57 (d, 3J= 6 
Hz, 1H, C6H5Me), 5.76 (m, 3H, C6H5Me), 6.01 (t, 3J= 6 Hz, 1H, C6H5Me), 7.85 (m, 
1H, py), 7.92 (d, 3J= 8 Hz, 2H, C6H4), 8.00 (d, 3J= 9 Hz, 2H, C6H4), 8.23 (m, 2H, py), 
8.77 (s, 1H, PhN=CH), 9.47 (d, 3J= 6 Hz, 1H, py). MS (ESI): m/z (%) = 227 (64) 
[M+H]2+, 453 (100) [M]+. 
WH-311: 1H NMR (500 MHz, D2O): δ (ppm) = 0.95 (dd, 3J= 4 Hz, 6H, (CH3)2CH), 
2.16 (s, 3H, Ar-CH3), 2.45 (sept, 3J= 4 Hz, 1H, CH3CHCH3), 5.46 (d, 3J= 10 Hz, 1H, 
MeC6H4iPr), 5.59 (d, 3J= 10 Hz, 1H, MeC6H4iPr), 5.68 (d, 3J= 10 Hz, 1H, 
MeC6H4iPr), 5.96 (d, 3J= 10 Hz, 1H, MeC6H4iPr), 7.64 (m, 5H, C6H5), 7.79 (m, 1H, 




py), 8.17 (m, 2H, py), 8.68 (s, 1H, PhN=CH), 9.41 (d, 3J= 9 Hz, 1H, py). MS (ESI): 
m/z (%) = 417 (17) [M-HCl]+, 453 (100) [M]+. 
WH-312: 1H NMR (500 MHz, D2O): δ (ppm) = 0.94 (dd, 3J= 12 Hz, 6H, (CH3)2CH), 
2.13 (s, 3H, Ar-CH3), 2.46 (sept, 3J= 12 Hz, 1H, CH3CHCH3), 5.44 (d, 3J= 10 Hz, 1H, 
MeC6H4iPr), 5.61 (d, 3J= 10 Hz, 1H, MeC6H4iPr), 5.68 (d, 3J= 10 Hz, 1H, 
MeC6H4iPr), 5.95 (d, 3J= 10 Hz, 1H, MeC6H4iPr), 7.85 (m, 4H, C6H4), 8.00 (s, 1H, 
py), 8.19 (m, 2H, py), 8.74 (s, 1H, PhN=CH), 9.42 (d, 3J= 9 Hz, 1H, py). MS (ESI): 
m/z (%) = 521 (100) [M]+. 
WH-313: 1H NMR (500 MHz, D2O): δ (ppm) = 0.94 (dd, 3J= 12 Hz, 6H, (CH3)2CH), 
2.14 (s, 3H, Ar-CH3), 2.46 (sept, 3J= 12 Hz, 1H, CH3CHCH3), 5.47 (d, 3J= 10 Hz, 1H, 
MeC6H4iPr), 5.62 (d, 3J= 10 Hz, 1H, MeC6H4iPr), 5.68 (d, 3J= 10 Hz, 1H, 
MeC6H4iPr), 5.94 (d, 3J= 10 Hz, 1H, MeC6H4iPr), 7.55 (m, 3H, C6H4), 7.71 (m, 1H, 
C6H4), 7.81 (m, 1H, py), 8.15 (m, 2H, py), 8.67 (s, 1H, PhN=CH), 9.40 (d, 3J= 9 Hz, 
1H, py). MS (ESI): m/z (%) = 487 (100) [M]+. 
WH-314: 1H NMR (500 MHz, 70˚C, D2O): δ (ppm) = 1.50 (dd, 3J= 7 Hz, 6H, 
(CH3)2CH), 2.60 (s, 3H, Ar-CH3), 3.05 (sept, 3J= 7 Hz, 1H, CH3CHCH3), 5.65 (s 
(broad), 1H, MeC6H4iPr), 5.95 (s (broad), 1H, MeC6H4iPr), 6.15 (d, 3J= 6 Hz, 1H, 
MeC6H4iPr), 6.25 (d, 3J= 6 Hz, 1H, MeC6H4iPr), 8.27 (m, 4H, napthyl), 8.48 (m, 1H, 
naphthyl), 8.69 (m, 2H, naphthyl), 8.69 (m, 1H, py), 8.76 (d, 3J= 7 Hz, 1H, py), 8.84 
(t, 3J= 8 Hz, 1H, py), 9.33 (s, 1H, PhN=CH), 10.03 (d, 3J= 6 Hz, 1H, py). MS (ESI): 
m/z (%) = 467 (60) [M-HCl]+, 503 (100) [M]+. 
WH-315: 1H NMR (500 MHz, 70˚C, D2O): δ (ppm) = 1.52 (dd, 3J= 7 Hz, 6H, 
(CH3)2CH), 2.62 (s, 3H, Ar-CH3), 3.09 (sept, 3J= 7 Hz, 1H, CH3CHCH3), 5.68 (s 
(broad), 1H, MeC6H4iPr), 6.01 (s (broad), 1H, MeC6H4iPr), 6.16 (d, 3J= 6 Hz, 1H, 
MeC6H4iPr), 6.25 (d, 3J= 6 Hz, 1H, MeC6H4iPr), 8.16 (m, 5H, napthyl), 8.78 (d, 3J= 8 
Hz, 1H, py), 8.85 (t, 3J= 8 Hz, 1H, py), 8.95 (d, 3J= 9 Hz, 1H, py), 9.33 (s, 1H, 
PhN=CH), 10.04 (d, 3J= 6 Hz, 1H, py). MS (ESI): m/z (%) = 519 (100) [M]+, 860 
(30). 
WH-316: 1H NMR (500 MHz, D2O): δ (ppm) = 0.92 (d, 3J= 12 Hz, 6H, (CH3)2CH), 
2.13 (s, 3H, Ar-CH3), 2.40 (sept, 3J= 12 Hz, 1H, CH3CHCH3), 5.46 (d, 3J= 10 Hz, 1H, 
MeC6H4iPr), 5.55 (d, 3J= 10 Hz, 1H, MeC6H4iPr), 5.64 (d, 3J= 10 Hz, 1H, 
MeC6H4iPr), 5.92 (d, 3J= 10 Hz, 1H, MeC6H4iPr), 7.09 (m, 2H, C6H4), 7.64 (m, 2H, 
C6H4), 7.73 (m, 1H, py), 8.10 (m, 2H, py), 8.55 (s, 1H, PhN=CH), 9.41 (d, 3J= 9 Hz, 
1H, py). MS (ESI): m/z (%) = 447 (6) [M-HCl]+, 483 (100) [M]+. 
WH-317: 1H NMR (500 MHz, D2O): δ (ppm) = 0.972 (t, 3J= 7 Hz, 6H, (CH3)2CH), 
2.17 (s, 3H, Ar-CH3), 2.48 (sept, 3J= 7 Hz, 1H, CH3CHCH3), 5.48 (d, 3J= 6 Hz, 1H, 
MeC6H4iPr), 5.61 (d, 3J= 6 Hz, 1H, MeC6H4iPr), 5.70 (d, 3J= 6 Hz, 1H, MeC6H4iPr), 
5.97 (d, 3J= 6 Hz, 1H, MeC6H4iPr), 7.79 (d, 3J= 8 Hz, 2H, C6H4), 7.84 (m, 1H, py), 
8.18 (d, 3J= 9 Hz, 2H, C6H4), 8.21 (m, 2H, py), 8.74 (s, 1H, PhN=CH), 9.45 (d, 3J= 6 
Hz, 1H, py). MS (ESI): m/z (%) = 497 (100) [M]+, 521 (65) [M-H+Na]+. 
WH-318: 1H NMR (500 MHz, D2O): δ (ppm) = 0.96 (d, 3J= 7 Hz, 6H, (CH3)2CH), 
2.15 (s, 3H, Ar-CH3), 2.47 (sept, 3J= 7 Hz, 1H, CH3CHCH3), 5.47 (d, 3J= 6 Hz, 1H, 
MeC6H4iPr), 5.60 (d, 3J= 6 Hz, 1H, MeC6H4iPr), 5.68 (d, 3J= 6 Hz, 1H, MeC6H4iPr), 
5.96 (d, 3J= 6 Hz, 1H, MeC6H4iPr), 7.78 (m, 2H, C6H4), 7.82 (m, 1H, py), 7.98 (m, 




2H, C6H4), 8.19 (m, 2H, py), 8.72 (s, 1H, PhN=CH), 9.43 (d, 3J= 9 Hz, 1H, py). MS 
(ESI): m/z (%) = 496 (100) [M]+. 
WH-319: 1H NMR (500 MHz, D2O): δ (ppm) = 0.95 (d, 3J= 7 Hz, 6H, (CH3)2CH), 
2.16 (s, 3H, Ar-CH3), 2.42 (sept, 3J= 7 Hz, 1H, CH3CHCH3), 5.48 (d, 3J= 6 Hz, 1H, 
MeC6H4iPr), 5.58 (d, 3J= 6 Hz, 1H, MeC6H4iPr), 5.67 (d, 3J= 6 Hz, 1H, MeC6H4iPr), 
5.94 (d, 3J= 6 Hz, 1H, MeC6H4iPr), 7.01 (d, 3J= 9 Hz, 2H, C6H4), 7.60 (d, 3J= 9 Hz, 
2H, C6H4), 7.75 (t, 3J= 6 Hz, 1H, py), 8.08 (d, 3J= 7 Hz, 1H, py), 8.15 (t, 3J= 8 Hz, 1H, 
py), 8.57 (s, 1H, PhN=CH), 9.37 (d, 3J= 6 Hz, 1H, py). MS (ESI): m/z (%) = 433 (5) 
[M-HCl]+, 469 (100) [M]+.  
WH-31a: 1H NMR (500 MHz, D2O): δ (ppm) = 0.97 (d, 3J= 7 Hz, 6H, (CH3)2CH), 
2.16 (s, 3H, Ar-CH3), 2.48 (sept, 3J= 7 Hz, 1H, CH3CHCH3), 5.49 (d, 3J= 6 Hz, 1H, 
MeC6H4iPr), 5.64 (d, 3J= 6 Hz, 1H, MeC6H4iPr), 5.71 (d, 3J= 6 Hz, 1H, MeC6H4iPr), 
5.98 (d, 3J= 6 Hz, 1H, MeC6H4iPr), 7.84 (dt, 3J= 6 Hz, 1H, py), 7.89 (m, 2H, C6H4), 
8.11 (d, 2H, C6H4), 8.22 (m, 2H, py), 8.79 (s, 1H, PhN=CH), 9.47 (d, 3J= 6 Hz, 1H, 
py). MS (ESI): m/z (%) = 496 (5) [M-HCl]+, 532 (100) [M]+. 
WH-31c: 1H NMR (500 MHz, D2O): δ (ppm) = 0.94 (d, 3J= 7 Hz, 6H, (CH3)2CH), 
2.14 (s, 3H, Ar-CH3), 2.45 (sept, 3J= 7 Hz, 1H, CH3CHCH3), 5.46 (d, 3J= 6 Hz, 1H, 
MeC6H4iPr), 5.59 (d, 3J= 6 Hz, 1H, MeC6H4iPr), 5.67 (d, 3J= 6 Hz, 1H, MeC6H4iPr), 
5.95 (d, 3J= 6 Hz, 1H, MeC6H4iPr), 7.78 (m, 2H, C6H4), 7.80 (m, 1H, py), 7.95 (m, 
2H, C6H4), 8.18 (m, 2H, py), 8.73 (s, 1H, PhN=CH), 9.41 (d, 3J= 5 Hz, 1H, py). MS 
(ESI): m/z (%) = 533 (100) [M]+, 805 (14), 889 (22). 
WH-31d: 1H NMR (500 MHz, D2O): δ (ppm) = 0.97 (d, 3J= 7 Hz, 6H, (CH3)2CH), 
2.16 (s, 3H, Ar-CH3), 2.49 (sept, 3J= 7 Hz, 1H, CH3CHCH3), 5.50 (d, 3J= 6 Hz, 1H, 
MeC6H4iPr), 5.65 (d, 3J= 6 Hz, 1H, MeC6H4iPr), 5.71 (d, 3J= 6 Hz, 1H, MeC6H4iPr), 
5.99 (d, 3J= 6 Hz, 1H, MeC6H4iPr), 7.84 (m, 1H, py), 7.90 (d, 3J= 8 Hz, 2H, C6H4), 
7.99 (d, 3J= 9 Hz, 2H, C6H4), 8.23 (m, 2H, py), 8.79 (s, 1H, PhN=CH), 9.45 (d, 3J= 6 
Hz, 1H, py). MS (ESI): m/z (%) = 248 (48) [M+H]2+, 290 (56), 459 (5) [M-HCl]+, 
495 (100) [M]+.  
WH-511: 1H NMR (500 MHz, D2O): δ (ppm) = 1.09 (dd, 3J= 6 Hz, 18H, (CH3)2CH), 
2.35 (sept, 3J= 6 Hz, 1H, CH3CHCH3),  5.82 (s, 3H, C6H3), 7.59 (m, 5H, C6H5), 7.83 
(t, 3J= 8 Hz, 1H, py), 8.16 (d, 3J= 8 Hz, 1H, py), 8.22 (t, 3J= 8 Hz, 1H, py), 8.62 (s, 
1H, PhN=CH), 9.38 (d, 3J= 5 Hz, 1H, py). MS (ESI): m/z (%) = 417 (17) [M-HCl]+, 
453 (100) [M]+. 
WH-512: 1H NMR (500 MHz, D2O): δ (ppm) = 1.08 (dd, 3J= 6 Hz, 18H, (CH3)2CH), 
2.34 (sept, 3J= 6 Hz, 1H, CH3CHCH3),  5.83 (s, 3H, C6H3), 7.80 (m, 1H, py), 7.87 (m, 
4H, C6H4), 8.23 (m, 2H, py), 8.68 (s, 1H, PhN=CH), 9.41 (d, 3J= 5 Hz, 1H, py). MS 
(ESI): m/z (%) = 373 (16), 591 (100) [M]+. 
WH-513: 1H NMR (500 MHz, D2O): δ (ppm) = 1.09 (dd, 3J= 7 Hz, 18H, (CH3)2CH), 
2.38 (sept, 3J= 7 Hz, 1H, CH3CHCH3),  5.84 (s, 3H, C6H3), 7.52 (m, 1H, C6H4), 7.58 
(d, 3J= 4 Hz, 2H, C6H4), 7.64 (m, 1H, C6H4), 7.84 (t, 3J= 6 Hz, 1H, py), 8.21 (m, 2H, 
py), 8.63 (s, 1H, PhN=CH), 9.39 (d, 3J= 6 Hz, 1H, py). MS (ESI): m/z (%) = 373 (18), 
559 (100) [M]+. 
WH-514: 1H NMR (500 MHz, 70˚C, D2O): δ (ppm) = 1.51 (s (broad), 9H, 
(CH3)2CH), 1.62 (dd, 3J= 7 Hz, 9H, (CH3)2CH), 2.69 (sept, 3J= 7 Hz, 1H, 




CH3CHCH3),  6.30 (s, 3H, C6H3), 8.26 (m, 5H, napthyl), 8.51 (t, 3J= 6 Hz, 1H, py), 
8.69 (d, 3J= 9 Hz, 1H, napthyl), 8.74 (d, 3J= 8 Hz,  1H, napthyl), 8.80 (d, 3J= 8 Hz, 
1H, py), 8.88 (t, 3J= 8 Hz, 1H, py), 9.31 (s, 1H, PhN=CH), 10.05 (d, 3J= 6 Hz, 1H, 
py). MS (ESI): m/z (%) = 373 (28), 573 (100) [M]+. 
WH-516: 1H NMR (500 MHz, D2O): δ (ppm) = 1.09 (dd, 3J= 7 Hz, 18H, (CH3)2CH), 
2.39 (sept, 3J= 7 Hz, 1H, CH3CHCH3),  3.90 (s, 3H, OMe), 5.75 (s, 3H, C6H3), 7.13 
(d, 3J= 9 Hz, 2H, C6H4), 7.58 (d, 3J= 9 Hz, 2H, C6H4), 7.76 (t, 3J= 8 Hz, 1H, py), 8.10 
(d, 3J= 8 Hz, 1H, py), 8.18 (t, 3J= 8 Hz, 1H, py), 8.52 (s, 1H, PhN=CH), 9.34 (d, 3J= 6 
Hz, 1H, py). MS (ESI): m/z (%) = 373 (14), 517 (22) [M-HCl]+, 553 (100) [M]+. 
WH-517: 1H NMR (500 MHz, D2O): δ (ppm) = 1.07 (dd, 3J= 7 Hz, 18H, (CH3)2CH), 
2.33 (sept, 3J= 7 Hz, 1H, CH3CHCH3),  5.82 (s, 3H, C6H3), 7.66 (d, 3J= 8 Hz, 2H, 
C6H4), 7.85 (m, 1H, py), 8.15 (d, 3J= 8 Hz, 2H, C6H4), 8.21 (m, 3H, py), 8.65 (s, 1H, 
PhN=CH), 9.40 (d, 3J= 5 Hz, 1H, py). MS (ESI): m/z (%) = 373 (12), 567 (100) [M]+. 
WH-518: 1H NMR (500 MHz, D2O): δ (ppm) = 1.05 (dd, 3J= 7 Hz, 18H, (CH3)2CH), 
2.31 (sept, 3J= 7 Hz, 1H, CH3CHCH3),  5.81 (s, 3H, C6H3), 7.66 (d, 3J= 8 Hz, 2H, 
C6H4), 7.82 (m, 1H, py), 7.98 (d, 3J= 9 Hz, 2H, C6H4), 8.19 (m, 2H, py), 8.63 (s, 1H, 
PhN=CH), 9.38 (d, 3J= 6 Hz, 1H, py). MS (ESI): m/z (%) = 373 (15) [M-HCl]+, 566 
(100) [M]+, 717 (17). 
WH-51a: 1H NMR (500 MHz, D2O): δ (ppm) = 1.05 (dd, 3J= 7 Hz, 18H, (CH3)2CH), 
2.31 (sept, 3J= 7 Hz, 1H, CH3CHCH3),  5.83 (s, 3H, C6H3), 7.77 (d, 3J= 9 Hz, 2H, 
C6H4), 7.85 (m, 1H, py), 8.10 (d, 3J= 8 Hz, 2H, C6H4), 8.21 (m, 2H, py), 8.69 (s, 1H, 
PhN=CH), 9.41 (d, 3J= 6 Hz, 1H, py). MS (ESI): m/z (%) = 373 (13), 602 (100) [M]+. 
WH-51c: 1H NMR (500 MHz, D2O): δ (ppm) = 1.09 (dd, 3J= 7 Hz, 18H, (CH3)2CH), 
2.38 (sept, 3J= 7 Hz, 1H, CH3CHCH3),  5.87 (s, 3H, C6H3), 7.82 (d, 3J= 9 Hz, 2H, 
C6H4), 7.87 (m, 1H, py), 8.03 (d, 3J= 8 Hz, 2H, C6H4), 8.25 (m, 2H, py), 8.72 (s, 1H, 
PhN=CH), 9.43 (d, 3J= 6 Hz, 1H, py). MS (ESI): m/z (%) = 283 [M+H]+, 373 (22), 
529 [M-HCl]+, 565 (100) [M]+. 
WH-411: 1H NMR (500 MHz, D2O): δ (ppm) = 1.81 (s, 18H, C6Me), 7.53 (m, 5H, 
C6H5), 7.78 (m, 1H, py), 8.08 (m, 2H, py), 8.50 (s, 1H, PhN=CH), 8.93 (d, 3J= 6 Hz, 
1H, py). MS (ESI): m/z (%) = 481 (100) [M]+. 
WH-416: 1H NMR (500 MHz, D2O): δ (ppm) = 1.80 (s, 18H, C6Me), 3.83 (s, 3H, 
OMe), 7.07 (d, 3J= 9 Hz, 2H, C6H4), 7.52 (d, 3J= 9 Hz, 2H, C6H4), 7.73 (m, 1H, py), 
7.99 (d, 3J= 7 Hz, 1H, py), 8.06 (dt, 3J= 7 Hz, 1H, py), 8.40 (s, 1H, PhN=CH), 8.89 (d, 
3J= 5 Hz, 1H, py). MS (ESI): m/z (%) = 511 (100) [M]+. 
WH-417: 1H NMR (500 MHz, D2O): δ (ppm) = 1.77 (s, 18H, C6Me), 7.61 (d, 3J= 8 
Hz, 2H, C6H4), 7.77 (m, 1H, py), 8.06 (m, 2H, C6H4), 8.07 (m, 2H, py), 8.51 (s, 1H, 
PhN=CH), 8.92 (d, 3J= 6 Hz, 1H, py).  
WH-418: 1H NMR (500 MHz, D2O): δ (ppm) = 1.80 (s, 18H, C6Me), 7.65 (d, 3J= 9 
Hz, 2H, C6H4), 7.78 (m, 1H, py), 7.93 (d, 3J= 9 Hz, 2H, C6H4), 8.08 (m, 2H, py), 8.52 
(s, 1H, PhN=CH), 8.94 (d, 3J= 6 Hz, 1H, py). MS (ESI): m/z (%) = 524 (100) [M]+. 
WH-41a: 1H NMR (500 MHz, D2O): δ (ppm) = 1.82 (s, 18H, C6Me), 7.78 (d, 3J= 8 
Hz, 2H, C6H4), 7.81 (m, 1H, py), 8.08 (d, 3J= 9 Hz, 2H, C6H4), 8.13 (m, 2H, py), 8.62 




(s, 1H, PhN=CH), 8.97 (d, 3J= 5 Hz, 1H, py). MS (ESI): m/z (%) = 524 (10) [M-
HCl]+, 560 (100) [M]+. 
WH-41d: 1H NMR (500 MHz, D2O): δ (ppm) = 1.84 (s, 18H, C6Me), 7.80 (d, 3J= 9 
Hz, 2H, C6H4), 7.81 (m, 1H, py), 7.98 (d, 3J= 8 Hz, 2H, C6H4), 8.14 (d, 3J= 4 Hz, 2H, 
py), 8.64 (s, 1H, PhN=CH), 8.98 (d, 3J= 6 Hz, 1H, py). MS (ESI): m/z (%) = 524 (10) 
[M-HCl]+, 560 (100) [M]+. 
WH-331: 1H NMR (500 MHz, 70˚C, D2O): δ (ppm) = 0.73 (dd, 3J= 7 Hz, 6H, 
(CH3)2CH), 2.18 (s, 3H, Ar-CH3), 2.18 (m, 1H, CH3CHCH3), 5.26 (d, 3J= 6 Hz, 1H, 
MeC6H4iPr), 5.62 (d, 3J= 6 Hz, 1H, MeC6H4iPr), 5.85 (d, 3J= 6 Hz, 2H, MeC6H4iPr), 
5.89 (d, 3J= 6 Hz, 2H, MeC6H4iPr), 7.56 (m, 3H, C6H5), 7.76 (m, 2H, C6H5), 7.87 (t, 
3J= 8 Hz, 1H, quinolinyl), 8.01 (d, 3J= 8 Hz, 1H, quinolinyl), 8.07 (m, 2H, 
quinolinyl), 8.54 (d, 3J= 8 Hz, 1H, quinolinyl), 8.63 (d, 3J= 8 Hz, 1H, quinolinyl), 
8.78 (s, 1H, PhN=CH). MS (ESI): m/z (%) = 467 (21) [M-HCl]+, 503 (100) [M]+. 
WH-121: 1H NMR (400 MHz, 1:1 D2O/DMSO-d6): δ (ppm) = 2.53 (s, 3H, CH3,py), 
5.76 (s, 6H, C6H6), 7.55 (m, 6H, Ph + Py), 7.92 (d, 3J= 7 Hz, 1H, Py), 8.70 (s, 1H, 
PhN=CH), 9.26 (d, 3J= 5 Hz, 1H, py). MS (ESI): m/z (%) = 411 (100) [M]+. 
WH-221: 1H NMR (400 MHz, 1:1 D2O/DMSO-d6): δ (ppm) = 1.99 (s, 3H, PhCH3), 
2.53 (s, 3H, CH3,py), 5.39 (d, 3J= 3 Hz, 1H, C6H5Me), 5.58 (m, 3H, C6H5Me), 5.87 (d, 
3J= 3 Hz, 1H, C6H5Me), 7.58 (m, 6H, Ph + Py), 7.91 (d, 3J= 8 Hz, 1H, Py), 8.70 (s, 
1H, PhN=CH), 9.20 (d, 3J= 5 Hz, 1H, py). MS (ESI): m/z (%) = 425 (100) [M]+. 
WH-321: 1H NMR (400 MHz, 1:1 D2O/DMSO-d6): δ (ppm) = 0.89 (d, 3J= 7 Hz, 6H, 
(CH3)2CH), 2.06 (s, 3H, Ar-CH3), 2.38 (sept, 3J= 7 Hz, 1H, CH3CHCH3), 2.54 (s, 3H, 
CH3,py), 5.36 (d, 3J= 6 Hz, 1H, MeC6H4iPr), 5.44 (d, 3J= 6 Hz, 1H, MeC6H4iPr), 5.56 
(d, 3J= 6 Hz, 1H, MeC6H4iPr), 5.83 (d, 3J= 6 Hz, 1H, MeC6H4iPr), 7.59 (m, 6H, Ph + 
Py),  7.93 (d, 3J= 8 Hz, 1H, py), 8.74 (s, 1H, PhN=CH), 9.20 (d, 3J= 6 Hz, 1H, py). 
MS (ESI): m/z (%) = 467 (100) [M]+. 
WH-421: : 1H NMR (400 MHz, 1:1 D2O/DMSO-d6): δ (ppm) = 1.73 (s, 18H, C6Me), 
2.53 (s, 3H, CH3,py), 7.59 (m, 6H, Ph + Py),  7.87 (d, 3J= 8 Hz, 1H, py), 8.61 (s, 1H, 
PhN=CH), 8.69 (d, 3J= 5 Hz, 1H, py) MS (ESI): m/z (%) = 495 (100) [M]+.  
WH-521: 1H NMR (400 MHz, 1:1 D2O/DMSO-d6): δ (ppm) = 0.93 (dd, 3J= 7 Hz, 
18H, (CH3)2CH), 2.19 (m, 1H, CH3CHCH3), 2.46 (s, 3H, CH3,py),  5.60 (s, 3H, C6H3), 
7.47 (m, 5H, C6H5), 7.60 (t, 3J= 8 Hz, 1H, py), 7.89 (d, 3J= 8 Hz, 1H, py), 8.63 (s, 1H, 
PhN=CH), 9.10 (d, 3J= 5 Hz, 1H, py). MS (ESI): m/z (%) = 501 (20) [M-HCl]+, 537 
(100) [M]+. 
WH-122: 1H NMR (400 MHz, 1:1 D2O/DMSO-d6): δ (ppm) = 2.53 (s, 3H, CH3,py), 
5.78 (s, 6H, C6H6), 7.62 (dd, 3J= 6 Hz, 1H, Py), 7.74 (t, 3J= 8 Hz, 1H, Ar(H)-CF3), 
7.84 (d, 3J= 8 Hz, 1H, Py), 7.94 (d, 3J= 8 Hz, 2H, Ar(H)-CF3), 7.94 (s, 1H, Ar(H)-
CF3), 8.80 (s, 1H, PhN=CH), 9.28 (d, 3J= 5 Hz, 1H, py). MS (ESI): m/z (%) = 479 
(100) [M]+. 
WH-222: 1H NMR (400 MHz, 1:1 D2O/DMSO-d6): δ (ppm) = 2.00 (s, 3H, PhCH3), 
2.54 (s, 3H, CH3,py), 5.32 (d, 3J= 4 Hz, 1H, C6H5Me), 5.61 (m, 3H, C6H5Me), 5.91 
(dd, 3J= 4 Hz, 1H, C6H5Me), 7.63 (dd, 3J= 6 Hz, 1H, Py), 7.74 (t, 3J= 8 Hz, 1H, 
Ar(H)-CF3), 7.84 (d, 3J= 8 Hz, 1H, Py), 7.93 (dd, 3J= 7 Hz, 2H, Ar(H)-CF3), 8.02 (s, 




1H, Ar(H)-CF3), 8.79 (s, 1H, PhN=CH), 9.22 (d, 3J= 5 Hz, 1H, py). MS (ESI): m/z 
(%) = 493 (100) [M]+. 
WH-322: 1H NMR (400 MHz, 1:1 D2O/DMSO-d6): δ (ppm) = 0.90 (dd, 3J= 7 Hz, 
6H, (CH3)2CH), 2.03 (s, 3H, Ar-CH3), 2.41 (sept, 3J= 7 Hz, 1H, CH3CHCH3), 2.53 (s, 
3H, CH3,py), 5.34 (d, 3J= 6 Hz, 1H, MeC6H4iPr), 5.51 (d, 3J= 6 Hz, 1H, MeC6H4iPr), 
5.58 (d, 3J= 6 Hz, 1H, MeC6H4iPr), 5.77 (d, 3J= 6 Hz, 1H, MeC6H4iPr), 7.65 (dd, 3J= 6 
Hz, 1H, py), 7.75 (t, 3J= 8 Hz, 1H, Ar(H)-CF3), 7.85 (d, 3J= 8 Hz, 1H, py), 7.92 (d, 3J= 
7 Hz, 1H, Ar(H)-CF3), 7.95 (d, 3J= 8 Hz, 1H, Ar(H)-CF3), 8.02 (s, 1H, Ar(H)-CF3), 
8.82 (s, 1H, PhN=CH), 9.22 (d, 3J= 5 Hz, 1H, py). MS (ESI): m/z (%) = 535 (100) 
[M]+. 
WH-422: 1H NMR (400 MHz, 1:1 D2O/DMSO-d6): δ (ppm) = 1.74 (s, 18H, C6Me), 
2.53 (s, 3H, CH3,py), 7.66 (dd, 3J= 6 Hz, 1H, py), 7.77 (t, 3J= 8 Hz, 1H, Ar(H)-CF3), 
7.84 (d, 3J= 8 Hz, 1H, py), 7.89 (t, 3J= 7 Hz, 2H, Ar(H)-CF3), 8.04 (s, 1H, Ar(H)-CF3), 
8.72 (m, 2H, PhN=CH + py) MS (ESI): m/z (%) = 563 (100) [M]+. 
WH-522: 1H NMR (400 MHz, 1:1 D2O/DMSO-d6): δ (ppm) = 0.96 (dd, 3J= 7 Hz, 
18H, (CH3)2CH), 2.22 (sept, 3J= 7 Hz, 1H, CH3CHCH3), 2.53 (s, 3H, CH3,py),  5.66 (s, 
3H, C6H3), 7.65 (dd, 3J= 6 Hz, 1H, py), 7.75 (t, 3J= 6 Hz, 1H, Ar(H)-CF3), 7.82 (d, 3J= 
8 Hz, 2H, Ar(H)-CF3), 7.88 (s, 1H, Ar(H)-CF3), 7.94 (d, 3J= 8 Hz, 1H, py), 8.74 (s, 
1H, PhN=CH), 9.15 (d, 3J= 5 Hz, 1H, py). MS (ESI): m/z (%) = 605 (100) [M]+. 
WH-123: 1H NMR (400 MHz, 1:1 D2O/DMSO-d6): δ (ppm) = 2.53 (s, 3H, CH3,py), 
5.79 (s, 6H, C6H6), 7.53 (m, 2H, Ar(H)-Cl), 7.62 (m, 2H, py + Ar(H)-Cl), 7.72 (s, 1H, 
Ar(H)-Cl), 7.93 (d, 3J= 8 Hz, 1H, py), 8.73 (s, 1H, PhN=CH), 9.26 (d, 3J= 5 Hz, 1H, 
py). MS (ESI): m/z (%) = 445 (100) [M]+. 
WH-223: 1H NMR (400 MHz, 1:1 D2O/DMSO-d6): δ (ppm) = 2.01 (s, 3H, PhCH3), 
2.54 (s, 3H, CH3,py), 5.38 (m, 1H, C6H5Me), 5.61 (m, 3H, C6H5Me), 5.89 (m, 1H, 
C6H5Me), 7.53 (m, 2H, Py + Ar(H)-Cl), 7.61 (m, 2H, Ar(H)-Cl), 7.73 (s, 1H, Ar(H)-
Cl), 7.92 (d, 3J= 8 Hz, 1H, py), 8.73 (s, 1H, PhN=CH), 9.20 (d, 3J= 5 Hz, 1H, py). MS 
(ESI): m/z (%) = 459 (100) [M]+. 
WH-323: 1H NMR (400 MHz, 1:1 D2O/DMSO-d6): δ (ppm) = 0.90 (t, 3J= 7 Hz, 6H, 
(CH3)2CH), 2.04 (s, 3H, Ar-CH3), 2.42 (sept, 3J= 7 Hz, 1H, CH3CHCH3), 2.54 (s, 3H, 
CH3,py), 5.38 (d, 3J= 6 Hz, 1H, MeC6H4iPr), 5.52 (d, 3J= 6 Hz, 1H, MeC6H4iPr), 5.58 
(d, 3J= 6 Hz, 1H, MeC6H4iPr), 5.79 (d, 3J= 6 Hz, 1H, MeC6H4iPr), 7.59 (m, 4H, Py + 
Ar(H)-Cl), 7.73 (s, 1H, Ar(H)-Cl), 7.94 (d, 3J= 8 Hz, 1H, Py), 8.76 (s, 1H, PhN=CH), 
9.21 (d, 3J= 5 Hz, 1H, py). MS (ESI): m/z (%) = 501 (100) [M]+. 
WH-423: 1H NMR (400 MHz, 1:1 D2O/DMSO-d6): δ (ppm) = 1.76 (s, 18H, C6Me), 
2.54 (s, 3H, CH3,py), 7.55 (m, 3H, Ar(H)-Cl), 7.64 (dd, 3J= 6 Hz, 1H, Py), 7.74 (s, 1H, 
Ar(H)-Cl), 7.89 (d, 3J= 8 Hz, 1H, py), 8.66 (m, 2H, PhN=CH), 8.70 (d, 3J= 5 Hz, 1H, 
py). MS (ESI): m/z (%) = 529 (100) [M]+. 
WH-523: 1H NMR (400 MHz, 1:1 D2O/DMSO-d6): δ (ppm) = 0.98 (dd, 3J= 7 Hz, 
18H, (CH3)2CH), 2.24 (s(broad), 3H, CH3CHCH3), 2.54 (s, 3H, CH3,py),  5.67 (s, 3H, 
C6H3), 7.57 (m, 5H, Py + Ar(H)-Cl), 7.93 (d, 3J= 8 Hz, 1H, Py), 8.70 (s, 1H, 
PhN=CH), 9.14 (s(broad), 1H, py). MS (ESI): m/z (%) = 571 (100) [M]+. 
 

























































































Appendix B – Mechanistic Studies Data 













































































































































































































































































































































































No Desired Product Formed 
Figure S2: (a) Reaction scheme of 3CA in acidic condition. (b) ESI-MS spectrum of the 
products. (c) 1H NMR spectrums of the products. (d) Reaction scheme of 3CA in basic 































































RA3 AD1 PA1 
[M2] 


























































































































































































































































































































Appendix C – CV% for 442 RAS Complexes 
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Stability of RAS-1H and RAS-1T in various conditions. Stability of RAS-1H and 
RAS-1T at 50 µM was determined by observing the change in UV-Vis spectrums 
over time. In general, the complexes are stable towards hydrolysis and ligand 
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Inhibition of Cell Death MTT Assay. The type of cell death induced by RAS-1H (1) 
and RAS-1T (2) was investigated by performing a 48 h cell viability assay in the 
absence and presence of inhibitors (a) Necroptosis inhibitor, necrostatin-1 (60 µM), 
(b) Necrosis inhibitor, IM-54 (10 µM) and (c) Ferroptosis inhibitor, ferrostatin-1 (10 
µM). In general, inhibitors did not reduced cell death, indicating that RAS-1H and 












ROS induction for 6h-treatment by fluorescence microscope. (Left panels) 
Fluorescence image taken at 585 nm after incubation with carboxy-H2DCFDA (20 
µM).; (Middle panels) overlay; (Right Panels) visible light image. 
 









ROS induction for 24h-treatment by fluorescence microscope. (Left panels) 
Fluorescence image taken at 585 nm after incubation with carboxy-H2DCFDA (20 
µM).; (Middle panels) overlay; (Right Panels) visible light image. 
 
